{"PMC7256915": [["Hydroxychloroquine is linked with a recent increase in cardiac adverse events (AEs) when used to manage COVID-19, say Sanofi representatives from Ireland.", [["cardiac", "ANATOMY", 55, 62], ["Hydroxychloroquine", "CHEMICAL", 0, 18], ["cardiac adverse events", "DISEASE", 55, 77], ["Hydroxychloroquine", "CHEMICAL", 0, 18], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 0, 18], ["cardiac", "ORGAN", 55, 62], ["Hydroxychloroquine", "TREATMENT", 0, 18], ["cardiac adverse events", "PROBLEM", 55, 77], ["COVID", "TEST", 104, 109], ["increase", "OBSERVATION_MODIFIER", 43, 51], ["cardiac", "ANATOMY", 55, 62]]]], "PMC7111312": [["IntroductionProteases with a two-\u03b2-barrel fold prototyped by chymotrypsin form one of the largest clans of proteolytic enzymes, called the PA clan, and are encoded by pro- and eukaryotes as well as many viruses (Rawlings et al., 2012).", [["chymotrypsin", "GENE_OR_GENE_PRODUCT", 61, 73], ["PA", "GENE_OR_GENE_PRODUCT", 139, 141], ["-\u03b2-barrel fold", "PROTEIN", 32, 46], ["chymotrypsin", "PROTEIN", 61, 73], ["proteolytic enzymes", "PROTEIN", 107, 126], ["PA clan", "PROTEIN", 139, 146], ["pro", "PROTEIN", 167, 170], ["IntroductionProteases", "TREATMENT", 0, 21], ["proteolytic enzymes", "TEST", 107, 126]]], ["The cellular chymotrypsin-like enzymes invariantly employ a canonical catalytic Ser-His-Asp triad (Hedstrom, 2002; Polgar, 2005) and have evolved, by duplication and diversification, a large spectrum of substrate specificities facilitating their diverse roles in many biological processes.", [["cellular", "ANATOMY", 4, 12], ["His", "CHEMICAL", 84, 87], ["Asp", "CHEMICAL", 88, 91], ["cellular", "CELL", 4, 12], ["cellular chymotrypsin-like enzymes", "PROTEIN", 4, 38], ["The cellular chymotrypsin", "TEST", 0, 25], ["a large spectrum of substrate specificities", "PROBLEM", 183, 226], ["large", "OBSERVATION_MODIFIER", 185, 190], ["biological processes", "OBSERVATION", 268, 288]]], ["Likewise, RNA viruses with single-stranded RNA genomes of positive polarity (ssRNA + viruses) often employ chymotrypsin-like enzymes to control genome expression and remodel host cell functions by targeting different proteins.IntroductionOne of the major monophyletic groups of RNA virus chymotrypsin-like enzymes is known as 3C and 3C-like proteases (3C/3CLpro; see below), which evolved by extensive diversification during virus speciation.", [["cell", "ANATOMY", 179, 183], ["chymotrypsin-like enzymes", "GENE_OR_GENE_PRODUCT", 107, 132], ["host cell", "CELL", 174, 183], ["chymotrypsin", "GENE_OR_GENE_PRODUCT", 288, 300], ["3C", "GENE_OR_GENE_PRODUCT", 333, 335], ["chymotrypsin", "PROTEIN", 107, 119], ["RNA virus chymotrypsin-like enzymes", "PROTEIN", 278, 313], ["3C and 3C-like proteases", "PROTEIN", 326, 350], ["3C", "PROTEIN", 352, 354], ["3CLpro", "PROTEIN", 355, 361], ["RNA viruses", "PROBLEM", 10, 21], ["positive polarity (ssRNA + viruses", "PROBLEM", 58, 92], ["chymotrypsin", "TEST", 107, 119], ["enzymes", "TEST", 125, 132], ["RNA virus chymotrypsin", "TEST", 278, 300], ["enzymes", "TEST", 306, 313], ["3C", "TEST", 326, 328], ["3C", "TEST", 333, 335], ["3C/3CLpro", "TREATMENT", 352, 361], ["virus speciation", "TREATMENT", 425, 441], ["RNA viruses", "OBSERVATION", 10, 21], ["positive polarity", "OBSERVATION_MODIFIER", 58, 75], ["host cell functions", "OBSERVATION", 174, 193], ["RNA virus", "OBSERVATION", 278, 287]]], ["In contrast to cellular and other viral homologs, these enzymes uniquely diversified the principal catalytic nucleophile residue to employ either the canonical Ser or an unconventional Cys (depending on the virus lineage) (Bazan and Fletterick, 1988; Gorbalenya et al., 1986, 1989a; Malcolm, 1995), while (somewhat counterintuitively) sharing a conserved narrow substrate specificity.", [["cellular", "ANATOMY", 15, 23], ["Ser", "CHEMICAL", 160, 163], ["Cys", "CHEMICAL", 185, 188], ["cellular", "CELL", 15, 23], ["Ser", "AMINO_ACID", 160, 163], ["enzymes", "PROTEIN", 56, 63], ["canonical Ser", "PROTEIN", 150, 163], ["these enzymes", "TEST", 50, 63], ["the principal catalytic nucleophile residue", "PROBLEM", 85, 128], ["an unconventional Cys", "TEST", 167, 188], ["nucleophile residue", "OBSERVATION", 109, 128]]], ["In those proteases that employ Cys as the principal nucleophile, the catalytic Asp may be replaced with another residue, either another acidic residue (Glu) (Matthews et al., 1994; Mosimann et al., 1997) or a residue with a side chain that has little or no similarity to that of Asp, further reflecting the pronounced sequence divergence of many ssRNA + virus proteases from their cellular homologs (Gorbalenya and Snijder, 1996).", [["cellular", "ANATOMY", 381, 389], ["Cys", "CHEMICAL", 31, 34], ["Asp", "CHEMICAL", 79, 82], ["Glu", "CHEMICAL", 152, 155], ["Cys", "CHEMICAL", 31, 34], ["Asp", "CHEMICAL", 79, 82], ["Glu", "CHEMICAL", 152, 155], ["Asp", "CHEMICAL", 279, 282], ["Cys", "AMINO_ACID", 31, 34], ["Asp", "AMINO_ACID", 79, 82], ["Glu", "AMINO_ACID", 152, 155], ["Asp", "AMINO_ACID", 279, 282], ["cellular", "CELL", 381, 389], ["proteases", "PROTEIN", 9, 18], ["ssRNA + virus proteases", "PROTEIN", 346, 369], ["cellular homologs", "PROTEIN", 381, 398], ["the principal nucleophile", "TREATMENT", 38, 63], ["the catalytic Asp", "TREATMENT", 65, 82], ["another residue", "PROBLEM", 104, 119], ["another acidic residue", "PROBLEM", 128, 150], ["a residue with a side chain", "PROBLEM", 207, 234], ["Asp", "PROBLEM", 279, 282], ["virus proteases", "TREATMENT", 354, 369]]], ["Probably, these replacements have evolved due to the exceptionally large mutation space that RNA viruses of this lineage explored in the course of their evolution (Lauber et al., 2013) and have been fixed to meet the distinct requirements for Ser and Cys residues in mediating the nucleophilic attack during catalysis (McGrath et al., 1989).Introduction3C/3CLpros possess a conserved substrate specificity that is predominantly directed against Gln or Glu in the P1 and a small residue in the P1\u2019 positions of the substrate (Gorbalenya et al., 1989b; Kr\u00e4usslich and Wimmer, 1988; Ziebuhr et al., 2000) (numbering according to the scheme introduced by Schechter and Berger (1967)).", [["Gln", "CHEMICAL", 445, 448], ["Glu", "CHEMICAL", 452, 455], ["Ser", "CHEMICAL", 243, 246], ["Cys", "CHEMICAL", 251, 254], ["Gln", "CHEMICAL", 445, 448], ["Glu", "CHEMICAL", 452, 455], ["Ser", "AMINO_ACID", 243, 246], ["Cys residues", "AMINO_ACID", 251, 263], ["3CLpros", "GENE_OR_GENE_PRODUCT", 356, 363], ["Gln", "AMINO_ACID", 445, 448], ["Glu", "AMINO_ACID", 452, 455], ["Introduction3C/3CLpros", "PROTEIN", 341, 363], ["P1", "PROTEIN", 463, 465], ["these replacements", "TREATMENT", 10, 28], ["the exceptionally large mutation space", "PROBLEM", 49, 87], ["Ser and Cys residues", "TREATMENT", 243, 263], ["Introduction3C/3CLpros", "TREATMENT", 341, 363], ["Gln or Glu in the P1", "PROBLEM", 445, 465], ["a small residue", "PROBLEM", 470, 485], ["replacements", "OBSERVATION", 16, 28], ["large", "OBSERVATION_MODIFIER", 67, 72], ["mutation", "OBSERVATION", 73, 81], ["viruses", "OBSERVATION_MODIFIER", 97, 104], ["nucleophilic attack", "OBSERVATION", 281, 300], ["P1", "ANATOMY", 463, 465], ["small", "OBSERVATION_MODIFIER", 472, 477], ["residue", "OBSERVATION", 478, 485]]], ["These substrate residues are accommodated in a protease substrate pocket that generally includes a highly conserved His residue (which differs from the catalytic His) and another residue, often Ser or Thr, which together define the S1 subsite homologous to that of cellular chymotrypsin-like proteases (Bazan and Fletterick, 1988; Gorbalenya et al., 1989a).", [["cellular", "ANATOMY", 265, 273], ["His", "CHEMICAL", 116, 119], ["His", "CHEMICAL", 162, 165], ["Ser", "CHEMICAL", 194, 197], ["Thr", "CHEMICAL", 201, 204], ["Ser", "AMINO_ACID", 194, 197], ["Thr", "AMINO_ACID", 201, 204], ["cellular", "CELL", 265, 273], ["protease substrate pocket", "PROTEIN", 47, 72], ["catalytic His", "PROTEIN", 152, 165], ["S1 subsite", "PROTEIN", 232, 242], ["cellular chymotrypsin-like proteases", "PROTEIN", 265, 301], ["These substrate residues", "PROBLEM", 0, 24], ["a protease substrate pocket", "PROBLEM", 45, 72], ["His residue", "PROBLEM", 116, 127], ["another residue", "PROBLEM", 171, 186], ["substrate residues", "OBSERVATION", 6, 24]]], ["These residues are generally considered valuable targets for the development of broadly acting antiviral drugs (Kuo et al., 2009; Yang et al., 2005; Banerjee et al., 2018; Pillaiyar et al., 2016).IntroductionViral 3C/3CLpros are produced as part of large polyproteins that contain the key replicative domains and several other proteins (for reviews see (Kr\u00e4usslich and Wimmer, 1988; Ziebuhr et al., 2000; Dougherty and Semler, 1993; Ryan and Flint, 1997)).", [["3CLpros", "GENE_OR_GENE_PRODUCT", 217, 224], ["IntroductionViral 3C/3CLpros", "PROTEIN", 196, 224], ["replicative domains", "PROTEIN", 289, 308], ["broadly acting antiviral drugs", "TREATMENT", 80, 110], ["IntroductionViral 3C/3CLpros", "TREATMENT", 196, 224], ["large polyproteins", "PROBLEM", 249, 267], ["large", "OBSERVATION_MODIFIER", 249, 254], ["polyproteins", "OBSERVATION", 255, 267]]], ["The individual proteins are released by the 3C/3CLpro in both cis- and trans-cleavage reactions, thereby regulating the formation of viral replication complexes in a timely coordinated manner.", [["3CLpro", "GENE_OR_GENE_PRODUCT", 47, 53], ["3C/3CLpro", "PROTEIN", 44, 53], ["viral replication complexes", "PROTEIN", 133, 160], ["the 3C/3CLpro", "TREATMENT", 40, 53], ["trans-cleavage reactions", "TREATMENT", 71, 95], ["viral replication complexes", "TREATMENT", 133, 160], ["viral replication", "OBSERVATION", 133, 150]]], ["In addition, some 3C/3CLpros may mediate the processing of capsid polyproteins to generate the proteins required for virus particle formation as well as cleaving cellular proteins to facilitate virus reproduction.", [["cellular", "ANATOMY", 162, 170], ["3CLpros", "GENE_OR_GENE_PRODUCT", 21, 28], ["cellular", "CELL", 162, 170], ["3CLpros", "PROTEIN", 21, 28], ["capsid polyproteins", "PROTEIN", 59, 78], ["cellular proteins", "PROTEIN", 162, 179], ["some 3C/3CLpros", "TREATMENT", 13, 28], ["capsid polyproteins", "PROBLEM", 59, 78], ["the proteins", "PROBLEM", 91, 103], ["virus particle formation", "PROBLEM", 117, 141], ["cleaving cellular proteins", "PROBLEM", 153, 179]]], ["Viruses encoding 3C/3CLpros belong to two large monophyletic orders, the Picornavirales (which infect uni- and multicellular eukaryotes) and the Nidovirales (which infect vertebrates and invertebrates), but also include several other virus families or groups, such as the plant Potyviridae and Sobemovirus, and the vertebrate Caliciviridae and Astroviridae, displaying more distant affinities to one of these two virus orders.", [["3CLpros", "GENE_OR_GENE_PRODUCT", 20, 27], ["Nidovirales", "GENE_OR_GENE_PRODUCT", 145, 156], ["Sobemovirus", "GENE_OR_GENE_PRODUCT", 294, 305], ["Caliciviridae", "GENE_OR_GENE_PRODUCT", 326, 339], ["Astroviridae", "GENE_OR_GENE_PRODUCT", 344, 356], ["3C/3CLpros", "PROTEIN", 17, 27], ["Viruses", "PROBLEM", 0, 7], ["3C/3CLpros", "TREATMENT", 17, 27], ["the Picornavirales", "TREATMENT", 69, 87], ["the Nidovirales", "TREATMENT", 141, 156], ["the plant Potyviridae", "TREATMENT", 268, 289], ["Sobemovirus", "TREATMENT", 294, 305], ["the vertebrate Caliciviridae", "TREATMENT", 311, 339], ["Astroviridae", "TREATMENT", 344, 356]]], ["Over the past years, our appreciation of the natural 3C/3CLpro diversity and conservation of specific residues has been steadily improved by comparative genomics, while our understanding of the roles and properties of these proteases in viral replication was largely based on just a few viruses of the above taxa, with a strong focus on viruses that (may) infect humans.", [["3CLpro", "GENE_OR_GENE_PRODUCT", 56, 62], ["humans", "ORGANISM", 363, 369], ["proteases", "PROTEIN", 224, 233], ["humans", "SPECIES", 363, 369], ["humans", "SPECIES", 363, 369], ["the natural 3C/3CLpro diversity", "TREATMENT", 41, 72], ["specific residues", "PROBLEM", 93, 110], ["these proteases", "TREATMENT", 218, 233], ["viral replication", "TREATMENT", 237, 254], ["steadily", "OBSERVATION_MODIFIER", 120, 128], ["improved", "OBSERVATION_MODIFIER", 129, 137], ["viral replication", "OBSERVATION", 237, 254]]], ["Specifically, the structural characterization of 3C/3CLpros remained limited to those encoded by several mammalian viruses and one avian virus of the Picornaviridae, Coronaviridae, Arteriviridae, Caliciviridae, and Astroviridae, and plant Potyviridae and Sobemovirus (Matthews et al., 1994; Banerjee et al., 2018; Phan et al., 2002; Nunn et al., 2005; Speroni et al., 2009; Gayathri et al., 2006; Damalanka et al., 2018; Weerawarna et al., 2016; Galasiti Kankanamalage et al., 2017; Takahashi et al., 2013; Kim et al., 2012; Muhaxhiri et al., 2013; Allaire et al., 1994; Anand et al., 2002, 2003; Bergmann et al., 1997; Xue et al., 2008; Yang et al., 2003; Barrette-Ng et al., 2002).", [["3CLpros", "GENE_OR_GENE_PRODUCT", 52, 59], ["mammalian viruses", "ORGANISM", 105, 122], ["avian virus", "ORGANISM", 131, 142], ["Picornaviridae", "GENE_OR_GENE_PRODUCT", 150, 164], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 166, 179], ["Arteriviridae", "GENE_OR_GENE_PRODUCT", 181, 194], ["Caliciviridae", "GENE_OR_GENE_PRODUCT", 196, 209], ["Astroviridae", "GENE_OR_GENE_PRODUCT", 215, 227], ["3CLpros", "PROTEIN", 52, 59], ["avian virus", "SPECIES", 131, 142], ["the structural characterization", "TEST", 14, 45], ["3C/3CLpros", "TEST", 49, 59], ["several mammalian viruses", "PROBLEM", 97, 122], ["the Picornaviridae", "TREATMENT", 146, 164], ["Coronaviridae", "TREATMENT", 166, 179], ["Arteriviridae", "TREATMENT", 181, 194], ["Caliciviridae", "TREATMENT", 196, 209], ["Astroviridae", "TREATMENT", 215, 227], ["et al.", "TEST", 624, 630], ["et al.", "TEST", 643, 649], ["Barrette", "TEST", 657, 665], ["mammalian viruses", "OBSERVATION", 105, 122]]], ["All these proteases have substrate specificities that are critically determined by the P1 position.IntroductionIn this study, we sought to address these knowledge gaps by determining the structure of a 3CLpro encoded by Cavally virus, an invertebrate nidovirus.", [["3CLpro", "GENE_OR_GENE_PRODUCT", 202, 208], ["Cavally virus", "ORGANISM", 220, 233], ["proteases", "PROTEIN", 10, 19], ["3CLpro", "PROTEIN", 202, 208], ["Cavally virus", "SPECIES", 220, 233], ["this study", "TEST", 114, 124], ["a 3CLpro", "TREATMENT", 200, 208], ["Cavally virus", "PROBLEM", 220, 233], ["an invertebrate nidovirus", "PROBLEM", 235, 260]]], ["The protease of this virus represents family C107 in the PA(C) subclan of chymotrypsin-like proteases in the MEROPS database (Rawlings et al., 2012) and displays a substrate specificity that is mainly directed toward the P2 position of the substrate (Blanck et al., 2014; Blanck and Ziebuhr, 2016).", [["chymotrypsin-like proteases", "GENE_OR_GENE_PRODUCT", 74, 101], ["protease", "PROTEIN", 4, 12], ["C107", "PROTEIN", 45, 49], ["PA(C) subclan", "PROTEIN", 57, 70], ["chymotrypsin-like proteases", "PROTEIN", 74, 101], ["P2 position", "PROTEIN", 221, 232], ["this virus", "PROBLEM", 16, 26], ["chymotrypsin", "PROBLEM", 74, 86]]], ["Cavally virus (CavV) is a member of the genus Alphamesonivirus in the family Mesoniviridae which, together with the families Arteriviridae, Coronaviridae, and Roniviridae as well as five others just approved by ICTV (Siddell et al., 2019), forms the order Nidovirales (Fig. 1).", [["Cavally virus", "ORGANISM", 0, 13], ["CavV", "GENE_OR_GENE_PRODUCT", 15, 19], ["Alphamesonivirus", "GENE_OR_GENE_PRODUCT", 46, 62], ["Mesoniviridae", "GENE_OR_GENE_PRODUCT", 77, 90], ["Arteriviridae", "GENE_OR_GENE_PRODUCT", 125, 138], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 140, 153], ["CavV", "SPECIES", 15, 19], ["the genus Alphamesonivirus", "TREATMENT", 36, 62], ["Mesoniviridae", "TREATMENT", 77, 90], ["the families Arteriviridae", "TREATMENT", 112, 138], ["Coronaviridae", "TREATMENT", 140, 153], ["Roniviridae", "TREATMENT", 159, 170]]], ["A distinct feature of previously characterized proteases from this virus order is the presence of an extra C-terminal domain with regulator function.", [["C", "CHEMICAL", 107, 108], ["proteases", "PROTEIN", 47, 56], ["C-terminal domain", "PROTEIN", 107, 124], ["previously characterized proteases", "PROBLEM", 22, 56], ["this virus", "TREATMENT", 62, 72], ["an extra C-terminal domain with regulator function", "PROBLEM", 98, 148], ["regulator function", "OBSERVATION", 130, 148]]], ["This domain was shown to adopt different folds in arteri- and coronavirus enzymes (representing protease families S32 and C30, respectively) (Anand et al., 2002; Barrette-Ng et al., 2002) while there is currently no structural information on other nidovirus 3CLpros, such as those of roni-, toro- and bafiniviruses, all of which representing distinct protease families in the MEROPS database (C62, S65, and S75, respectively); toro- and bafiniviruses belong to distinct subfamilies of the newly established family Tobaniviridae.IntroductionHere, we present the first crystal structures of a mesonivirus 3CLpro, both for the free enzyme and in complex with a covalently bound inhibitor.", [["arteri", "GENE_OR_GENE_PRODUCT", 50, 56], ["coronavirus", "ORGANISM", 62, 73], ["nidovirus 3CLpros", "ORGANISM", 248, 265], ["roni-", "GENE_OR_GENE_PRODUCT", 284, 289], ["toro", "GENE_OR_GENE_PRODUCT", 291, 295], ["bafiniviruses", "GENE_OR_GENE_PRODUCT", 301, 314], ["toro", "GENE_OR_GENE_PRODUCT", 427, 431], ["bafiniviruses", "GENE_OR_GENE_PRODUCT", 437, 450], ["Tobaniviridae", "GENE_OR_GENE_PRODUCT", 514, 527], ["arteri", "PROTEIN", 50, 56], ["coronavirus enzymes", "PROTEIN", 62, 81], ["protease families", "PROTEIN", 96, 113], ["S32", "PROTEIN", 114, 117], ["C30", "PROTEIN", 122, 125], ["protease families", "PROTEIN", 351, 368], ["S75", "PROTEIN", 407, 410], ["Tobaniviridae", "PROTEIN", 514, 527], ["arteri", "TEST", 50, 56], ["coronavirus enzymes", "TEST", 62, 81], ["other nidovirus 3CLpros", "TREATMENT", 242, 265], ["bafiniviruses", "TREATMENT", 301, 314], ["the MEROPS database", "TEST", 372, 391], ["C62", "TEST", 393, 396], ["S65", "TEST", 398, 401], ["toro", "TEST", 427, 431], ["bafiniviruses", "TREATMENT", 437, 450], ["a mesonivirus 3CLpro", "TREATMENT", 589, 609], ["the free enzyme", "TEST", 620, 635], ["a covalently bound inhibitor", "TREATMENT", 656, 684]]], ["The protein structure comprises a two-\u03b2-barrel fold that is linked to a large C-terminal helical domain of >100 residues.", [["C", "CHEMICAL", 78, 79], ["-\u03b2-barrel fold", "PROTEIN", 37, 51], ["C-terminal helical domain", "PROTEIN", 78, 103], ["The protein structure", "PROBLEM", 0, 21], ["a two-\u03b2-barrel fold", "PROBLEM", 32, 51], ["a large C-terminal helical domain", "TREATMENT", 70, 103], ["protein structure", "OBSERVATION", 4, 21], ["large", "OBSERVATION_MODIFIER", 72, 77]]], ["The structure analysis identifies critical residues involved in substrate binding and suggests that mesonivirus 3CLpros employ a catalytic system that depends on (i) Cys153 (principal nucleophile), (ii) His48 (general base), and (iii) a water molecule mediating a polar contact between (iv) Asp216 and the catalytic His48.", [["Cys153", "CHEMICAL", 166, 172], ["His48", "CHEMICAL", 203, 208], ["Cys", "CHEMICAL", 166, 169], ["His48", "CHEMICAL", 203, 208], ["Asp216", "CHEMICAL", 291, 297], ["mesonivirus 3CLpros", "SIMPLE_CHEMICAL", 100, 119], ["Cys153", "AMINO_ACID", 166, 172], ["His48", "AMINO_ACID", 203, 208], ["(iv) Asp216", "SIMPLE_CHEMICAL", 286, 297], ["His48", "GENE_OR_GENE_PRODUCT", 316, 321], ["mesonivirus 3CLpros", "PROTEIN", 100, 119], ["Asp216", "PROTEIN", 291, 297], ["catalytic His48", "PROTEIN", 306, 321], ["The structure analysis", "TEST", 0, 22], ["critical residues", "PROBLEM", 34, 51], ["the catalytic His48", "TREATMENT", 302, 321], ["critical residues", "OBSERVATION", 34, 51]]], ["A strikingly similar arrangement was previously reported for coronavirus 3CLpro structures, which share very low sequence identity (<10%) with 3CLpro orthologs from other nidovirus families, further supporting the universal key roles of these residues in the respective enzymes (Fig. 2).Overall structure of CavV 3CLpro ::: ResultsThe CavV 3CLpro crystal structure determined at 1.94 \u00c5 resolution shows two 3CLpro molecules in the asymmetric unit (Fig. 3A).", [["3CLpro", "CHEMICAL", 407, 413], ["coronavirus 3CLpro", "ORGANISM", 61, 79], ["3CLpro", "GENE_OR_GENE_PRODUCT", 143, 149], ["CavV 3CLpro", "SIMPLE_CHEMICAL", 308, 319], ["3CLpro orthologs", "DNA", 143, 159], ["enzymes", "PROTEIN", 270, 277], ["CavV 3CLpro", "PROTEIN", 308, 319], ["CavV 3CLpro crystal structure", "PROTEIN", 335, 364], ["3CLpro molecules", "PROTEIN", 407, 423], ["coronavirus 3CLpro structures", "PROBLEM", 61, 90], ["3CLpro orthologs", "PROBLEM", 143, 159], ["these residues", "PROBLEM", 237, 251], ["the respective enzymes", "TEST", 255, 277], ["The CavV 3CLpro crystal structure", "TEST", 331, 364], ["asymmetric", "OBSERVATION_MODIFIER", 431, 441]]], ["The two molecules, named A (residues 1\u2013314) and B (residues 1\u2013305), form a dimer with an overall contact surface of 1728 \u00c52, involving 4 salt bridges and 24 hydrogen bonds as calculated by PDBePISA (Krissinel and Henrick, 2007).", [["hydrogen", "CHEMICAL", 157, 165], ["B", "PROTEIN", 48, 49], ["dimer", "PROTEIN", 75, 80], ["A (residues", "TEST", 25, 36]]], ["Molecules A and B are quite similar, with a root-mean-square deviation (RMSD) of 0.59 \u00c5 (as determined for all equivalent C\u03b1 atoms).Overall structure of CavV 3CLpro ::: ResultsEach molecule is comprised of three domains, called I, II, and III, respectively.", [["C\u03b1", "CHEMICAL", 122, 124], ["B", "GENE_OR_GENE_PRODUCT", 16, 17], ["CavV 3CLpro", "SIMPLE_CHEMICAL", 153, 164], ["C\u03b1 atoms", "PROTEIN", 122, 130], ["CavV 3CLpro", "PROTEIN", 153, 164], ["I, II, and III", "PROTEIN", 228, 242], ["similar", "OBSERVATION_MODIFIER", 28, 35], ["root", "OBSERVATION_MODIFIER", 44, 48], ["square deviation", "OBSERVATION", 54, 70]]], ["Domains I and II have a chymotrypsin-like, two-\u03b2-barrel fold that is formed by seven and six \u03b2-strands, respectively (\u03b22-\u03b28 and \u03b29-\u03b213 plus \u03b215).", [["chymotrypsin", "GENE_OR_GENE_PRODUCT", 24, 36], ["\u03b22-\u03b28", "GENE_OR_GENE_PRODUCT", 118, 123], ["\u03b29-\u03b213", "GENE_OR_GENE_PRODUCT", 128, 134], ["I and II", "PROTEIN", 8, 16], ["chymotrypsin", "PROTEIN", 24, 36], ["\u03b2-strands", "PROTEIN", 93, 102], ["\u03b22", "PROTEIN", 118, 120], ["\u03b28", "PROTEIN", 121, 123], ["\u03b29", "PROTEIN", 128, 130], ["\u03b213", "PROTEIN", 131, 134], ["\u03b215", "PROTEIN", 140, 143], ["a chymotrypsin-like, two-\u03b2-barrel fold", "PROBLEM", 22, 60], ["chymotrypsin", "OBSERVATION", 24, 36], ["seven", "OBSERVATION_MODIFIER", 79, 84], ["strands", "OBSERVATION_MODIFIER", 95, 102]]], ["The principal catalytic residues, Cys153 and His48 (Blanck et al., 2014), are part of strand \u03b29 and 310 helix \u019e6, respectively, and are positioned in the center of the active-site cleft located between domains I and II.", [["Cys", "CHEMICAL", 34, 37], ["His48", "CHEMICAL", 45, 50], ["Cys153", "AMINO_ACID", 34, 40], ["\u03b29", "PROTEIN", 93, 95], ["active-site cleft", "PROTEIN", 168, 185], ["I and II", "PROTEIN", 210, 218], ["Cys", "TEST", 34, 37], ["His48", "TEST", 45, 50], ["principal", "OBSERVATION_MODIFIER", 4, 13], ["catalytic residues", "OBSERVATION", 14, 32], ["active", "OBSERVATION_MODIFIER", 168, 174], ["site", "OBSERVATION_MODIFIER", 175, 179], ["cleft", "OBSERVATION", 180, 185]]], ["Domain II is connected to the C-terminal domain III, the latter being formed by seven helices (\u019e7 and \u03b12 to \u03b17) (Fig. 3A).", [["C", "CHEMICAL", 30, 31], ["Domain II", "GENE_OR_GENE_PRODUCT", 0, 9], ["Domain II", "PROTEIN", 0, 9], ["C-terminal domain III", "PROTEIN", 30, 51], ["helices", "PROTEIN", 86, 93], ["\u03b12", "PROTEIN", 102, 104], ["\u03b17", "PROTEIN", 108, 110], ["Fig. 3A", "PROTEIN", 113, 120]]], ["Due to partially poor electron density, residues 51\u201355, 191\u2013194, and 214\u2013220 of chain A as well as residues 27\u201330 and 306\u2013314 of chain B were omitted from the model.", [["electron", "SIMPLE_CHEMICAL", 22, 30], ["chain B", "GENE_OR_GENE_PRODUCT", 129, 136], ["chain A", "PROTEIN", 80, 87], ["chain B", "PROTEIN", 129, 136], ["partially poor electron density", "PROBLEM", 7, 38], ["partially", "OBSERVATION_MODIFIER", 7, 16], ["poor", "OBSERVATION_MODIFIER", 17, 21], ["electron density", "OBSERVATION", 22, 38]]], ["The C-terminal part of chain A wraps around chain B and thereby comes in close contact to the active site of chain B.Overall structure of CavV 3CLpro ::: ResultsThe N-terminal domains I and II of CavV 3CLpro resemble those of related enzymes from the Coronaviridae and Arteriviridae and the 3C/3CLpro enzymes from other RNA + viruses that lack an extra C-terminal domain (Fig. 3B) (Matthews et al., 1994; Mosimann et al., 1997; Phan et al., 2002; Speroni et al., 2009; Muhaxhiri et al., 2013; Allaire et al., 1994; Anand et al., 2002, 2003; Bergmann et al., 1997; Xue et al., 2008; Yang et al., 2003; Barrette-Ng et al., 2002; Zhao et al., 2008).CavV 3CLpro active site ::: ResultsThe S\u03b3 atom of the catalytic Cys153 in chain B is in H-bond distance to the carbonyl oxygen of Phe150 (3.5 \u00c5), the carbonyl oxygen of Cys169 (3.3 \u00c5), and the N\u03b5 of the catalytic His48 (3.7 \u00c5), respectively.", [["oxygen", "CHEMICAL", 766, 772], ["Phe150", "CHEMICAL", 776, 782], ["oxygen", "CHEMICAL", 805, 811], ["C", "CHEMICAL", 4, 5], ["C", "CHEMICAL", 353, 354], ["S\u03b3", "CHEMICAL", 685, 687], ["Cys153", "CHEMICAL", 710, 716], ["H", "CHEMICAL", 734, 735], ["carbonyl", "CHEMICAL", 757, 765], ["oxygen", "CHEMICAL", 766, 772], ["Phe150", "CHEMICAL", 776, 782], ["carbonyl", "CHEMICAL", 796, 804], ["oxygen", "CHEMICAL", 805, 811], ["Cys169", "CHEMICAL", 815, 821], ["CavV 3CLpro", "SIMPLE_CHEMICAL", 138, 149], ["CavV 3CLpro", "GENE_OR_GENE_PRODUCT", 196, 207], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 251, 264], ["Arteriviridae", "CANCER", 269, 282], ["3CLpro", "GENE_OR_GENE_PRODUCT", 294, 300], ["S\u03b3 atom", "SIMPLE_CHEMICAL", 685, 692], ["Cys153", "AMINO_ACID", 710, 716], ["carbonyl oxygen", "SIMPLE_CHEMICAL", 757, 772], ["Phe150", "SIMPLE_CHEMICAL", 776, 782], ["carbonyl oxygen", "SIMPLE_CHEMICAL", 796, 811], ["Cys169", "AMINO_ACID", 815, 821], ["C-terminal part", "PROTEIN", 4, 19], ["chain A", "PROTEIN", 23, 30], ["chain B", "PROTEIN", 44, 51], ["CavV 3CLpro", "PROTEIN", 138, 149], ["N-terminal domains I and II", "PROTEIN", 165, 192], ["CavV 3CLpro", "PROTEIN", 196, 207], ["enzymes", "PROTEIN", 234, 241], ["Coronaviridae and Arteriviridae and the 3C/3CLpro enzymes", "PROTEIN", 251, 308], ["C-terminal domain", "PROTEIN", 353, 370], ["Fig. 3B", "PROTEIN", 372, 379], ["CavV 3CLpro active site", "DNA", 646, 669], ["catalytic Cys153", "PROTEIN", 700, 716], ["chain B", "PROTEIN", 720, 727], ["N\u03b5", "PROTEIN", 839, 841], ["catalytic His48", "PROTEIN", 849, 864], ["The C-terminal part of chain A wraps around chain B", "TREATMENT", 0, 51], ["CavV 3CLpro", "TREATMENT", 196, 207], ["the Coronaviridae", "TREATMENT", 247, 264], ["Arteriviridae", "TREATMENT", 269, 282], ["the 3C/3CLpro enzymes", "TEST", 287, 308], ["viruses", "PROBLEM", 326, 333], ["et al.", "TEST", 568, 574], ["et al.", "TEST", 587, 593], ["Barrette", "TEST", 601, 609], ["the carbonyl oxygen", "TREATMENT", 753, 772], ["Phe150", "TEST", 776, 782], ["the carbonyl oxygen", "TREATMENT", 792, 811], ["the catalytic His48", "TEST", 845, 864]]], ["The N\u03b4 of catalytic His48 makes also contact to the carboxylate side chain of Asp216 through water molecule 558 with distances of 2.7 \u00c5 and 2.9 \u00c5, respectively, forming an angle of 118.9\u00b0 (chain B).", [["His48", "CHEMICAL", 20, 25], ["Asp216", "CHEMICAL", 78, 84], ["His48", "CHEMICAL", 20, 25], ["carboxylate", "CHEMICAL", 52, 63], ["Asp216", "CHEMICAL", 78, 84], ["His48", "AMINO_ACID", 20, 25], ["Asp216", "SIMPLE_CHEMICAL", 78, 84], ["N\u03b4", "PROTEIN", 4, 6], ["catalytic His48", "PROTEIN", 10, 25], ["chain B", "PROTEIN", 189, 196], ["angle", "OBSERVATION_MODIFIER", 172, 177]]], ["This water molecule establishes another H-bond to water molecule 548 (2.7 \u00c5), which is also hydrogen-bonded to O\u03b3 of Thr88 (3.0 \u00c5) and the side chain oxygen of Tyr215 (2.7 \u00c5) (Fig. 4).", [["oxygen", "CHEMICAL", 150, 156], ["H", "CHEMICAL", 40, 41], ["hydrogen", "CHEMICAL", 92, 100], ["O\u03b3", "CHEMICAL", 111, 113], ["Thr88", "CHEMICAL", 117, 122], ["oxygen", "CHEMICAL", 150, 156], ["Tyr215", "CHEMICAL", 160, 166], ["Thr88", "AMINO_ACID", 117, 122], ["oxygen", "SIMPLE_CHEMICAL", 150, 156], ["Tyr215", "AMINO_ACID", 160, 166], ["O\u03b3", "PROTEIN", 111, 113], ["Thr88", "PROTEIN", 117, 122], ["the side chain oxygen", "TEST", 135, 156]]], ["Furthermore, Asp216 forms a salt bridge to Arg47 with H-bond distances of 2.8 and 3.0 \u00c5, respectively.", [["Asp216", "CHEMICAL", 13, 19], ["Asp216", "CHEMICAL", 13, 19], ["Arg47", "CHEMICAL", 43, 48], ["H", "CHEMICAL", 54, 55], ["Asp216", "GENE_OR_GENE_PRODUCT", 13, 19], ["Arg47", "SIMPLE_CHEMICAL", 43, 48], ["Asp216", "PROTEIN", 13, 19], ["a salt bridge", "TREATMENT", 26, 39]]], ["In monomer A, the residues of the active site exhibit a higher flexibility compared to the residues of chain B, which is indicated by (i) a slightly more disordered electron density for His48, (ii) an alternative side chain conformation for Cys153 (56% conformer A, 44% conformer B), and (iii) the lack of visible Asp216.Structure of a CavV 3CLpro/inhibitor complex ::: Results", [["His48", "CHEMICAL", 186, 191], ["Cys153", "CHEMICAL", 241, 247], ["Asp216", "CHEMICAL", 314, 320], ["His48", "CHEMICAL", 186, 191], ["Cys153", "CHEMICAL", 241, 247], ["Asp", "CHEMICAL", 314, 317], ["monomer A", "SIMPLE_CHEMICAL", 3, 12], ["electron", "SIMPLE_CHEMICAL", 165, 173], ["His48", "SIMPLE_CHEMICAL", 186, 191], ["Cys153", "SIMPLE_CHEMICAL", 241, 247], ["Asp216", "AMINO_ACID", 314, 320], ["CavV 3CLpro", "GENE_OR_GENE_PRODUCT", 336, 347], ["chain B", "PROTEIN", 103, 110], ["CavV 3CLpro/inhibitor complex", "PROTEIN", 336, 365], ["the active site", "PROBLEM", 30, 45], ["a higher flexibility", "PROBLEM", 54, 74], ["a slightly more disordered electron density", "PROBLEM", 138, 181], ["Cys153", "TEST", 241, 247], ["visible Asp", "PROBLEM", 306, 317], ["a CavV 3CLpro/inhibitor complex", "TREATMENT", 334, 365], ["active", "OBSERVATION_MODIFIER", 34, 40], ["higher flexibility", "OBSERVATION", 56, 74]]]], "565448756b464b9cee9109d7728cdd1d3c0af5cc": [], "PMC7091597": [["IntroductionA variety of viruses, such as adenovirus (Ad) and poxvirus, have been explored as vaccine and gene delivery vectors for the prevention and/or treatment of various human diseases.1, 2 Among the viral vectors, recombinant Ad is a preferred and promising delivery system1 since the virus exhibits relatively low cytotoxicity, large cloning capacity, replication to high titres and ability to infect both dividing and undividing cells.", [["cells", "ANATOMY", 437, 442], ["adenovirus", "ORGANISM", 42, 52], ["Ad", "ORGANISM", 54, 56], ["human", "ORGANISM", 175, 180], ["Ad", "ORGANISM", 232, 234], ["cells", "CELL", 437, 442], ["dividing and undividing cells", "CELL_TYPE", 413, 442], ["human", "SPECIES", 175, 180], ["Ad", "SPECIES", 54, 56], ["human", "SPECIES", 175, 180], ["Ad", "SPECIES", 232, 234], ["IntroductionA variety of viruses", "PROBLEM", 0, 32], ["adenovirus (Ad)", "TREATMENT", 42, 57], ["poxvirus", "TREATMENT", 62, 70], ["vaccine", "TREATMENT", 94, 101], ["gene delivery vectors", "TREATMENT", 106, 127], ["treatment", "TREATMENT", 154, 163], ["various human diseases", "PROBLEM", 167, 189], ["the viral vectors", "TREATMENT", 201, 218], ["promising delivery system1", "TREATMENT", 254, 280], ["the virus", "PROBLEM", 287, 296], ["relatively low cytotoxicity", "PROBLEM", 306, 333], ["large cloning capacity", "PROBLEM", 335, 357], ["high titres", "PROBLEM", 374, 385], ["viruses", "OBSERVATION", 25, 32], ["viral vectors", "OBSERVATION", 205, 218], ["low cytotoxicity", "OBSERVATION", 317, 333], ["large", "OBSERVATION_MODIFIER", 335, 340], ["cloning capacity", "OBSERVATION", 341, 357]]], ["Recently, adenoviral vectors were found to be very effective for mucosal vaccination due to their natural tropism for the mucosal surfaces.2 It is noted, however, that the main cellular receptor for Ad, coxsackievirus and adenovirus receptor (CAR), has been readily detected in a wide range of human tissues, which may potentially have undesirable consequences.3, 4, 5 These findings prompted several groups to conduct various genetic modifications of the Ads to improve the delivery efficiency and/or minimize the relatively random distribution of the injected Ads by re-targeting the Ads to dendritic cells (DCs).IntroductionDCs are antigen-presenting cells playing crucial roles in establishing antigen-specific adaptive immune response and therefore stimulate potent immune responses.", [["mucosal", "ANATOMY", 65, 72], ["mucosal", "ANATOMY", 122, 129], ["cellular", "ANATOMY", 177, 185], ["tissues", "ANATOMY", 300, 307], ["dendritic cells", "ANATOMY", 593, 608], ["DCs", "ANATOMY", 610, 613], ["cells", "ANATOMY", 654, 659], ["adenoviral", "ORGANISM", 10, 20], ["mucosal", "ORGANISM_SUBDIVISION", 65, 72], ["mucosal surfaces", "MULTI-TISSUE_STRUCTURE", 122, 138], ["cellular", "CELL", 177, 185], ["Ad, coxsackievirus", "ORGANISM", 199, 217], ["adenovirus receptor", "GENE_OR_GENE_PRODUCT", 222, 241], ["CAR", "GENE_OR_GENE_PRODUCT", 243, 246], ["human", "ORGANISM", 294, 299], ["tissues", "TISSUE", 300, 307], ["Ads", "ORGANISM", 456, 459], ["Ads", "GENE_OR_GENE_PRODUCT", 562, 565], ["Ads", "GENE_OR_GENE_PRODUCT", 586, 589], ["dendritic cells", "CELL", 593, 608], ["DCs", "CELL", 610, 613], ["cells", "CELL", 654, 659], ["Ad, coxsackievirus and adenovirus receptor", "PROTEIN", 199, 241], ["CAR", "PROTEIN", 243, 246], ["Ads", "PROTEIN", 586, 589], ["dendritic cells", "CELL_TYPE", 593, 608], ["DCs", "CELL_TYPE", 610, 613], ["antigen-presenting cells", "CELL_TYPE", 635, 659], ["human", "SPECIES", 294, 299], ["adenoviral", "SPECIES", 10, 20], ["human", "SPECIES", 294, 299], ["adenoviral vectors", "TREATMENT", 10, 28], ["mucosal vaccination", "TREATMENT", 65, 84], ["Ad", "PROBLEM", 199, 201], ["coxsackievirus", "PROBLEM", 203, 217], ["the delivery efficiency", "TREATMENT", 471, 494], ["mucosal", "ANATOMY", 122, 129], ["surfaces", "ANATOMY_MODIFIER", 130, 138], ["human tissues", "ANATOMY", 294, 307], ["dendritic cells", "OBSERVATION", 593, 608]]], ["The possibilities of DC-based strategies for immunotherapy and immunoprotection of cancer, infectious disease and transplantation have been vigorously investigated during the past several years.1 However, DCs are deficient in expression of the CAR receptor, presenting a challenge for effective transduction of these cells by Ads.1 In addition, there is also a concern that the cytopathic effect of high-dose Ad on DCs could compromise clinical value of recombinant Ads.3 To overcome these limitations, re-targeting delivery strategies via modification of the tropism of the virus have been developed for better transduction into DCs.", [["DC", "ANATOMY", 21, 23], ["cancer", "ANATOMY", 83, 89], ["DCs", "ANATOMY", 205, 208], ["cells", "ANATOMY", 317, 322], ["DCs", "ANATOMY", 415, 418], ["DCs", "ANATOMY", 630, 633], ["cancer", "DISEASE", 83, 89], ["infectious disease", "DISEASE", 91, 109], ["Ads.1", "CHEMICAL", 326, 331], ["DC", "CELL", 21, 23], ["cancer", "CANCER", 83, 89], ["DCs", "CELL", 205, 208], ["CAR receptor", "GENE_OR_GENE_PRODUCT", 244, 256], ["cells", "CELL", 317, 322], ["Ads.1", "GENE_OR_GENE_PRODUCT", 326, 331], ["Ad", "ORGANISM", 409, 411], ["DCs", "CELL", 415, 418], ["Ads.3", "GENE_OR_GENE_PRODUCT", 466, 471], ["DCs", "CELL", 630, 633], ["DC", "CELL_TYPE", 21, 23], ["DCs", "CELL_TYPE", 205, 208], ["CAR receptor", "PROTEIN", 244, 256], ["DCs", "CELL_TYPE", 415, 418], ["DCs", "CELL_TYPE", 630, 633], ["DC-based strategies", "TREATMENT", 21, 40], ["immunotherapy", "TREATMENT", 45, 58], ["immunoprotection", "TREATMENT", 63, 79], ["cancer", "PROBLEM", 83, 89], ["infectious disease", "PROBLEM", 91, 109], ["transplantation", "TREATMENT", 114, 129], ["effective transduction of these cells", "TREATMENT", 285, 322], ["the cytopathic effect", "PROBLEM", 374, 395], ["re-targeting delivery strategies", "TREATMENT", 503, 535], ["the virus", "PROBLEM", 571, 580], ["cancer", "OBSERVATION", 83, 89], ["infectious", "OBSERVATION", 91, 101], ["cytopathic", "OBSERVATION_MODIFIER", 378, 388]]], ["One approach involves genetic modification of the fiber/knob proteins of Ad to target the surface intergrins of DCs.6, 7 Another approach is to target the CD40 surface receptor of DCs8, 9 since the CD40 receptor may play essential roles in promoting both DC activation and antigen presentation.10, 11, 12, 13, 14 To this end, the viruses were usually complexed with bi-specific adaptor molecules comprised of either anti-Ad single-chain antibody or the extracellular domain of CAR with the targeting CD40 ligand (CD40L).8, 9 While marked improvement of transduction efficiency and enhanced immune responses against the transgenes delivered by various targeted Ad vectors have been reported by others and us, systematic analyses of biodistribution, toxicity and immune responses following various administration routes remains poorly documented.", [["surface", "ANATOMY", 90, 97], ["DCs", "ANATOMY", 112, 115], ["surface", "ANATOMY", 160, 167], ["DC", "ANATOMY", 255, 257], ["extracellular", "ANATOMY", 453, 466], ["toxicity", "DISEASE", 748, 756], ["Ad", "ORGANISM", 73, 75], ["DCs", "CELL", 112, 115], ["CD40", "GENE_OR_GENE_PRODUCT", 155, 159], ["DCs8", "GENE_OR_GENE_PRODUCT", 180, 184], ["CD40", "GENE_OR_GENE_PRODUCT", 198, 202], ["DC", "CELL", 255, 257], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 453, 466], ["CAR", "GENE_OR_GENE_PRODUCT", 477, 480], ["CD40", "GENE_OR_GENE_PRODUCT", 500, 504], ["CD40L", "GENE_OR_GENE_PRODUCT", 513, 518], ["Ad", "ORGANISM", 660, 662], ["fiber/knob proteins", "PROTEIN", 50, 69], ["DCs", "CELL_TYPE", 112, 115], ["CD40 surface receptor", "PROTEIN", 155, 176], ["DCs8", "PROTEIN", 180, 184], ["CD40 receptor", "PROTEIN", 198, 211], ["DC", "CELL_TYPE", 255, 257], ["bi-specific adaptor molecules", "PROTEIN", 366, 395], ["anti-Ad single-chain antibody", "PROTEIN", 416, 445], ["extracellular domain", "PROTEIN", 453, 473], ["CAR", "PROTEIN", 477, 480], ["CD40 ligand", "PROTEIN", 500, 511], ["CD40L", "PROTEIN", 513, 518], ["Ad", "SPECIES", 660, 662], ["the fiber/knob proteins", "TREATMENT", 46, 69], ["the CD40 receptor", "TREATMENT", 194, 211], ["the viruses", "PROBLEM", 326, 337], ["bi-specific adaptor molecules", "TREATMENT", 366, 395], ["anti-Ad single-chain antibody", "TREATMENT", 416, 445], ["the targeting CD40 ligand", "TREATMENT", 486, 511], ["transduction efficiency", "PROBLEM", 553, 576], ["enhanced immune responses", "TREATMENT", 581, 606], ["the transgenes", "TREATMENT", 615, 629], ["various targeted Ad vectors", "TREATMENT", 643, 670], ["toxicity", "PROBLEM", 748, 756], ["immune responses", "TREATMENT", 761, 777], ["various administration routes", "TREATMENT", 788, 817], ["viruses", "OBSERVATION", 330, 337], ["marked", "OBSERVATION_MODIFIER", 531, 537], ["improvement", "OBSERVATION_MODIFIER", 538, 549], ["transduction efficiency", "OBSERVATION", 553, 576]]], ["Uncertainties also remain with respect to other forms of delivery (DNA- and protein-based system).", [["DNA", "CELLULAR_COMPONENT", 67, 70], ["DNA", "TEST", 67, 70]]], ["For instance, even though CD40L has been consistently shown to enhance Th1 (cellular) immune response, its role in Th2 (humoral) response remains unclear, with some reports suggesting an increased antibody response and others reporting no adjuvant effect of CD40L.15, 16, 17, 18, 19 Lack of knowledge in these areas could substantially hinder the transition from laboratory investigations to clinical application of CD40-targeted gene delivery and genetic vaccination.IntroductionThis study focused on the in vivo analyses of the biodistribution and immunogenicity of a modified Ad complexed with an adaptor protein (CFm40L), a fusion protein comprised of human Ad receptor CAR fused to mouse CD40L via a trimerization motif.9 We reported previously that CFm40L can significantly enhance in vitro gene transfer to DCs expressing CD40.9 Here we demonstrate that the modified Ad, denoted as tAd in this report, irrespective of the route of administration, can profoundly alter the patterns of biodistribution and immune responses against the transgene.", [["cellular", "ANATOMY", 76, 84], ["DCs", "ANATOMY", 814, 817], ["CFm40L", "CHEMICAL", 755, 761], ["CD40L", "GENE_OR_GENE_PRODUCT", 26, 31], ["cellular", "CELL", 76, 84], ["Th2", "GENE_OR_GENE_PRODUCT", 115, 118], ["CD40L", "GENE_OR_GENE_PRODUCT", 258, 263], ["CD40", "GENE_OR_GENE_PRODUCT", 416, 420], ["Ad", "ORGANISM", 579, 581], ["CFm40L", "GENE_OR_GENE_PRODUCT", 617, 623], ["human", "ORGANISM", 656, 661], ["Ad", "ORGANISM", 662, 664], ["CAR", "GENE_OR_GENE_PRODUCT", 674, 677], ["mouse", "ORGANISM", 687, 692], ["CD40L", "GENE_OR_GENE_PRODUCT", 693, 698], ["CFm40L", "GENE_OR_GENE_PRODUCT", 755, 761], ["DCs", "CELL", 814, 817], ["CD40.9", "GENE_OR_GENE_PRODUCT", 829, 835], ["Ad", "ORGANISM", 874, 876], ["tAd", "GENE_OR_GENE_PRODUCT", 889, 892], ["CD40L", "PROTEIN", 26, 31], ["CD40L", "PROTEIN", 258, 263], ["CD40", "PROTEIN", 416, 420], ["adaptor protein", "PROTEIN", 600, 615], ["CFm40L", "PROTEIN", 617, 623], ["fusion protein", "PROTEIN", 628, 642], ["CAR", "PROTEIN", 674, 677], ["mouse CD40L", "PROTEIN", 687, 698], ["trimerization motif", "PROTEIN", 705, 724], ["CFm40L", "PROTEIN", 755, 761], ["DCs", "CELL_TYPE", 814, 817], ["CD40.9", "CELL_LINE", 829, 835], ["tAd", "DNA", 889, 892], ["human", "SPECIES", 656, 661], ["mouse", "SPECIES", 687, 692], ["human", "SPECIES", 656, 661], ["mouse", "SPECIES", 687, 692], ["CD40L", "TEST", 26, 31], ["an increased antibody response", "PROBLEM", 184, 214], ["CD40L", "TEST", 258, 263], ["laboratory investigations", "TEST", 363, 388], ["CD40", "TREATMENT", 416, 420], ["targeted gene delivery", "TREATMENT", 421, 443], ["genetic vaccination", "TREATMENT", 448, 467], ["This study", "TEST", 480, 490], ["an adaptor protein (CFm", "TREATMENT", 597, 620], ["a fusion protein", "TREATMENT", 626, 642], ["a trimerization motif", "TREATMENT", 703, 724], ["increased", "OBSERVATION_MODIFIER", 187, 196], ["antibody response", "OBSERVATION", 197, 214]]], ["The potential mechanisms underlying these differences between the unmodified and targeted vectors are discussed.CFm40L facilitates Ad transduction of CD40(+) DCs in the presence of Ad-neutralizing antibodies ::: ResultsWe showed previously that CFm40L could direct Ad into CD40(+) DCs.9 In addition, we have also found that the mouse bone marrow-derived DCs stimulated by Ad\u2013CFm40L complex resulted in elevated levels of maturation markers (CD11c, CD11c, CD54, CD40, CD80, CD86 and I-Ad).9 Prior to the initiation of the biodistribution study in Balb/c mice, we first tested whether anti-CD40 mAb could prevent in vitro gene transfer by tAd-Luc (Ad5 expressing luciferase gene and conjugated with CFm40L).", [["DCs", "ANATOMY", 158, 161], ["CD40(+) DCs.9", "ANATOMY", 273, 286], ["bone marrow", "ANATOMY", 334, 345], ["DCs", "ANATOMY", 354, 357], ["CFm40L", "GENE_OR_GENE_PRODUCT", 112, 118], ["Ad", "ORGANISM", 131, 133], ["CD40", "GENE_OR_GENE_PRODUCT", 150, 154], ["DCs", "CELL", 158, 161], ["Ad", "ORGANISM", 181, 183], ["CFm40L", "GENE_OR_GENE_PRODUCT", 245, 251], ["Ad", "ORGANISM", 265, 267], ["CD40", "GENE_OR_GENE_PRODUCT", 273, 277], ["mouse", "ORGANISM", 328, 333], ["bone marrow-derived DCs", "CELL", 334, 357], ["Ad\u2013CFm40L", "GENE_OR_GENE_PRODUCT", 372, 381], ["CD11c", "GENE_OR_GENE_PRODUCT", 441, 446], ["CD11c", "GENE_OR_GENE_PRODUCT", 448, 453], ["CD54", "GENE_OR_GENE_PRODUCT", 455, 459], ["CD40", "GENE_OR_GENE_PRODUCT", 461, 465], ["CD80", "GENE_OR_GENE_PRODUCT", 467, 471], ["CD86", "GENE_OR_GENE_PRODUCT", 473, 477], ["Balb/c mice", "ORGANISM", 546, 557], ["anti-CD40 mAb", "GENE_OR_GENE_PRODUCT", 583, 596], ["tAd-Luc", "GENE_OR_GENE_PRODUCT", 637, 644], ["Ad5", "ORGANISM", 646, 649], ["luciferase", "GENE_OR_GENE_PRODUCT", 661, 671], ["CFm40L", "PROTEIN", 112, 118], ["CD40", "PROTEIN", 150, 154], ["DCs", "CELL_TYPE", 158, 161], ["Ad-neutralizing antibodies", "PROTEIN", 181, 207], ["CD40", "PROTEIN", 273, 277], ["mouse bone marrow-derived DCs", "CELL_LINE", 328, 357], ["Ad\u2013CFm40L complex", "PROTEIN", 372, 389], ["maturation markers", "PROTEIN", 421, 439], ["CD11c", "PROTEIN", 441, 446], ["CD11c", "PROTEIN", 448, 453], ["CD54", "PROTEIN", 455, 459], ["CD40", "PROTEIN", 461, 465], ["CD80", "PROTEIN", 467, 471], ["CD86", "PROTEIN", 473, 477], ["anti-CD40 mAb", "PROTEIN", 583, 596], ["tAd-Luc (Ad5 expressing luciferase gene", "DNA", 637, 676], ["mouse", "SPECIES", 328, 333], ["mice", "SPECIES", 553, 557], ["mouse", "SPECIES", 328, 333], ["mice", "SPECIES", 553, 557], ["Ad5", "SPECIES", 646, 649], ["CFm", "TEST", 112, 115], ["the mouse bone marrow", "PROBLEM", 324, 345], ["elevated levels of maturation markers", "PROBLEM", 402, 439], ["CD11c", "TEST", 441, 446], ["CD11c", "TEST", 448, 453], ["CD54", "TEST", 455, 459], ["CD40", "TEST", 461, 465], ["CD80", "TEST", 467, 471], ["CD86", "TEST", 473, 477], ["I", "TEST", 482, 483], ["the biodistribution study", "TEST", 517, 542], ["anti-CD40 mAb", "TREATMENT", 583, 596], ["Ad5 expressing luciferase gene", "TREATMENT", 646, 676], ["bone marrow", "ANATOMY", 334, 345]]], ["To this end, Ad-Luc conjugated with CFm40L as described previously9 was used to transduce human CD40(+) DCs in the presence or absence of anti-CD40L.", [["DCs", "ANATOMY", 104, 107], ["Ad", "ORGANISM", 13, 15], ["Luc", "ORGANISM", 16, 19], ["human", "ORGANISM", 90, 95], ["CD40", "GENE_OR_GENE_PRODUCT", 96, 100], ["DCs", "CELL", 104, 107], ["anti-CD40L", "GENE_OR_GENE_PRODUCT", 138, 148], ["Luc", "PROTEIN", 16, 19], ["CFm40L", "DNA", 36, 42], ["CD40", "PROTEIN", 96, 100], ["DCs", "CELL_TYPE", 104, 107], ["anti-CD40L", "PROTEIN", 138, 148], ["human", "SPECIES", 90, 95], ["human", "SPECIES", 90, 95], ["CFm", "TREATMENT", 36, 39], ["anti-CD40L", "TREATMENT", 138, 148]]], ["As compared with the unmodified Ad, the relative luciferase activity for the CFm40L-complexed Ads is 1307-fold higher with the addition of 80 ng CFm40L, 1491-fold with 120 ng and 1799-fold with 200 ng (Figure 1a), respectively.", [["Ad", "ORGANISM", 32, 34], ["luciferase", "GENE_OR_GENE_PRODUCT", 49, 59], ["CFm40L", "GENE_OR_GENE_PRODUCT", 77, 83], ["Ads", "GENE_OR_GENE_PRODUCT", 94, 97], ["luciferase", "PROTEIN", 49, 59], ["CFm40L", "PROTEIN", 77, 83], ["the CFm40L", "TEST", 73, 83], ["luciferase activity", "OBSERVATION", 49, 68]]], ["Each reaction had four replicates.", [["Each reaction", "PROBLEM", 0, 13]]], ["Importantly, the addition of 0.5 and 2.0 \u03bcg of anti-CD40L mAb into the pre-complexed Ads largely prevented the enhanced luciferase activities, while pre-mixing with 2.0 \u03bcg of normal mouse immunoglobulin (Ig) G did not show any inhibition of luciferase activity.", [["anti-CD40L", "GENE_OR_GENE_PRODUCT", 47, 57], ["Ads", "GENE_OR_GENE_PRODUCT", 85, 88], ["luciferase", "GENE_OR_GENE_PRODUCT", 120, 130], ["mouse", "ORGANISM", 182, 187], ["immunoglobulin (Ig) G", "GENE_OR_GENE_PRODUCT", 188, 209], ["luciferase", "GENE_OR_GENE_PRODUCT", 241, 251], ["anti-CD40L mAb", "PROTEIN", 47, 61], ["luciferase", "PROTEIN", 120, 130], ["normal mouse immunoglobulin (Ig) G", "PROTEIN", 175, 209], ["luciferase", "PROTEIN", 241, 251], ["mouse", "SPECIES", 182, 187], ["mouse", "SPECIES", 182, 187], ["anti-CD40L mAb", "TREATMENT", 47, 61], ["normal mouse immunoglobulin (Ig)", "TREATMENT", 175, 207], ["any inhibition of luciferase activity", "PROBLEM", 223, 260], ["luciferase activities", "OBSERVATION", 120, 141], ["luciferase activity", "OBSERVATION", 241, 260]]], ["Also as a control, Ads pre-complexed with 120 ng of bovine serum albumin (BSA) did not result in enhancement of luciferase activity in the transduced cells.", [["serum", "ANATOMY", 59, 64], ["cells", "ANATOMY", 150, 155], ["Ads", "ORGANISM", 19, 22], ["bovine", "ORGANISM", 52, 58], ["serum", "ORGANISM_SUBSTANCE", 59, 64], ["albumin", "GENE_OR_GENE_PRODUCT", 65, 72], ["BSA", "SIMPLE_CHEMICAL", 74, 77], ["luciferase", "GENE_OR_GENE_PRODUCT", 112, 122], ["cells", "CELL", 150, 155], ["luciferase", "PROTEIN", 112, 122], ["transduced cells", "CELL_LINE", 139, 155], ["bovine", "SPECIES", 52, 58], ["bovine", "SPECIES", 52, 58], ["bovine serum albumin (BSA", "TEST", 52, 77], ["luciferase activity in the transduced cells", "PROBLEM", 112, 155], ["luciferase activity", "OBSERVATION", 112, 131], ["transduced cells", "OBSERVATION", 139, 155]]], ["These results further confirmed that the enhanced gene transduction into both human and murine DCs by Ads complexed with CFm40L is mediated by the CD40 receptor.", [["DCs", "ANATOMY", 95, 98], ["human", "ORGANISM", 78, 83], ["murine", "ORGANISM", 88, 94], ["DCs", "CELL", 95, 98], ["Ads", "GENE_OR_GENE_PRODUCT", 102, 105], ["CFm40L", "GENE_OR_GENE_PRODUCT", 121, 127], ["CD40 receptor", "GENE_OR_GENE_PRODUCT", 147, 160], ["human and murine DCs", "CELL_TYPE", 78, 98], ["CFm40L", "PROTEIN", 121, 127], ["CD40 receptor", "PROTEIN", 147, 160], ["human", "SPECIES", 78, 83], ["murine", "SPECIES", 88, 94], ["human", "SPECIES", 78, 83]]], ["We next determined whether tAd could still transduce DCs in the presence of Ad-neutralizing antibodies.", [["DCs", "ANATOMY", 53, 56], ["tAd", "GENE_OR_GENE_PRODUCT", 27, 30], ["DCs", "CELL", 53, 56], ["Ad", "ORGANISM", 76, 78], ["tAd", "PROTEIN", 27, 30], ["DCs", "CELL_TYPE", 53, 56], ["Ad-neutralizing antibodies", "PROTEIN", 76, 102], ["Ad", "SPECIES", 76, 78], ["Ad-neutralizing antibodies", "PROBLEM", 76, 102]]], ["Towards this end, we infected human peripheral blood-derived DCs with Ad\u2013CFm40L complexes in the presence of Ad-negative and Ad-positive ascites fluids collected from ovarian cancer patients from a phase I gene therapy clinical trial.", [["peripheral blood", "ANATOMY", 36, 52], ["DCs", "ANATOMY", 61, 64], ["ascites fluids", "ANATOMY", 137, 151], ["ovarian cancer", "ANATOMY", 167, 181], ["ascites", "DISEASE", 137, 144], ["ovarian cancer", "DISEASE", 167, 181], ["human", "ORGANISM", 30, 35], ["peripheral blood-derived DCs", "CELL", 36, 64], ["Ad\u2013CFm40L", "GENE_OR_GENE_PRODUCT", 70, 79], ["Ad-", "GENE_OR_GENE_PRODUCT", 109, 112], ["Ad", "ORGANISM", 125, 127], ["ovarian cancer", "CANCER", 167, 181], ["patients", "ORGANISM", 182, 190], ["human peripheral blood-derived DCs", "CELL_TYPE", 30, 64], ["Ad\u2013CFm40L complexes", "PROTEIN", 70, 89], ["human", "SPECIES", 30, 35], ["patients", "SPECIES", 182, 190], ["human", "SPECIES", 30, 35], ["Ad\u2013CFm40L complexes", "TREATMENT", 70, 89], ["Ad-", "TEST", 109, 112], ["Ad-positive ascites fluids", "PROBLEM", 125, 151], ["ovarian cancer", "PROBLEM", 167, 181], ["a phase I gene therapy", "TREATMENT", 196, 218], ["infected", "OBSERVATION", 21, 29], ["ascites", "OBSERVATION", 137, 144], ["ovarian", "ANATOMY", 167, 174], ["cancer", "OBSERVATION", 175, 181]]], ["The ascites M56 (patient \u2018M\u2019, day 56 after Ad administration) has been shown to have high (>1:16 000) Ad-neutralizing antibody titres, and the ascites B0 (patient \u2018B\u2019, day 0 of Ad administration) to have none.20 Furthermore, the ability of the ascites M56 to neutralize Ad infectivity and the lack of neutralizing capability by the ascites B0 was previously documented in the same studies.20 We again confirmed the absence of anti-Ad antibodies in ascites B0 and their presence in ascites M56 with the titre of 1:65 610 in Ad enzyme-linked immunosorbent assay (ELISA; Supplementary Figure S1).", [["ascites", "ANATOMY", 4, 11], ["ascites", "ANATOMY", 143, 150], ["ascites", "ANATOMY", 244, 251], ["ascites", "ANATOMY", 332, 339], ["ascites B0", "ANATOMY", 448, 458], ["ascites M56", "ANATOMY", 481, 492], ["ascites", "DISEASE", 4, 11], ["ascites", "DISEASE", 143, 150], ["ascites", "DISEASE", 244, 251], ["ascites", "DISEASE", 332, 339], ["ascites", "DISEASE", 448, 455], ["ascites", "DISEASE", 481, 488], ["1:65 610", "CHEMICAL", 511, 519], ["patient", "ORGANISM", 17, 24], ["Ad", "ORGANISM", 43, 45], ["patient", "ORGANISM", 155, 162], ["Ad", "ORGANISM", 177, 179], ["Ad", "ORGANISM", 270, 272], ["anti-Ad antibodies", "GENE_OR_GENE_PRODUCT", 426, 444], ["Ad", "ORGANISM", 523, 525], ["anti-Ad antibodies", "PROTEIN", 426, 444], ["patient", "SPECIES", 17, 24], ["patient", "SPECIES", 155, 162], ["The ascites", "PROBLEM", 0, 11], ["neutralizing antibody titres", "TEST", 105, 133], ["the ascites B0", "PROBLEM", 139, 153], ["Ad administration", "TREATMENT", 177, 194], ["the ascites", "PROBLEM", 240, 251], ["Ad infectivity", "PROBLEM", 270, 284], ["neutralizing capability", "PROBLEM", 301, 324], ["the ascites B0", "PROBLEM", 328, 342], ["anti-Ad antibodies in ascites B0", "PROBLEM", 426, 458], ["ascites", "PROBLEM", 481, 488], ["the titre", "TEST", 498, 507], ["Ad enzyme", "TEST", 523, 532], ["immunosorbent assay", "TEST", 540, 559], ["ELISA", "TEST", 561, 566], ["ascites", "OBSERVATION", 4, 11], ["ascites", "OBSERVATION", 143, 150], ["ascites", "OBSERVATION", 244, 251], ["ascites", "OBSERVATION", 332, 339], ["ascites", "OBSERVATION", 448, 455], ["ascites", "OBSERVATION", 481, 488]]], ["Then Ad vector-encoding luciferase was pre-complexed with CFm40L (50 ng per 1.25 \u00d7 106 PFU per 2.5 \u00d7 104 cells) mixed with the ascites at 1:1 and 1:1000 dilutions and applied to DCs.", [["cells", "ANATOMY", 105, 110], ["ascites", "ANATOMY", 127, 134], ["DCs", "ANATOMY", 178, 181], ["ascites", "DISEASE", 127, 134], ["Ad", "ORGANISM", 5, 7], ["luciferase", "GENE_OR_GENE_PRODUCT", 24, 34], ["cells", "CELL", 105, 110], ["DCs", "CELL", 178, 181], ["Ad vector", "DNA", 5, 14], ["luciferase", "PROTEIN", 24, 34], ["DCs", "CELL_TYPE", 178, 181], ["encoding luciferase", "PROBLEM", 15, 34], ["CFm", "TREATMENT", 58, 61], ["the ascites", "PROBLEM", 123, 134], ["ascites", "OBSERVATION", 127, 134]]], ["Luciferase activity was measured in cell lysates 36 h post transduction.", [["cell lysates", "ANATOMY", 36, 48], ["cell lysates", "CELL", 36, 48], ["Luciferase activity", "PROBLEM", 0, 19]]], ["The results (Figure 1b) indicate that neutralizing antibodies had no inhibitory effects on CFm40L mediated Ad-Luc transduction of human DCs.CFm40L directs more rapid capturing of the vector by the liver, thymus and lung following i.v. administration ::: ResultsThe tAds encoding firefly luciferase reporter gene (tAd-Luc) were then injected into Balb/c mice intravenous (i.v.) for the analysis of tissue distribution.", [["DCs", "ANATOMY", 136, 139], ["liver", "ANATOMY", 197, 202], ["thymus", "ANATOMY", 204, 210], ["lung", "ANATOMY", 215, 219], ["intravenous", "ANATOMY", 358, 369], ["tissue", "ANATOMY", 397, 403], ["CFm40L", "CHEMICAL", 140, 146], ["CFm40L", "GENE_OR_GENE_PRODUCT", 91, 97], ["Ad", "ORGANISM", 107, 109], ["Luc", "GENE_OR_GENE_PRODUCT", 110, 113], ["human", "ORGANISM", 130, 135], ["DCs", "CELL", 136, 139], ["CFm40L", "GENE_OR_GENE_PRODUCT", 140, 146], ["liver", "ORGAN", 197, 202], ["thymus", "ORGAN", 204, 210], ["lung", "ORGAN", 215, 219], ["tAds", "GENE_OR_GENE_PRODUCT", 265, 269], ["luciferase", "GENE_OR_GENE_PRODUCT", 287, 297], ["tAd-Luc", "GENE_OR_GENE_PRODUCT", 313, 320], ["Balb/c mice", "ORGANISM", 346, 357], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 358, 369], ["tissue", "TISSUE", 397, 403], ["neutralizing antibodies", "PROTEIN", 38, 61], ["human DCs", "CELL_TYPE", 130, 139], ["CFm40L", "PROTEIN", 140, 146], ["tAds", "DNA", 265, 269], ["firefly luciferase reporter gene", "DNA", 279, 311], ["tAd", "DNA", 313, 316], ["Luc", "DNA", 317, 320], ["human", "SPECIES", 130, 135], ["mice", "SPECIES", 353, 357], ["human", "SPECIES", 130, 135], ["mice", "SPECIES", 353, 357], ["neutralizing antibodies", "TEST", 38, 61], ["inhibitory effects", "PROBLEM", 69, 87], ["CFm", "TEST", 91, 94], ["human DCs", "TREATMENT", 130, 139], ["CFm", "TEST", 140, 143], ["The tAds encoding firefly luciferase reporter gene (tAd-Luc", "TREATMENT", 261, 320], ["Balb/c mice intravenous", "TREATMENT", 346, 369], ["the analysis", "TEST", 381, 393], ["more", "OBSERVATION_MODIFIER", 155, 159], ["rapid", "OBSERVATION_MODIFIER", 160, 165], ["capturing", "OBSERVATION", 166, 175], ["vector", "ANATOMY_MODIFIER", 183, 189], ["liver", "ANATOMY", 197, 202], ["thymus", "ANATOMY", 204, 210], ["lung", "ANATOMY", 215, 219], ["tissue", "OBSERVATION", 397, 403]]], ["A total of 1 \u00d7 1010 VP (viral particle) of Ad was chosen for Ad and tAd since excess amount of Ad (>1\u20132 \u00d7 1010) could saturate tissue macrophages in mice following systemic administration, resulting in non-receptor-mediated process.21 For tAd preparation, 1 \u00d7 109 PFU (\u223c1 \u00d7 1010 VP) of Ads were complexed with 16 \u03bcg of CFm40L, equivalent to 80 ng of CFm40L for 5 \u00d7 106 PFU of Ad.", [["tissue macrophages", "ANATOMY", 127, 145], ["Ad", "ORGANISM", 43, 45], ["Ad", "ORGANISM", 61, 63], ["Ad", "ORGANISM", 95, 97], ["tissue macrophages", "CELL", 127, 145], ["mice", "ORGANISM", 149, 153], ["non-receptor", "GENE_OR_GENE_PRODUCT", 202, 214], ["Ads", "ORGANISM", 286, 289], ["tissue macrophages", "CELL_TYPE", 127, 145], ["non-receptor", "PROTEIN", 202, 214], ["mice", "SPECIES", 149, 153], ["Ad", "SPECIES", 43, 45], ["mice", "SPECIES", 149, 153], ["Ad.", "SPECIES", 376, 379], ["VP (viral particle)", "TREATMENT", 20, 39], ["Ad", "PROBLEM", 61, 63], ["systemic administration", "TREATMENT", 164, 187], ["non-receptor-mediated process", "PROBLEM", 202, 231], ["VP", "TEST", 279, 281], ["Ads", "TEST", 286, 289]]], ["We chose this ratio between Ad and CFm40L since 80 ng of CFm40L is sufficient to complex 2.5 \u00d7 106 Ad for enhanced transduction in vitro (Figure 1a).", [["CFm40L", "CHEMICAL", 57, 63], ["Ad", "ORGANISM", 28, 30], ["Ad", "ORGANISM", 99, 101]]], ["In agreement with other reports with i.v. administration,14, 22, 23, 24, 25 the Ad was detected after 3 and 7 days in a wide range of tissues, with the liver and spleen expressing the highest luciferase activities on day 3, followed by mesenteric lymph nodes (a visible cluster of lymph nodes inside the peritoneal cavity), heart, colon and others (Figure 2a).", [["tissues", "ANATOMY", 134, 141], ["liver", "ANATOMY", 152, 157], ["spleen", "ANATOMY", 162, 168], ["mesenteric lymph nodes", "ANATOMY", 236, 258], ["lymph nodes", "ANATOMY", 281, 292], ["peritoneal cavity", "ANATOMY", 304, 321], ["heart", "ANATOMY", 324, 329], ["colon", "ANATOMY", 331, 336], ["Ad", "ORGANISM", 80, 82], ["tissues", "TISSUE", 134, 141], ["liver", "ORGAN", 152, 157], ["spleen", "ORGAN", 162, 168], ["luciferase", "GENE_OR_GENE_PRODUCT", 192, 202], ["mesenteric lymph nodes", "MULTI-TISSUE_STRUCTURE", 236, 258], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 281, 292], ["peritoneal cavity", "MULTI-TISSUE_STRUCTURE", 304, 321], ["heart", "ORGAN", 324, 329], ["colon", "ORGAN", 331, 336], ["luciferase", "PROTEIN", 192, 202], ["mesenteric lymph nodes", "PROBLEM", 236, 258], ["a visible cluster of lymph nodes", "PROBLEM", 260, 292], ["liver", "ANATOMY", 152, 157], ["spleen", "ANATOMY", 162, 168], ["highest", "OBSERVATION_MODIFIER", 184, 191], ["luciferase activities", "OBSERVATION", 192, 213], ["mesenteric", "ANATOMY", 236, 246], ["lymph nodes", "OBSERVATION", 247, 258], ["lymph nodes", "OBSERVATION", 281, 292], ["peritoneal cavity", "ANATOMY", 304, 321], ["heart", "ANATOMY", 324, 329], ["colon", "ANATOMY", 331, 336]]], ["Yet, a noticeably altered biodistribution was observed with tAd-Luc (Figure 2b), that is in addition to the predominant disposition to the liver and spleen, the viruses were also effectively captured by thymus and the lung on day 3 (Figure 2b).Localized expression of transgenes following i.d. administration ::: ResultsFollowing intradermal (i.d.) administration, high levels of luciferase expression were detected in the skin surrounding the injection site and in the local draining lymph nodes (inguinal) for both Ad-Luc and tAd-Luc and, as expected, the luciferase activity with tAd-Luc administration was significantly lower than that with Ad-Luc (\u223c300 times lower) since tAd-Luc could only get into CD40(+) cells and express the luciferase gene (Figures 3a and b), consistent with results shown in Figure 1a.", [["liver", "ANATOMY", 139, 144], ["spleen", "ANATOMY", 149, 155], ["thymus", "ANATOMY", 203, 209], ["lung", "ANATOMY", 218, 222], ["skin", "ANATOMY", 423, 427], ["site", "ANATOMY", 454, 458], ["lymph nodes", "ANATOMY", 485, 496], ["inguinal", "ANATOMY", 498, 506], ["CD40(+) cells", "ANATOMY", 705, 718], ["tAd-Luc", "CHEMICAL", 583, 590], ["tAd-Luc", "GENE_OR_GENE_PRODUCT", 60, 67], ["Figure 2b", "GENE_OR_GENE_PRODUCT", 69, 78], ["liver", "ORGAN", 139, 144], ["spleen", "ORGAN", 149, 155], ["thymus", "ORGAN", 203, 209], ["lung", "ORGAN", 218, 222], ["intradermal", "IMMATERIAL_ANATOMICAL_ENTITY", 330, 341], ["luciferase", "GENE_OR_GENE_PRODUCT", 380, 390], ["skin", "ORGAN", 423, 427], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 485, 496], ["inguinal", "ORGAN", 498, 506], ["Ad", "ORGANISM", 517, 519], ["Luc", "GENE_OR_GENE_PRODUCT", 520, 523], ["tAd-Luc", "GENE_OR_GENE_PRODUCT", 528, 535], ["luciferase", "GENE_OR_GENE_PRODUCT", 558, 568], ["tAd-Luc", "GENE_OR_GENE_PRODUCT", 583, 590], ["Ad-Luc", "GENE_OR_GENE_PRODUCT", 645, 651], ["tAd-Luc", "GENE_OR_GENE_PRODUCT", 677, 684], ["CD40", "GENE_OR_GENE_PRODUCT", 705, 709], ["luciferase", "GENE_OR_GENE_PRODUCT", 735, 745], ["Figures 3a", "GENE_OR_GENE_PRODUCT", 752, 762], ["b", "GENE_OR_GENE_PRODUCT", 767, 768], ["tAd", "PROTEIN", 60, 63], ["Luc", "PROTEIN", 64, 67], ["luciferase", "PROTEIN", 380, 390], ["Ad-Luc and tAd-Luc", "DNA", 517, 535], ["luciferase", "PROTEIN", 558, 568], ["tAd", "PROTEIN", 583, 586], ["Luc", "PROTEIN", 587, 590], ["tAd", "PROTEIN", 677, 680], ["Luc", "PROTEIN", 681, 684], ["CD40(+) cells", "CELL_LINE", 705, 718], ["luciferase gene", "DNA", 735, 750], ["a noticeably altered biodistribution", "PROBLEM", 5, 41], ["tAd", "TEST", 60, 63], ["the viruses", "PROBLEM", 157, 168], ["intradermal (i.d.) administration", "TREATMENT", 330, 363], ["high levels of luciferase expression", "PROBLEM", 365, 401], ["tAd-Luc administration", "TREATMENT", 583, 605], ["noticeably", "OBSERVATION_MODIFIER", 7, 17], ["altered", "OBSERVATION_MODIFIER", 18, 25], ["biodistribution", "OBSERVATION", 26, 41], ["liver", "ANATOMY", 139, 144], ["spleen", "ANATOMY", 149, 155], ["viruses", "OBSERVATION", 161, 168], ["thymus", "ANATOMY", 203, 209], ["lung", "ANATOMY", 218, 222], ["luciferase expression", "OBSERVATION", 380, 401], ["skin", "ANATOMY", 423, 427], ["local", "OBSERVATION_MODIFIER", 470, 475], ["draining", "OBSERVATION_MODIFIER", 476, 484], ["lymph nodes", "OBSERVATION", 485, 496], ["inguinal", "ANATOMY", 498, 506]]], ["Clearly, no virus was detected in other organs and tissues, suggesting the viruses were processed near the injection site sites and local draining lymph nodes, with little spillover of the virus into the circulation.CF40mL prevented inadvertent infection of the brain and attenuated local inflammatory reaction in the lung following i.n. administration ::: ResultsFollowing intranasal (i.n.) delivery of Ad-Luc, there was gene transfer with the Ad in various organs/tissues with the i.n. injection (Figure 4a).", [["organs", "ANATOMY", 40, 46], ["tissues", "ANATOMY", 51, 58], ["injection site sites", "ANATOMY", 107, 127], ["lymph nodes", "ANATOMY", 147, 158], ["brain", "ANATOMY", 262, 267], ["lung", "ANATOMY", 318, 322], ["organs", "ANATOMY", 459, 465], ["tissues", "ANATOMY", 466, 473], ["CF40mL", "CHEMICAL", 216, 222], ["infection of the brain", "DISEASE", 245, 267], ["organs", "ORGAN", 40, 46], ["tissues", "TISSUE", 51, 58], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 147, 158], ["CF40mL", "SIMPLE_CHEMICAL", 216, 222], ["brain", "ORGAN", 262, 267], ["lung", "ORGAN", 318, 322], ["Ad", "ORGANISM", 404, 406], ["Luc", "GENE_OR_GENE_PRODUCT", 407, 410], ["Ad", "ORGANISM", 445, 447], ["organs", "ORGAN", 459, 465], ["tissues", "TISSUE", 466, 473], ["injection site sites", "DNA", 107, 127], ["virus", "PROBLEM", 12, 17], ["the viruses", "PROBLEM", 71, 82], ["local draining lymph nodes", "PROBLEM", 132, 158], ["little spillover of the virus into the circulation", "PROBLEM", 165, 215], ["inadvertent infection of the brain", "PROBLEM", 233, 267], ["attenuated local inflammatory reaction", "PROBLEM", 272, 310], ["no", "UNCERTAINTY", 9, 11], ["virus", "OBSERVATION", 12, 17], ["organs", "ANATOMY", 40, 46], ["tissues", "ANATOMY", 51, 58], ["viruses", "OBSERVATION", 75, 82], ["local", "OBSERVATION_MODIFIER", 132, 137], ["draining", "OBSERVATION_MODIFIER", 138, 146], ["lymph nodes", "OBSERVATION", 147, 158], ["virus", "OBSERVATION", 189, 194], ["circulation", "ANATOMY", 204, 215], ["inadvertent", "OBSERVATION_MODIFIER", 233, 244], ["infection", "OBSERVATION", 245, 254], ["brain", "ANATOMY", 262, 267], ["attenuated", "OBSERVATION_MODIFIER", 272, 282], ["local", "OBSERVATION_MODIFIER", 283, 288], ["inflammatory", "OBSERVATION", 289, 301], ["lung", "ANATOMY", 318, 322]]], ["It is of note that the expression level of luciferase in the brain is high following Ad-Luc administration (Figure 4a), only second to the one detected in the lung.", [["brain", "ANATOMY", 61, 66], ["lung", "ANATOMY", 159, 163], ["Ad-Luc", "CHEMICAL", 85, 91], ["luciferase", "GENE_OR_GENE_PRODUCT", 43, 53], ["brain", "ORGAN", 61, 66], ["Ad", "ORGANISM", 85, 87], ["Luc", "GENE_OR_GENE_PRODUCT", 88, 91], ["lung", "ORGAN", 159, 163], ["luciferase", "PROTEIN", 43, 53], ["Ad-Luc administration", "TREATMENT", 85, 106], ["brain", "ANATOMY", 61, 66], ["high", "OBSERVATION_MODIFIER", 70, 74], ["lung", "ANATOMY", 159, 163]]], ["Clearly, the infection of the brain was largely ablated with the use of tAd-Luc, but not the infection of other tissues such as lung, heart, thymus, colon, muscle and mesenteric lymph nodes (Figures 4a and b), suggesting CAR-mediated inadvertent infection of the brain by non-modified Ad.", [["brain", "ANATOMY", 30, 35], ["tissues", "ANATOMY", 112, 119], ["lung", "ANATOMY", 128, 132], ["heart", "ANATOMY", 134, 139], ["thymus", "ANATOMY", 141, 147], ["colon", "ANATOMY", 149, 154], ["muscle", "ANATOMY", 156, 162], ["mesenteric lymph nodes", "ANATOMY", 167, 189], ["brain", "ANATOMY", 263, 268], ["infection", "DISEASE", 13, 22], ["infection", "DISEASE", 93, 102], ["infection of the brain", "DISEASE", 246, 268], ["brain", "ORGAN", 30, 35], ["tAd-Luc", "GENE_OR_GENE_PRODUCT", 72, 79], ["tissues", "TISSUE", 112, 119], ["lung", "ORGAN", 128, 132], ["heart", "ORGAN", 134, 139], ["thymus", "ORGAN", 141, 147], ["colon", "ORGAN", 149, 154], ["muscle", "ORGAN", 156, 162], ["mesenteric lymph nodes", "MULTI-TISSUE_STRUCTURE", 167, 189], ["CAR", "GENE_OR_GENE_PRODUCT", 221, 224], ["brain", "ORGAN", 263, 268], ["tAd", "PROTEIN", 72, 75], ["Luc", "PROTEIN", 76, 79], ["CAR", "PROTEIN", 221, 224], ["the infection of the brain", "PROBLEM", 9, 35], ["tAd-Luc", "TREATMENT", 72, 79], ["the infection of other tissues such as lung, heart, thymus, colon, muscle and mesenteric lymph nodes", "PROBLEM", 89, 189], ["CAR-mediated inadvertent infection of the brain", "PROBLEM", 221, 268], ["infection", "OBSERVATION", 13, 22], ["brain", "ANATOMY", 30, 35], ["ablated", "OBSERVATION", 48, 55], ["infection", "OBSERVATION", 93, 102], ["lung", "ANATOMY", 128, 132], ["heart", "ANATOMY", 134, 139], ["thymus", "ANATOMY", 141, 147], ["colon", "ANATOMY", 149, 154], ["muscle", "ANATOMY", 156, 162], ["mesenteric", "ANATOMY", 167, 177], ["lymph nodes", "OBSERVATION", 178, 189], ["inadvertent", "OBSERVATION_MODIFIER", 234, 245], ["infection", "OBSERVATION", 246, 255], ["brain", "ANATOMY", 263, 268]]], ["This interpretation is further supported by the observation that pre-complex of Ad-Luc with BSA did not prevent brain infection (Figure 4c).", [["brain", "ANATOMY", 112, 117], ["brain infection", "DISEASE", 112, 127], ["Ad", "ORGANISM", 80, 82], ["Luc", "GENE_OR_GENE_PRODUCT", 83, 86], ["BSA", "GENE_OR_GENE_PRODUCT", 92, 95], ["brain", "ORGAN", 112, 117], ["brain infection", "PROBLEM", 112, 127], ["brain", "ANATOMY", 112, 117], ["infection", "OBSERVATION", 118, 127]]], ["Interestingly, no significant difference of virus deposition between tAd-Luc and Ad-Luc in the heart was observed following i.n. administration (Figures 4a and b), an observation that differs from that following i.v. injection, which shows the heart took up more Ad-Luc than tAd-Luc following i.v. administration (Figure 2).", [["heart", "ANATOMY", 95, 100], ["heart", "ANATOMY", 244, 249], ["tAd-Luc", "GENE_OR_GENE_PRODUCT", 69, 76], ["Ad-Luc", "GENE_OR_GENE_PRODUCT", 81, 87], ["heart", "ORGAN", 95, 100], ["i.v.", "SIMPLE_CHEMICAL", 212, 216], ["heart", "ORGAN", 244, 249], ["Ad", "ORGANISM", 263, 265], ["Luc", "GENE_OR_GENE_PRODUCT", 266, 269], ["tAd-Luc", "GENE_OR_GENE_PRODUCT", 275, 282], ["i.v.", "IMMATERIAL_ANATOMICAL_ENTITY", 293, 297], ["tAd-Luc and Ad-Luc", "DNA", 69, 87], ["tAd", "PROTEIN", 275, 278], ["Luc", "PROTEIN", 279, 282], ["virus deposition", "PROBLEM", 44, 60], ["no", "UNCERTAINTY", 15, 17], ["significant", "OBSERVATION_MODIFIER", 18, 29], ["difference", "OBSERVATION_MODIFIER", 30, 40], ["virus", "OBSERVATION", 44, 49], ["heart", "ANATOMY", 95, 100], ["heart", "ANATOMY", 244, 249]]], ["We have no definite explanation for these findings.", [["no definite explanation for", "UNCERTAINTY", 8, 35]]], ["It is plausible, however, that since the heart is in close proximity of the lung, tAd-Luc could gain access more easily to the heart following i.n. delivery than with the i.v. route (tail vein).CF40mL prevented inadvertent infection of the brain and attenuated local inflammatory reaction in the lung following i.n. administration ::: ResultsThe high level of luciferase activity in the lung following i.n. administration prompted us to conduct histological examination of the lung.", [["heart", "ANATOMY", 41, 46], ["lung", "ANATOMY", 76, 80], ["heart", "ANATOMY", 127, 132], ["tail vein", "ANATOMY", 183, 192], ["brain", "ANATOMY", 240, 245], ["lung", "ANATOMY", 296, 300], ["lung", "ANATOMY", 387, 391], ["lung", "ANATOMY", 477, 481], ["CF40mL", "CHEMICAL", 194, 200], ["infection of the brain", "DISEASE", 223, 245], ["heart", "ORGAN", 41, 46], ["lung", "ORGAN", 76, 80], ["tAd-Luc", "GENE_OR_GENE_PRODUCT", 82, 89], ["heart", "ORGAN", 127, 132], ["tail vein", "MULTI-TISSUE_STRUCTURE", 183, 192], ["CF40mL", "SIMPLE_CHEMICAL", 194, 200], ["brain", "ORGAN", 240, 245], ["lung", "ORGAN", 296, 300], ["luciferase", "GENE_OR_GENE_PRODUCT", 360, 370], ["lung", "ORGAN", 387, 391], ["lung", "ORGAN", 477, 481], ["tAd", "PROTEIN", 82, 85], ["Luc", "PROTEIN", 86, 89], ["luciferase", "PROTEIN", 360, 370], ["the i.v. route (tail vein", "TREATMENT", 167, 192], ["inadvertent infection of the brain", "PROBLEM", 211, 245], ["attenuated local inflammatory reaction", "PROBLEM", 250, 288], ["histological examination", "TEST", 445, 469], ["heart", "ANATOMY", 41, 46], ["lung", "ANATOMY", 76, 80], ["heart", "ANATOMY", 127, 132], ["tail vein", "ANATOMY", 183, 192], ["inadvertent", "OBSERVATION_MODIFIER", 211, 222], ["infection", "OBSERVATION", 223, 232], ["brain", "ANATOMY", 240, 245], ["attenuated", "OBSERVATION_MODIFIER", 250, 260], ["local", "OBSERVATION_MODIFIER", 261, 266], ["inflammatory", "OBSERVATION", 267, 279], ["lung", "ANATOMY", 296, 300], ["high", "OBSERVATION_MODIFIER", 346, 350], ["luciferase activity", "OBSERVATION", 360, 379], ["lung", "ANATOMY", 387, 391], ["lung", "ANATOMY", 477, 481]]], ["As compared to the control mice injected with buffers only (Figure 5, panel a), i.n. delivery of Ad-Luc resulted in moderate accumulations of mononuclear leukocytes in many peribronchial and perivascular areas, typical of inflammatory reactions (Figure 5, panel b).", [["mononuclear leukocytes", "ANATOMY", 142, 164], ["peribronchial", "ANATOMY", 173, 186], ["perivascular areas", "ANATOMY", 191, 209], ["Ad-Luc", "CHEMICAL", 97, 103], ["mice", "ORGANISM", 27, 31], ["Ad", "ORGANISM", 97, 99], ["Luc", "GENE_OR_GENE_PRODUCT", 100, 103], ["mononuclear leukocytes", "CELL", 142, 164], ["peribronchial", "TISSUE", 173, 186], ["perivascular areas", "TISSUE", 191, 209], ["Luc", "PROTEIN", 100, 103], ["mononuclear leukocytes", "CELL_TYPE", 142, 164], ["mice", "SPECIES", 27, 31], ["mice", "SPECIES", 27, 31], ["buffers", "TREATMENT", 46, 53], ["moderate accumulations of mononuclear leukocytes in many peribronchial and perivascular areas", "PROBLEM", 116, 209], ["inflammatory reactions", "PROBLEM", 222, 244], ["moderate", "OBSERVATION_MODIFIER", 116, 124], ["accumulations", "OBSERVATION_MODIFIER", 125, 138], ["mononuclear leukocytes", "OBSERVATION", 142, 164], ["many", "OBSERVATION_MODIFIER", 168, 172], ["peribronchial", "ANATOMY", 173, 186], ["perivascular", "ANATOMY_MODIFIER", 191, 203], ["inflammatory", "OBSERVATION_MODIFIER", 222, 234]]], ["Following the i.n. administration of Ad-NP expressing the nucleocapsid protein (NP) of SARS-CoV (SARS-CoV NP was used here as a model antigen), however, there are much more significant accumulations of mononuclear leukocytes in the peribronchial and perivascular areas throughout the entire histological section and infiltration of mononuclear cells in the alveolar spaces (Figure 5, panel c).", [["mononuclear leukocytes", "ANATOMY", 202, 224], ["peribronchial", "ANATOMY", 232, 245], ["perivascular areas", "ANATOMY", 250, 268], ["mononuclear cells", "ANATOMY", 332, 349], ["alveolar spaces", "ANATOMY", 357, 372], ["Ad-NP", "CHEMICAL", 37, 42], ["Ad-NP", "ORGANISM", 37, 42], ["nucleocapsid protein", "GENE_OR_GENE_PRODUCT", 58, 78], ["SARS-CoV", "ORGANISM", 87, 95], ["SARS-CoV NP", "ORGANISM", 97, 108], ["mononuclear leukocytes", "CELL", 202, 224], ["peribronchial", "TISSUE", 232, 245], ["perivascular areas", "IMMATERIAL_ANATOMICAL_ENTITY", 250, 268], ["mononuclear cells", "CELL", 332, 349], ["alveolar spaces", "MULTI-TISSUE_STRUCTURE", 357, 372], ["nucleocapsid protein", "PROTEIN", 58, 78], ["NP", "PROTEIN", 80, 82], ["mononuclear leukocytes", "CELL_TYPE", 202, 224], ["mononuclear cells", "CELL_TYPE", 332, 349], ["SARS-CoV", "SPECIES", 87, 95], ["SARS-CoV", "SPECIES", 97, 105], ["Ad-NP", "TREATMENT", 37, 42], ["SARS", "PROBLEM", 87, 91], ["CoV (SARS-CoV NP", "TREATMENT", 92, 108], ["mononuclear leukocytes in the peribronchial and perivascular areas", "PROBLEM", 202, 268], ["infiltration of mononuclear cells in the alveolar spaces", "PROBLEM", 316, 372], ["significant", "OBSERVATION_MODIFIER", 173, 184], ["accumulations", "OBSERVATION_MODIFIER", 185, 198], ["mononuclear leukocytes", "OBSERVATION", 202, 224], ["peribronchial", "ANATOMY", 232, 245], ["perivascular", "ANATOMY_MODIFIER", 250, 262], ["areas", "ANATOMY_MODIFIER", 263, 268], ["entire", "OBSERVATION_MODIFIER", 284, 290], ["histological section", "OBSERVATION", 291, 311], ["infiltration", "OBSERVATION_MODIFIER", 316, 328], ["mononuclear cells", "OBSERVATION", 332, 349], ["alveolar", "ANATOMY_MODIFIER", 357, 365]]], ["In the severely affected area, the airway epithelial cells demonstrate mild-to-moderate damage and sloughing, revealing an \u2018exaggerated\u2019 inflammatory reaction in the lung (Figure 5, panels c and e).", [["area", "ANATOMY", 25, 29], ["airway epithelial cells", "ANATOMY", 35, 58], ["lung", "ANATOMY", 166, 170], ["airway epithelial cells", "CELL", 35, 58], ["lung", "ORGAN", 166, 170], ["airway epithelial cells", "CELL_TYPE", 35, 58], ["the airway epithelial cells", "TEST", 31, 58], ["mild-to-moderate damage", "PROBLEM", 71, 94], ["sloughing", "PROBLEM", 99, 108], ["an \u2018exaggerated\u2019 inflammatory reaction in the lung", "PROBLEM", 120, 170], ["severely", "OBSERVATION_MODIFIER", 7, 15], ["affected", "OBSERVATION_MODIFIER", 16, 24], ["airway", "ANATOMY", 35, 41], ["epithelial cells", "OBSERVATION", 42, 58], ["mild", "OBSERVATION_MODIFIER", 71, 75], ["to-moderate", "OBSERVATION_MODIFIER", 76, 87], ["damage", "OBSERVATION", 88, 94], ["sloughing", "OBSERVATION", 99, 108], ["exaggerated", "OBSERVATION_MODIFIER", 124, 135], ["\u2019", "OBSERVATION_MODIFIER", 135, 136], ["inflammatory", "OBSERVATION_MODIFIER", 137, 149], ["reaction", "OBSERVATION", 150, 158], ["lung", "ANATOMY", 166, 170]]], ["The reason for the visible damage to the airway epithelial cell layers by Ad-NP but not by Ad-Luc could be due to the intrinsic property of NP, a strong immunogen in severe acute respiratory syndrome (SARS) patients, as was suggested (see below for discussion).", [["airway epithelial cell layers", "ANATOMY", 41, 70], ["acute respiratory syndrome", "DISEASE", 173, 199], ["SARS", "DISEASE", 201, 205], ["airway epithelial cell layers", "TISSUE", 41, 70], ["Ad-NP", "GENE_OR_GENE_PRODUCT", 74, 79], ["Ad", "ORGANISM", 91, 93], ["Luc", "GENE_OR_GENE_PRODUCT", 94, 97], ["patients", "ORGANISM", 207, 215], ["Luc", "PROTEIN", 94, 97], ["patients", "SPECIES", 207, 215], ["the visible damage to the airway epithelial cell layers", "PROBLEM", 15, 70], ["severe acute respiratory syndrome", "PROBLEM", 166, 199], ["airway", "ANATOMY", 41, 47], ["epithelial cell", "OBSERVATION", 48, 63], ["NP", "OBSERVATION", 140, 142], ["severe", "OBSERVATION_MODIFIER", 166, 172], ["acute", "OBSERVATION_MODIFIER", 173, 178], ["respiratory syndrome", "OBSERVATION", 179, 199]]], ["It is of note that with the addition of CFm40L (denoted as tAd-NP), the excessive infiltration of inflammatory cells and the damage of epithelial cells were abolished (Figure 5, panel d).", [["inflammatory cells", "ANATOMY", 98, 116], ["epithelial cells", "ANATOMY", 135, 151], ["CFm40L", "CHEMICAL", 40, 46], ["tAd-NP", "GENE_OR_GENE_PRODUCT", 59, 65], ["cells", "CELL", 111, 116], ["epithelial cells", "CELL", 135, 151], ["inflammatory cells", "CELL_TYPE", 98, 116], ["epithelial cells", "CELL_TYPE", 135, 151], ["CFm", "TREATMENT", 40, 43], ["tAd-NP", "TREATMENT", 59, 65], ["the excessive infiltration of inflammatory cells", "PROBLEM", 68, 116], ["the damage of epithelial cells", "PROBLEM", 121, 151], ["excessive", "OBSERVATION_MODIFIER", 72, 81], ["infiltration", "OBSERVATION", 82, 94], ["inflammatory cells", "OBSERVATION", 98, 116], ["epithelial cells", "OBSERVATION", 135, 151]]], ["Taken together, a significantly altered pattern of biodistribution of Ad complexed with CFm40L was observed following i.v. and i.n. administrations.", [["CFm40L", "CHEMICAL", 88, 94], ["Ad", "ORGANISM", 70, 72], ["CFm40L", "GENE_OR_GENE_PRODUCT", 88, 94], ["CFm", "TREATMENT", 88, 91], ["biodistribution", "OBSERVATION_MODIFIER", 51, 66]]], ["Attenuation of inadvertent infection of the brain and aggravated local inflammation has been demonstrated in the airway of the lung following i.n. administration.", [["brain", "ANATOMY", 44, 49], ["airway", "ANATOMY", 113, 119], ["lung", "ANATOMY", 127, 131], ["infection of the brain", "DISEASE", 27, 49], ["inflammation", "DISEASE", 71, 83], ["brain", "ORGAN", 44, 49], ["airway", "MULTI-TISSUE_STRUCTURE", 113, 119], ["lung", "ORGAN", 127, 131], ["inadvertent infection of the brain", "PROBLEM", 15, 49], ["aggravated local inflammation", "PROBLEM", 54, 83], ["inadvertent", "OBSERVATION_MODIFIER", 15, 26], ["infection", "OBSERVATION", 27, 36], ["brain", "ANATOMY", 44, 49], ["aggravated", "OBSERVATION_MODIFIER", 54, 64], ["local", "OBSERVATION_MODIFIER", 65, 70], ["inflammation", "OBSERVATION", 71, 83], ["airway", "ANATOMY", 113, 119], ["lung", "ANATOMY", 127, 131]]], ["Finally, none of the Ad preparations (unconjugated or conjugated, irrespective of administration route) resulted in detectable signs of systematic toxicity following analyses of various blood biomarkers (blood chemistry) pertinent to vital organs such as kidney, heart and liver (data not shown), even though visible damages to the airway epithelial cells were found following i.n. administration of Ad-NP.", [["blood", "ANATOMY", 186, 191], ["blood", "ANATOMY", 204, 209], ["organs", "ANATOMY", 240, 246], ["kidney", "ANATOMY", 255, 261], ["heart", "ANATOMY", 263, 268], ["liver", "ANATOMY", 273, 278], ["airway epithelial cells", "ANATOMY", 332, 355], ["toxicity", "DISEASE", 147, 155], ["Ad-NP.", "CHEMICAL", 400, 406], ["Ad", "ORGANISM", 21, 23], ["unconjugated", "SIMPLE_CHEMICAL", 38, 50], ["blood", "ORGANISM_SUBSTANCE", 186, 191], ["blood", "ORGANISM_SUBSTANCE", 204, 209], ["organs", "ORGAN", 240, 246], ["kidney", "ORGAN", 255, 261], ["heart", "ORGAN", 263, 268], ["liver", "ORGAN", 273, 278], ["airway epithelial cells", "CELL", 332, 355], ["Ad", "ORGANISM", 400, 402], ["airway epithelial cells", "CELL_TYPE", 332, 355], ["administration route", "TREATMENT", 82, 102], ["systematic toxicity", "PROBLEM", 136, 155], ["various blood biomarkers", "TEST", 178, 202], ["blood chemistry", "TEST", 204, 219], ["kidney, heart and liver", "TEST", 255, 278], ["visible damages to the airway epithelial cells", "PROBLEM", 309, 355], ["kidney", "ANATOMY", 255, 261], ["heart", "ANATOMY", 263, 268], ["liver", "ANATOMY", 273, 278], ["airway", "ANATOMY", 332, 338], ["epithelial cells", "OBSERVATION", 339, 355]]], ["We also conducted immunohistological examinations of available lung tissues using antibodies against both luciferase and CD11c, one of the surface markers for DCs.", [["lung tissues", "ANATOMY", 63, 75], ["surface", "ANATOMY", 139, 146], ["DCs", "ANATOMY", 159, 162], ["lung tissues", "TISSUE", 63, 75], ["luciferase", "GENE_OR_GENE_PRODUCT", 106, 116], ["CD11c", "GENE_OR_GENE_PRODUCT", 121, 126], ["DCs", "CELL", 159, 162], ["luciferase", "PROTEIN", 106, 116], ["CD11c", "PROTEIN", 121, 126], ["DCs", "CELL_TYPE", 159, 162], ["immunohistological examinations", "TEST", 18, 49], ["antibodies", "TREATMENT", 82, 92], ["DCs", "PROBLEM", 159, 162], ["lung", "ANATOMY", 63, 67]]], ["Preliminary results suggest that the tAd-Luc was mainly found in CD11c(+) cells, while Ad-Luc were not restricted to CD11c(+) cells (Supplementary Figure S2).", [["CD11c(+) cells", "ANATOMY", 65, 79], ["CD11c(+) cells", "ANATOMY", 117, 131], ["tAd-Luc", "GENE_OR_GENE_PRODUCT", 37, 44], ["CD11c", "GENE_OR_GENE_PRODUCT", 65, 70], ["Ad-Luc", "GENE_OR_GENE_PRODUCT", 87, 93], ["CD11c", "GENE_OR_GENE_PRODUCT", 117, 122], ["tAd", "DNA", 37, 40], ["Luc", "PROTEIN", 41, 44], ["CD11c(+) cells", "CELL_TYPE", 65, 79], ["Luc", "PROTEIN", 90, 93], ["CD11c(+) cells", "CELL_TYPE", 117, 131], ["the tAd-Luc", "TEST", 33, 44], ["CD11c", "TEST", 65, 70], ["cells", "TEST", 74, 79], ["Ad-Luc", "TEST", 87, 93], ["CD11c", "TEST", 117, 122]]], ["Clearly, more vigorous investigations will be needed to identify all cell types that also express CD40.CFm40L elicited a more sustained Ag-specific cellular immune response ::: ResultsTo determine the adjuvant and targeting effects of CFm40L, Ad expressing the SARS-CoV NP protein (Ad-NP) was compared with the same virus complexed with CFm40L (tAd-NP) following either i.d. or i.n. administration, with tAd-Luc serving as the baseline control.", [["cell", "ANATOMY", 69, 73], ["cellular", "ANATOMY", 148, 156], ["CFm40L", "CHEMICAL", 103, 109], ["Ag", "CHEMICAL", 136, 138], ["tAd-NP", "CHEMICAL", 345, 351], ["Ag", "CHEMICAL", 136, 138], ["cell", "CELL", 69, 73], ["CD40", "GENE_OR_GENE_PRODUCT", 98, 102], ["CFm40L", "GENE_OR_GENE_PRODUCT", 103, 109], ["Ag", "GENE_OR_GENE_PRODUCT", 136, 138], ["cellular", "CELL", 148, 156], ["Ad", "ORGANISM", 243, 245], ["SARS-CoV NP", "ORGANISM", 261, 272], ["Ad-NP", "ORGANISM", 282, 287], ["tAd-NP", "GENE_OR_GENE_PRODUCT", 345, 351], ["tAd-Luc", "GENE_OR_GENE_PRODUCT", 404, 411], ["CD40", "PROTEIN", 98, 102], ["CFm40L", "PROTEIN", 103, 109], ["Ag", "PROTEIN", 136, 138], ["SARS-CoV NP protein", "PROTEIN", 261, 280], ["NP", "PROTEIN", 285, 287], ["tAd", "PROTEIN", 404, 407], ["Luc", "PROTEIN", 408, 411], ["SARS-CoV", "SPECIES", 261, 269], ["vigorous investigations", "TEST", 14, 37], ["CFm", "TEST", 103, 106], ["the adjuvant", "TREATMENT", 197, 209], ["CFm", "TREATMENT", 235, 238], ["the SARS", "TEST", 257, 265], ["CoV NP protein", "TEST", 266, 280], ["tAd-NP)", "TREATMENT", 345, 352]]], ["We chose the same amount of virus used in the above biodistribution experiments.", [["virus", "TREATMENT", 28, 33], ["virus", "OBSERVATION", 28, 33]]], ["Thirty days post-prime, the mice were boosted once.", [["mice", "ORGANISM", 28, 32], ["mice", "SPECIES", 28, 32], ["mice", "SPECIES", 28, 32]]], ["The splenocytes were isolated on days 0, 15 and 30 post boosting for the determination of interferon-\u03b3 (IFN-\u03b3) and interleukin-2 (IL-2).", [["splenocytes", "ANATOMY", 4, 15], ["splenocytes", "CELL", 4, 15], ["interferon-\u03b3", "GENE_OR_GENE_PRODUCT", 90, 102], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 104, 109], ["interleukin-2", "GENE_OR_GENE_PRODUCT", 115, 128], ["IL-2", "GENE_OR_GENE_PRODUCT", 130, 134], ["splenocytes", "CELL_TYPE", 4, 15], ["interferon-\u03b3", "PROTEIN", 90, 102], ["IFN", "PROTEIN", 104, 107], ["interleukin-2 (IL-2", "PROTEIN", 115, 134], ["the determination", "TEST", 69, 86], ["interferon", "TREATMENT", 90, 100], ["IFN", "TEST", 104, 107], ["interleukin", "TEST", 115, 126], ["splenocytes", "ANATOMY", 4, 15]]], ["As shown in Figures 6a and b, following i.d. administration, both IFN-\u03b3 and IL-2 specific for SARS-CoV NP, have been increased in mice immunized with either Ad-NP or tAd-NP compared with the control (mice receiving Ad-Luc).", [["tAd-NP", "CHEMICAL", 166, 172], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 66, 71], ["IL-2", "GENE_OR_GENE_PRODUCT", 76, 80], ["SARS-CoV NP", "ORGANISM", 94, 105], ["mice", "ORGANISM", 130, 134], ["Ad-NP", "ORGANISM", 157, 162], ["tAd-NP", "GENE_OR_GENE_PRODUCT", 166, 172], ["mice", "ORGANISM", 200, 204], ["Ad-Luc", "ORGANISM", 215, 221], ["IFN", "PROTEIN", 66, 69], ["IL", "PROTEIN", 76, 78], ["mice", "SPECIES", 130, 134], ["mice", "SPECIES", 200, 204], ["SARS-CoV", "SPECIES", 94, 102], ["mice", "SPECIES", 130, 134], ["mice", "SPECIES", 200, 204], ["IFN", "TEST", 66, 69], ["IL", "TREATMENT", 76, 78], ["SARS", "PROBLEM", 94, 98], ["CoV NP", "TREATMENT", 99, 105], ["tAd-NP", "TREATMENT", 166, 172], ["increased", "OBSERVATION_MODIFIER", 117, 126]]], ["However, it is of note that on day 30 after boosting, the levels of IFN-\u03b3 and IL-2 in mice receiving tAd-NP were substantially higher than those immunized with Ad-NP, suggesting a more sustained Th1 response with the use of CFm40L (Figures 6a and b).", [["tAd-NP", "CHEMICAL", 101, 107], ["CFm40L", "CHEMICAL", 224, 230], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 68, 73], ["IL-2", "GENE_OR_GENE_PRODUCT", 78, 82], ["mice", "ORGANISM", 86, 90], ["tAd-NP", "SIMPLE_CHEMICAL", 101, 107], ["Ad-NP", "ORGANISM", 160, 165], ["IFN", "PROTEIN", 68, 71], ["IL-2", "PROTEIN", 78, 82], ["mice", "SPECIES", 86, 90], ["mice", "SPECIES", 86, 90], ["the levels", "TEST", 54, 64], ["IFN", "TEST", 68, 71], ["IL", "TEST", 78, 80], ["tAd-NP", "TREATMENT", 101, 107], ["Th1 response", "OBSERVATION", 195, 207]]], ["Furthermore, such an enhancement of Ag-specific host immune response by CFm40L has also been observed with the i.n. injection route (Figures 6c and d).", [["Ag", "CHEMICAL", 36, 38], ["Ag", "CHEMICAL", 36, 38], ["CFm40L", "CHEMICAL", 72, 78], ["Ag", "GENE_OR_GENE_PRODUCT", 36, 38], ["Ag", "PROTEIN", 36, 38], ["an enhancement of Ag", "PROBLEM", 18, 38]]], ["Collectively, these data revealed that CFm40L elicited a more sustained Ag-specific cellular immune response (P<0.01).CFm40L delayed Ag-specific humoral responses and reduced IgG 1/IgG 2a ratio ::: ResultsSpecific IgG and IgA antibodies against the NP protein were determined by ELISA to measure the antibodies present in the sera or the trachea and lung (mucosal antibodies).", [["cellular", "ANATOMY", 84, 92], ["sera", "ANATOMY", 326, 330], ["trachea", "ANATOMY", 338, 345], ["lung", "ANATOMY", 350, 354], ["mucosal", "ANATOMY", 356, 363], ["CFm40L", "CHEMICAL", 39, 45], ["Ag", "CHEMICAL", 72, 74], ["CFm40L", "CHEMICAL", 118, 124], ["Ag", "CHEMICAL", 133, 135], ["Ag", "CHEMICAL", 72, 74], ["Ag", "CHEMICAL", 133, 135], ["CFm40L", "SIMPLE_CHEMICAL", 39, 45], ["Ag", "GENE_OR_GENE_PRODUCT", 72, 74], ["cellular", "CELL", 84, 92], ["CFm40L", "GENE_OR_GENE_PRODUCT", 118, 124], ["Ag", "GENE_OR_GENE_PRODUCT", 133, 135], ["IgG 1", "GENE_OR_GENE_PRODUCT", 175, 180], ["IgG 2a", "GENE_OR_GENE_PRODUCT", 181, 187], ["IgG", "GENE_OR_GENE_PRODUCT", 214, 217], ["IgA antibodies against the NP protein", "GENE_OR_GENE_PRODUCT", 222, 259], ["sera", "ORGANISM_SUBSTANCE", 326, 330], ["trachea", "MULTI-TISSUE_STRUCTURE", 338, 345], ["lung", "ORGAN", 350, 354], ["mucosal", "MULTI-TISSUE_STRUCTURE", 356, 363], ["CFm40L", "PROTEIN", 39, 45], ["Ag", "PROTEIN", 72, 74], ["CFm40L", "PROTEIN", 118, 124], ["Ag", "PROTEIN", 133, 135], ["IgG 1", "PROTEIN", 175, 180], ["IgG 2a", "PROTEIN", 181, 187], ["IgG", "PROTEIN", 214, 217], ["IgA antibodies", "PROTEIN", 222, 236], ["NP protein", "PROTEIN", 249, 259], ["antibodies", "PROTEIN", 300, 310], ["mucosal antibodies", "PROTEIN", 356, 374], ["these data", "TEST", 14, 24], ["a more sustained Ag", "PROBLEM", 55, 74], ["Ag", "TEST", 133, 135], ["specific humoral responses", "TEST", 136, 162], ["reduced IgG", "TEST", 167, 178], ["ResultsSpecific IgG", "TEST", 198, 217], ["IgA antibodies", "TEST", 222, 236], ["the NP protein", "TEST", 245, 259], ["ELISA", "TEST", 279, 284], ["the antibodies", "TEST", 296, 310], ["cellular immune response", "OBSERVATION", 84, 108], ["trachea", "ANATOMY", 338, 345], ["lung", "ANATOMY", 350, 354], ["mucosal antibodies", "ANATOMY", 356, 374]]], ["Surprisingly, the levels of IgG and IgA in the sera following tAd-NP administration (i.d.) was significantly lower than that with Ad-NP immunization via the i.d. administration route (P<0.01) (Figures 7a and b).CFm40L delayed Ag-specific humoral responses and reduced IgG 1/IgG 2a ratio ::: ResultsNext we determined the titres of IgG and IgA present in the sera and trachea/lung lavage following i.n. administration and found that the humoral responses were similar to that with the i.d. route.", [["sera", "ANATOMY", 47, 51], ["sera", "ANATOMY", 358, 362], ["trachea", "ANATOMY", 367, 374], ["lung lavage", "ANATOMY", 375, 386], ["tAd-NP", "CHEMICAL", 62, 68], ["Ad-NP", "CHEMICAL", 130, 135], ["CFm40L", "CHEMICAL", 211, 217], ["Ag", "CHEMICAL", 226, 228], ["Ag", "CHEMICAL", 226, 228], ["IgG", "GENE_OR_GENE_PRODUCT", 28, 31], ["IgA", "GENE_OR_GENE_PRODUCT", 36, 39], ["sera", "ORGANISM_SUBSTANCE", 47, 51], ["tAd-NP", "SIMPLE_CHEMICAL", 62, 68], ["Ad", "ORGANISM", 130, 132], ["CFm40L", "GENE_OR_GENE_PRODUCT", 211, 217], ["Ag", "GENE_OR_GENE_PRODUCT", 226, 228], ["IgG 1", "GENE_OR_GENE_PRODUCT", 268, 273], ["IgG 2a", "GENE_OR_GENE_PRODUCT", 274, 280], ["IgG", "GENE_OR_GENE_PRODUCT", 331, 334], ["IgA", "GENE_OR_GENE_PRODUCT", 339, 342], ["sera", "ORGANISM_SUBSTANCE", 358, 362], ["trachea", "MULTI-TISSUE_STRUCTURE", 367, 374], ["lung lavage", "MULTI-TISSUE_STRUCTURE", 375, 386], ["IgG", "PROTEIN", 28, 31], ["IgA", "PROTEIN", 36, 39], ["CFm40L", "PROTEIN", 211, 217], ["Ag", "PROTEIN", 226, 228], ["IgG 1", "PROTEIN", 268, 273], ["IgG 2a", "PROTEIN", 274, 280], ["IgG", "PROTEIN", 331, 334], ["IgA", "PROTEIN", 339, 342], ["Ad", "SPECIES", 130, 132], ["the levels", "TEST", 14, 24], ["IgG", "TEST", 28, 31], ["IgA", "TEST", 36, 39], ["tAd-NP administration", "TREATMENT", 62, 83], ["Ad-NP immunization", "TREATMENT", 130, 148], ["Ag", "TEST", 226, 228], ["specific humoral responses", "TEST", 229, 255], ["reduced IgG", "TEST", 260, 271], ["the titres", "TEST", 317, 327], ["IgG", "TEST", 331, 334], ["the sera", "TEST", 354, 362], ["trachea/lung lavage", "TREATMENT", 367, 386], ["trachea", "ANATOMY", 367, 374], ["lung", "ANATOMY", 375, 379], ["lavage", "OBSERVATION", 380, 386]]], ["As shown in Figure 8, both the IgG and IgA titres in mice immunized with tAd-NP were significantly lower than those with Ad-NP, especially on Days 0 and 15 post-boosting (P<0.01).", [["IgG", "GENE_OR_GENE_PRODUCT", 31, 34], ["IgA", "GENE_OR_GENE_PRODUCT", 39, 42], ["mice", "ORGANISM", 53, 57], ["tAd-NP", "ORGANISM", 73, 79], ["Ad-NP", "ORGANISM", 121, 126], ["IgG", "PROTEIN", 31, 34], ["IgA", "PROTEIN", 39, 42], ["mice", "SPECIES", 53, 57], ["mice", "SPECIES", 53, 57], ["the IgG", "TEST", 27, 34], ["IgA titres", "TREATMENT", 39, 49], ["tAd-NP", "TREATMENT", 73, 79], ["Ad-NP", "TREATMENT", 121, 126]]], ["It is of note, however, that the antibody titres did reach similar levels 30 days post-boosting following i.n. administration (Figure 8).", [["the antibody titres", "TEST", 29, 48]]], ["In addition, similar findings in terms of Ag-specific antibody responses against a different transgene (luciferase) were also obtained with the use of tAd-Luc (Supplementary Figure S3).", [["Ag", "CHEMICAL", 42, 44], ["Ag", "CHEMICAL", 42, 44], ["Ag", "GENE_OR_GENE_PRODUCT", 42, 44], ["luciferase", "GENE_OR_GENE_PRODUCT", 104, 114], ["tAd-Luc", "GENE_OR_GENE_PRODUCT", 151, 158], ["Ag", "PROTEIN", 42, 44], ["luciferase", "PROTEIN", 104, 114], ["tAd", "PROTEIN", 151, 154], ["Luc", "PROTEIN", 155, 158], ["Ag", "TEST", 42, 44], ["a different transgene (luciferase", "TREATMENT", 81, 114], ["tAd-Luc", "TREATMENT", 151, 158]]], ["These data collectively suggest that the reduction of Ag-specific humoral responses is not linked to the identity of the transgene but to the use of CFm40L in conjunction with adenoviral vectors.CFm40L delayed Ag-specific humoral responses and reduced IgG 1/IgG 2a ratio ::: ResultsWe then determined the relative ratio of IgG1 and IgG2a delivered by either unmodified or CD40-targeted vectors.", [["Ag", "CHEMICAL", 54, 56], ["Ag", "CHEMICAL", 210, 212], ["Ag", "CHEMICAL", 54, 56], ["Ag", "CHEMICAL", 210, 212], ["Ag", "GENE_OR_GENE_PRODUCT", 54, 56], ["CFm40L", "GENE_OR_GENE_PRODUCT", 149, 155], ["adenoviral", "ORGANISM", 176, 186], ["Ag", "GENE_OR_GENE_PRODUCT", 210, 212], ["IgG 1", "GENE_OR_GENE_PRODUCT", 252, 257], ["IgG 2a", "GENE_OR_GENE_PRODUCT", 258, 264], ["IgG1", "GENE_OR_GENE_PRODUCT", 323, 327], ["IgG2a", "GENE_OR_GENE_PRODUCT", 332, 337], ["CD40", "GENE_OR_GENE_PRODUCT", 372, 376], ["Ag", "PROTEIN", 54, 56], ["Ag", "PROTEIN", 210, 212], ["IgG 1", "PROTEIN", 252, 257], ["IgG 2a", "PROTEIN", 258, 264], ["IgG1", "PROTEIN", 323, 327], ["IgG2a", "PROTEIN", 332, 337], ["CD40", "PROTEIN", 372, 376], ["Ag", "TEST", 54, 56], ["CFm", "TREATMENT", 149, 152], ["adenoviral vectors", "TREATMENT", 176, 194], ["Ag", "TEST", 210, 212], ["specific humoral responses", "TEST", 213, 239], ["IgG", "TEST", 252, 255], ["IgG2a", "TREATMENT", 332, 337]]], ["To this end, horseradish peroxidase (HRP)-conjugated anti-mouse IgG1 and IgG2a were used in place of HRP-conjugated anti-mouse IgG in ELISA.26 As shown in Figure 9a, a reduced ratio of IgG1 and IgG2a was observed with the use of the targeted vector.", [["horseradish peroxidase", "SIMPLE_CHEMICAL", 13, 35], ["HRP", "SIMPLE_CHEMICAL", 37, 40], ["IgG1", "GENE_OR_GENE_PRODUCT", 64, 68], ["IgG2a", "GENE_OR_GENE_PRODUCT", 73, 78], ["HRP", "SIMPLE_CHEMICAL", 101, 104], ["IgG1", "GENE_OR_GENE_PRODUCT", 185, 189], ["IgG2a", "GENE_OR_GENE_PRODUCT", 194, 199], ["horseradish peroxidase (HRP)-conjugated anti-mouse IgG1", "PROTEIN", 13, 68], ["IgG2a", "PROTEIN", 73, 78], ["HRP", "PROTEIN", 101, 104], ["anti-mouse IgG", "PROTEIN", 116, 130], ["IgG1", "PROTEIN", 185, 189], ["IgG2a", "PROTEIN", 194, 199], ["horseradish", "SPECIES", 13, 24], ["anti-mouse", "SPECIES", 53, 63], ["anti-mouse", "SPECIES", 116, 126], ["horseradish peroxidase (HRP)", "TREATMENT", 13, 41], ["conjugated anti-mouse IgG1", "TREATMENT", 42, 68], ["IgG2a", "TREATMENT", 73, 78], ["HRP", "TEST", 101, 104], ["a reduced ratio of IgG1", "TREATMENT", 166, 189], ["the targeted vector", "TREATMENT", 229, 248]]], ["We also observed lower levels of IL-4 (Figure 9b).", [["IL-4", "GENE_OR_GENE_PRODUCT", 33, 37], ["IL-4", "PROTEIN", 33, 37], ["lower levels", "OBSERVATION_MODIFIER", 17, 29]]], ["These data, in addition to the increased levels of Th1 cytokines (IL-2 and IFN; Figure 6), suggest that the CD40-targeted immunization might have elicited a Th1-skewed immune response.CFm40L attenuates anti-Ad vector antibody responses ::: ResultsWe then determined whether conjugation of Ad with CFm40L could affect generation of anti-Ad antibody responses.", [["CFm40L", "CHEMICAL", 184, 190], ["CFm40L", "CHEMICAL", 297, 303], ["CFm40L", "CHEMICAL", 297, 303], ["IL-2", "GENE_OR_GENE_PRODUCT", 66, 70], ["IFN", "GENE_OR_GENE_PRODUCT", 75, 78], ["CD40", "GENE_OR_GENE_PRODUCT", 108, 112], ["CFm40L", "GENE_OR_GENE_PRODUCT", 184, 190], ["anti-Ad", "GENE_OR_GENE_PRODUCT", 202, 209], ["Ad", "ORGANISM", 289, 291], ["CFm40L", "GENE_OR_GENE_PRODUCT", 297, 303], ["anti-Ad antibody", "GENE_OR_GENE_PRODUCT", 331, 347], ["Th1 cytokines", "PROTEIN", 51, 64], ["IL-2", "PROTEIN", 66, 70], ["IFN", "PROTEIN", 75, 78], ["CD40", "PROTEIN", 108, 112], ["CFm40L", "PROTEIN", 184, 190], ["anti-Ad vector antibody", "PROTEIN", 202, 225], ["CFm40L", "PROTEIN", 297, 303], ["anti-Ad antibody", "PROTEIN", 331, 347], ["These data", "TEST", 0, 10], ["the increased levels of Th1 cytokines", "PROBLEM", 27, 64], ["IL", "TEST", 66, 68], ["the CD40-targeted immunization", "TREATMENT", 104, 134], ["CFm", "TEST", 184, 187], ["CFm", "TEST", 297, 300]]], ["To this end, we analysed Ad-specific IgA in lung lavage collected from the same mice immunized with tAd-NP (i.n. administration) by ELISA.", [["lung lavage", "ANATOMY", 44, 55], ["tAd-NP", "CHEMICAL", 100, 106], ["IgA", "GENE_OR_GENE_PRODUCT", 37, 40], ["lung lavage", "MULTI-TISSUE_STRUCTURE", 44, 55], ["mice", "ORGANISM", 80, 84], ["tAd-NP", "SIMPLE_CHEMICAL", 100, 106], ["IgA", "PROTEIN", 37, 40], ["mice", "SPECIES", 80, 84], ["mice", "SPECIES", 80, 84], ["lung lavage", "TEST", 44, 55], ["tAd-NP", "TREATMENT", 100, 106], ["lung", "ANATOMY", 44, 48], ["lavage", "OBSERVATION", 49, 55]]], ["We used sucrose gradient-purified Ad viral lysate derived from Ad-E (Ads expressing a different exogenous gene) as antigens in place of the NP protein in the ELISA.", [["lysate", "ANATOMY", 43, 49], ["sucrose", "CHEMICAL", 8, 15], ["sucrose", "CHEMICAL", 8, 15], ["sucrose", "SIMPLE_CHEMICAL", 8, 15], ["Ad", "ORGANISM", 34, 36], ["Ad-E", "ORGANISM", 63, 67], ["Ads", "ORGANISM", 69, 72], ["exogenous gene", "DNA", 96, 110], ["antigens", "PROTEIN", 115, 123], ["NP protein", "PROTEIN", 140, 150], ["sucrose gradient", "TREATMENT", 8, 24], ["Ad viral lysate", "TREATMENT", 34, 49]]], ["As shown in Figure 10, the antibody responses against the other Ad proteins were markedly suppressed in mice immunized with tAd-NP compared with that following immunization with Ad-NP.", [["tAd-NP", "CHEMICAL", 124, 130], ["Ad-NP", "CHEMICAL", 178, 183], ["Ad", "ORGANISM", 64, 66], ["mice", "ORGANISM", 104, 108], ["tAd-NP", "ORGANISM", 124, 130], ["Ad-NP", "ORGANISM", 178, 183], ["Ad proteins", "PROTEIN", 64, 75], ["mice", "SPECIES", 104, 108], ["mice", "SPECIES", 104, 108], ["Ad", "SPECIES", 178, 180], ["the antibody responses", "TEST", 23, 45], ["the other Ad proteins", "PROBLEM", 54, 75], ["tAd-NP", "TREATMENT", 124, 130]]], ["Furthermore, these data also provided additional evidence that the decreased Ag-specific antibody responses were linked to the use of CFm40L/adenoviral vectors not to the identity of the transgene, in agreement with Figures 7, 8 and Supplementary Figure S3.Biodistribution of tAd following intravascular administration ::: DiscussionAs expected from in vitro transduction assay, the adaptor protein CFm40L, comprised of human Ad receptor CAR fused to mouse CD40L, noticeably altered the pattern of tissue distribution of the viruses in vivo, with predominant deposition of the viruses detected in the liver, spleen, thymus and lung (Figure 2).", [["intravascular", "ANATOMY", 290, 303], ["tissue", "ANATOMY", 498, 504], ["liver", "ANATOMY", 601, 606], ["spleen", "ANATOMY", 608, 614], ["thymus", "ANATOMY", 616, 622], ["lung", "ANATOMY", 627, 631], ["Ag", "CHEMICAL", 77, 79], ["Ag", "CHEMICAL", 77, 79], ["Ag", "GENE_OR_GENE_PRODUCT", 77, 79], ["CFm40L", "GENE_OR_GENE_PRODUCT", 134, 140], ["adenoviral", "ORGANISM", 141, 151], ["tAd", "SIMPLE_CHEMICAL", 276, 279], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 290, 303], ["CFm40L", "GENE_OR_GENE_PRODUCT", 399, 405], ["human", "ORGANISM", 420, 425], ["Ad", "ORGANISM", 426, 428], ["CAR", "GENE_OR_GENE_PRODUCT", 438, 441], ["mouse", "ORGANISM", 451, 456], ["CD40L", "GENE_OR_GENE_PRODUCT", 457, 462], ["tissue", "TISSUE", 498, 504], ["liver", "ORGAN", 601, 606], ["spleen", "ORGAN", 608, 614], ["thymus", "ORGAN", 616, 622], ["lung", "ORGAN", 627, 631], ["Ag", "PROTEIN", 77, 79], ["CFm40L", "PROTEIN", 134, 140], ["tAd", "PROTEIN", 276, 279], ["adaptor protein", "PROTEIN", 383, 398], ["CFm40L", "PROTEIN", 399, 405], ["CAR", "PROTEIN", 438, 441], ["mouse CD40L", "PROTEIN", 451, 462], ["human", "SPECIES", 420, 425], ["mouse", "SPECIES", 451, 456], ["human", "SPECIES", 420, 425], ["mouse", "SPECIES", 451, 456], ["the decreased Ag-specific antibody responses", "PROBLEM", 63, 107], ["CFm40L/adenoviral vectors", "TREATMENT", 134, 159], ["the adaptor protein CFm", "TREATMENT", 379, 402], ["the viruses in vivo", "PROBLEM", 521, 540], ["predominant deposition of the viruses", "PROBLEM", 547, 584], ["decreased", "OBSERVATION_MODIFIER", 67, 76], ["tissue", "OBSERVATION", 498, 504], ["viruses", "OBSERVATION", 525, 532], ["predominant", "OBSERVATION_MODIFIER", 547, 558], ["deposition", "OBSERVATION", 559, 569], ["viruses", "OBSERVATION", 577, 584], ["liver", "ANATOMY", 601, 606], ["spleen", "ANATOMY", 608, 614], ["thymus", "ANATOMY", 616, 622], ["lung", "ANATOMY", 627, 631]]], ["Such an altered biodistribution pattern is unlikely due to detargeting of CAR since modified adenoviral vectors ablated for CAR have been shown to have an overall reduced efficiency of gene expression in tissues but not a change of biodistribution pattern.36, 37 In contrast, we found the expression levels of transgenes delivered by the two vectors were comparable in certain tissues such as liver and spleen (i.v. administration).", [["tissues", "ANATOMY", 204, 211], ["tissues", "ANATOMY", 377, 384], ["liver", "ANATOMY", 393, 398], ["spleen", "ANATOMY", 403, 409], ["CAR", "GENE_OR_GENE_PRODUCT", 74, 77], ["adenoviral", "ORGANISM", 93, 103], ["CAR", "GENE_OR_GENE_PRODUCT", 124, 127], ["tissues", "TISSUE", 204, 211], ["tissues", "TISSUE", 377, 384], ["liver", "ORGAN", 393, 398], ["spleen", "ORGAN", 403, 409], ["CAR", "PROTEIN", 74, 77], ["CAR", "PROTEIN", 124, 127], ["an altered biodistribution pattern", "PROBLEM", 5, 39], ["modified adenoviral vectors", "TREATMENT", 84, 111], ["gene expression in tissues", "PROBLEM", 185, 211], ["altered", "OBSERVATION_MODIFIER", 8, 15], ["biodistribution pattern", "OBSERVATION", 16, 39], ["unlikely due to", "UNCERTAINTY", 43, 58], ["overall", "OBSERVATION_MODIFIER", 155, 162], ["reduced", "OBSERVATION_MODIFIER", 163, 170], ["efficiency", "OBSERVATION", 171, 181], ["gene expression", "OBSERVATION", 185, 200], ["biodistribution pattern", "OBSERVATION", 232, 255], ["liver", "ANATOMY", 393, 398], ["spleen", "ANATOMY", 403, 409]]], ["Furthermore, we observed the thymus and lung took up more tAd than Ad, a fact that also differs from the detargeting of CAR following i.v. administration.36, 38 These data suggest that the altered biodistribution pattern is due to CD40 targeting rather than detargeting of CAR.Biodistribution of tAd following intravascular administration ::: DiscussionThe higher expression of tAd in lung may suggest the likely presence of abundant CD40(+) cells in these organs.", [["thymus", "ANATOMY", 29, 35], ["lung", "ANATOMY", 40, 44], ["intravascular", "ANATOMY", 310, 323], ["lung", "ANATOMY", 385, 389], ["CD40(+) cells", "ANATOMY", 434, 447], ["organs", "ANATOMY", 457, 463], ["thymus", "ORGAN", 29, 35], ["lung", "ORGAN", 40, 44], ["Ad", "ORGANISM", 67, 69], ["CAR", "GENE_OR_GENE_PRODUCT", 120, 123], ["CD40", "GENE_OR_GENE_PRODUCT", 231, 235], ["CAR", "GENE_OR_GENE_PRODUCT", 273, 276], ["tAd", "SIMPLE_CHEMICAL", 296, 299], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 310, 323], ["tAd", "GENE_OR_GENE_PRODUCT", 378, 381], ["lung", "ORGAN", 385, 389], ["CD40", "GENE_OR_GENE_PRODUCT", 434, 438], ["organs", "ORGAN", 457, 463], ["CAR", "PROTEIN", 120, 123], ["CD40", "PROTEIN", 231, 235], ["CAR", "PROTEIN", 273, 276], ["tAd", "PROTEIN", 296, 299], ["tAd", "PROTEIN", 378, 381], ["CD40(+) cells", "CELL_TYPE", 434, 447], ["These data", "TEST", 161, 171], ["the altered biodistribution pattern", "PROBLEM", 185, 220], ["CD40 targeting", "PROBLEM", 231, 245], ["The higher expression of tAd in lung", "PROBLEM", 353, 389], ["abundant CD40(+) cells in these organs", "PROBLEM", 425, 463], ["thymus", "ANATOMY", 29, 35], ["lung", "ANATOMY", 40, 44], ["altered", "OBSERVATION_MODIFIER", 189, 196], ["biodistribution pattern", "OBSERVATION", 197, 220], ["higher", "OBSERVATION_MODIFIER", 357, 363], ["expression", "OBSERVATION_MODIFIER", 364, 374], ["tAd", "OBSERVATION", 378, 381], ["lung", "ANATOMY", 385, 389], ["may suggest the likely", "UNCERTAINTY", 390, 412], ["abundant", "OBSERVATION_MODIFIER", 425, 433], ["CD40", "OBSERVATION", 434, 438], ["organs", "ANATOMY", 457, 463]]], ["It has been shown that epithelial/endothelial cells and antigen-presenting cells (DCs, activated monocytes and B cells) are CD40(+).39 The presence of these CD40(+) cells in the lung may suggest that the innate host defences are well in place to fend off invading pathogens from the air.", [["epithelial", "ANATOMY", 23, 33], ["endothelial cells", "ANATOMY", 34, 51], ["antigen-presenting cells", "ANATOMY", 56, 80], ["DCs", "ANATOMY", 82, 85], ["monocytes", "ANATOMY", 97, 106], ["B cells", "ANATOMY", 111, 118], ["CD40(+) cells", "ANATOMY", 157, 170], ["lung", "ANATOMY", 178, 182], ["epithelial", "CELL", 23, 33], ["endothelial cells", "CELL", 34, 51], ["antigen-presenting cells", "CELL", 56, 80], ["DCs", "CELL", 82, 85], ["monocytes", "CELL", 97, 106], ["B cells", "CELL", 111, 118], ["CD40", "GENE_OR_GENE_PRODUCT", 124, 128], ["CD40", "GENE_OR_GENE_PRODUCT", 157, 161], ["lung", "ORGAN", 178, 182], ["epithelial/endothelial cells", "CELL_TYPE", 23, 51], ["antigen-presenting cells", "CELL_TYPE", 56, 80], ["DCs", "CELL_TYPE", 82, 85], ["activated monocytes", "CELL_TYPE", 87, 106], ["B cells", "CELL_TYPE", 111, 118], ["CD40", "PROTEIN", 124, 128], ["CD40(+) cells", "CELL_TYPE", 157, 170], ["epithelial/endothelial cells", "TEST", 23, 51], ["antigen", "TEST", 56, 63], ["presenting cells", "PROBLEM", 64, 80], ["DCs", "TEST", 82, 85], ["activated monocytes", "TEST", 87, 106], ["B cells", "TEST", 111, 118], ["CD40", "TEST", 124, 128], ["these CD40(+) cells in the lung", "PROBLEM", 151, 182], ["epithelial", "ANATOMY_MODIFIER", 23, 33], ["endothelial cells", "OBSERVATION", 34, 51], ["CD40", "OBSERVATION", 157, 161], ["lung", "ANATOMY", 178, 182], ["may suggest", "UNCERTAINTY", 183, 194], ["host defences", "OBSERVATION", 211, 224], ["air", "OBSERVATION", 283, 286]]], ["It is interesting that under normal circumstances the lung is not the major tissue/organ that takes up unmodified Ad following intravascular administration (Figure 2a).", [["lung", "ANATOMY", 54, 58], ["tissue", "ANATOMY", 76, 82], ["organ", "ANATOMY", 83, 88], ["intravascular", "ANATOMY", 127, 140], ["lung", "ORGAN", 54, 58], ["tissue", "TISSUE", 76, 82], ["organ", "ORGAN", 83, 88], ["Ad", "ORGANISM", 114, 116], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 127, 140], ["intravascular administration", "TREATMENT", 127, 155], ["normal", "OBSERVATION", 29, 35], ["lung", "ANATOMY", 54, 58], ["organ", "ANATOMY", 83, 88]]], ["The pulmonary intravascular macrophages, however, can take up unexpectedly high amounts of the Ad5 virus in animals with hepatic disorders, such as cirrhosis, resulting in severe pulmonary pathology.5 Clearly, better understanding of the biodistribution of both unmodified and modified Ad vector is of importance, given that such knowledge helps understand the clearance of virus vector as well as identify the tissues/organs, which could be predisposed to adverse events during the course of gene therapy.5, 40Biodistribution of tAd following i.n. administration ::: DiscussionAs a result of comparison between Ad and tAd following i.n. administration, it appears that the inadvertent infection of central nervous system (CNS) is mediated by the CAR receptor but not other receptors, such as \u03b1v\u03b2 integrin, and heparin sulphate glycosaminoglycans, which were shown to mediate the entry of Ads.36, 41, 42 As discussed above, inadvertent infection of the CNS by live viral vectors could be a safety concern if the vectors are given i.n.43, 44 Moreover, we observed visible lesions of the lungs, especially the airway epithelial cells, in mice receiving unmodified Ad-NP.", [["pulmonary intravascular macrophages", "ANATOMY", 4, 39], ["hepatic", "ANATOMY", 121, 128], ["pulmonary", "ANATOMY", 179, 188], ["tissues", "ANATOMY", 411, 418], ["organs", "ANATOMY", 419, 425], ["central nervous system", "ANATOMY", 699, 721], ["CNS", "ANATOMY", 723, 726], ["CNS", "ANATOMY", 953, 956], ["lesions", "ANATOMY", 1071, 1078], ["lungs", "ANATOMY", 1086, 1091], ["airway epithelial cells", "ANATOMY", 1108, 1131], ["hepatic disorders", "DISEASE", 121, 138], ["cirrhosis", "DISEASE", 148, 157], ["infection of central nervous system", "DISEASE", 686, 721], ["heparin sulphate", "CHEMICAL", 811, 827], ["infection", "DISEASE", 936, 945], ["Ads.36, 41, 42", "CHEMICAL", 889, 903], ["pulmonary intravascular macrophages", "CELL", 4, 39], ["Ad5 virus", "ORGANISM", 95, 104], ["hepatic", "ORGAN", 121, 128], ["pulmonary", "ORGAN", 179, 188], ["Ad", "ORGANISM", 286, 288], ["tissues", "TISSUE", 411, 418], ["organs", "ORGAN", 419, 425], ["tAd", "SIMPLE_CHEMICAL", 530, 533], ["Ad", "ORGANISM", 612, 614], ["tAd", "GENE_OR_GENE_PRODUCT", 619, 622], ["central nervous system", "ANATOMICAL_SYSTEM", 699, 721], ["CNS", "ANATOMICAL_SYSTEM", 723, 726], ["CAR receptor", "GENE_OR_GENE_PRODUCT", 747, 759], ["\u03b1v\u03b2 integrin", "GENE_OR_GENE_PRODUCT", 793, 805], ["heparin sulphate glycosaminoglycans", "SIMPLE_CHEMICAL", 811, 846], ["CNS", "ANATOMICAL_SYSTEM", 953, 956], ["lesions", "PATHOLOGICAL_FORMATION", 1071, 1078], ["lungs", "ORGAN", 1086, 1091], ["airway epithelial cells", "CELL", 1108, 1131], ["mice", "ORGANISM", 1136, 1140], ["Ad", "ORGANISM", 1162, 1164], ["pulmonary intravascular macrophages", "CELL_TYPE", 4, 39], ["CAR receptor", "PROTEIN", 747, 759], ["\u03b1v\u03b2 integrin", "PROTEIN", 793, 805], ["airway epithelial cells", "CELL_TYPE", 1108, 1131], ["mice", "SPECIES", 1136, 1140], ["Ad5 virus", "SPECIES", 95, 104], ["mice", "SPECIES", 1136, 1140], ["The pulmonary intravascular macrophages", "PROBLEM", 0, 39], ["the Ad5 virus", "PROBLEM", 91, 104], ["hepatic disorders", "PROBLEM", 121, 138], ["cirrhosis", "PROBLEM", 148, 157], ["severe pulmonary pathology", "PROBLEM", 172, 198], ["virus vector", "TREATMENT", 374, 386], ["the tissues/organs", "PROBLEM", 407, 425], ["adverse events", "PROBLEM", 457, 471], ["gene therapy", "TREATMENT", 493, 505], ["the inadvertent infection of central nervous system", "PROBLEM", 670, 721], ["\u03b1v\u03b2 integrin", "TREATMENT", 793, 805], ["heparin sulphate glycosaminoglycans", "TREATMENT", 811, 846], ["inadvertent infection of the CNS", "PROBLEM", 924, 956], ["live viral vectors", "TREATMENT", 960, 978], ["visible lesions of the lungs", "PROBLEM", 1063, 1091], ["the airway epithelial cells", "PROBLEM", 1104, 1131], ["pulmonary", "ANATOMY", 4, 13], ["intravascular macrophages", "OBSERVATION", 14, 39], ["Ad5 virus", "OBSERVATION", 95, 104], ["hepatic", "ANATOMY", 121, 128], ["disorders", "OBSERVATION", 129, 138], ["cirrhosis", "OBSERVATION", 148, 157], ["severe", "OBSERVATION_MODIFIER", 172, 178], ["pulmonary", "ANATOMY", 179, 188], ["pathology", "OBSERVATION", 189, 198], ["organs", "ANATOMY", 419, 425], ["inadvertent", "OBSERVATION_MODIFIER", 674, 685], ["infection", "OBSERVATION", 686, 695], ["central", "ANATOMY_MODIFIER", 699, 706], ["nervous system", "ANATOMY", 707, 721], ["infection", "OBSERVATION", 936, 945], ["CNS", "ANATOMY", 953, 956], ["visible", "OBSERVATION_MODIFIER", 1063, 1070], ["lesions", "OBSERVATION", 1071, 1078], ["lungs", "ANATOMY", 1086, 1091], ["airway", "ANATOMY", 1108, 1114], ["epithelial cells", "OBSERVATION", 1115, 1131]]], ["Such deleterious effects of Ad-NP were apparently caused by strong local inflammatory reactions as suggested by a massive infiltration of lymphocytes and macrophages.", [["lymphocytes", "ANATOMY", 138, 149], ["macrophages", "ANATOMY", 154, 165], ["Ad-NP", "GENE_OR_GENE_PRODUCT", 28, 33], ["lymphocytes", "CELL", 138, 149], ["macrophages", "CELL", 154, 165], ["lymphocytes", "CELL_TYPE", 138, 149], ["macrophages", "CELL_TYPE", 154, 165], ["Ad-NP", "TREATMENT", 28, 33], ["strong local inflammatory reactions", "PROBLEM", 60, 95], ["a massive infiltration of lymphocytes and macrophages", "PROBLEM", 112, 165], ["strong", "OBSERVATION_MODIFIER", 60, 66], ["local", "OBSERVATION_MODIFIER", 67, 72], ["inflammatory", "OBSERVATION", 73, 85], ["massive", "OBSERVATION_MODIFIER", 114, 121], ["infiltration", "OBSERVATION", 122, 134], ["lymphocytes", "ANATOMY", 138, 149], ["macrophages", "ANATOMY", 154, 165]]], ["Yet, no such exaggerated local inflammatory reactions were observed in mice receiving tAd-NP.", [["tAd-NP", "CHEMICAL", 86, 92], ["mice", "ORGANISM", 71, 75], ["tAd-NP", "GENE_OR_GENE_PRODUCT", 86, 92], ["mice", "SPECIES", 71, 75], ["mice", "SPECIES", 71, 75], ["such exaggerated local inflammatory reactions", "PROBLEM", 8, 53], ["no such", "UNCERTAINTY", 5, 12], ["exaggerated", "OBSERVATION_MODIFIER", 13, 24], ["local", "OBSERVATION_MODIFIER", 25, 30], ["inflammatory", "OBSERVATION", 31, 43]]], ["At this time, we have no definite explanation for the marked differences of local inflammatory reactions between Ad-NP and tAd-NP.", [["Ad-NP", "CHEMICAL", 113, 118], ["Ad-NP", "SIMPLE_CHEMICAL", 113, 118], ["tAd-NP", "GENE_OR_GENE_PRODUCT", 123, 129], ["local inflammatory reactions", "PROBLEM", 76, 104], ["no definite explanation for", "UNCERTAINTY", 22, 49], ["marked", "OBSERVATION_MODIFIER", 54, 60], ["local", "OBSERVATION_MODIFIER", 76, 81], ["inflammatory", "OBSERVATION", 82, 94]]], ["Yet, it is interesting to note that we and others reported that the SARS-CoV NP protein itself, used in this study as model antigen, could alter cellular signal transduction pathways, stimulate pro-inflammatory cytokine production and/or even cell death.45, 46 Therefore, the excessive inflammatory reactions or toxicity induced by Ad-NP are likely due to the combined immunostimulatory or immunopathologic effects of Ad infection and NP protein.", [["cellular", "ANATOMY", 145, 153], ["cell", "ANATOMY", 243, 247], ["SARS", "DISEASE", 68, 72], ["death", "DISEASE", 248, 253], ["toxicity", "DISEASE", 312, 320], ["Ad-NP", "CHEMICAL", 332, 337], ["infection", "DISEASE", 421, 430], ["SARS-CoV", "ORGANISM", 68, 76], ["cellular", "CELL", 145, 153], ["cell", "CELL", 243, 247], ["Ad-NP", "ORGANISM", 332, 337], ["Ad", "ORGANISM", 418, 420], ["SARS-CoV NP protein", "PROTEIN", 68, 87], ["cytokine", "PROTEIN", 211, 219], ["NP protein", "PROTEIN", 435, 445], ["SARS-CoV", "SPECIES", 68, 76], ["Ad", "SPECIES", 418, 420], ["the SARS-CoV NP protein itself", "PROBLEM", 64, 94], ["this study", "TEST", 104, 114], ["pro-inflammatory cytokine production", "PROBLEM", 194, 230], ["even cell death", "PROBLEM", 238, 253], ["the excessive inflammatory reactions", "PROBLEM", 272, 308], ["toxicity", "PROBLEM", 312, 320], ["Ad-NP", "TREATMENT", 332, 337], ["Ad infection", "PROBLEM", 418, 430], ["NP protein", "TREATMENT", 435, 445], ["excessive", "OBSERVATION_MODIFIER", 276, 285], ["inflammatory", "OBSERVATION", 286, 298], ["likely due to", "UNCERTAINTY", 342, 355]]], ["This notion is also supported by the observation that Ad-Luc failed to induce the same magnitude of local inflammatory reactions (Figure 5b).Ag-specific immune responses ::: DiscussionThe substantially increased production of Ag-specific IL-2 and IFN-\u03b3 with the use of tAd-NP at later time points was largely expected since ligation of CD40 has been suggested to promote the activation and antigen-presenting functions of DCs, which express CD40 and are well known to initiate immune response.39 Interestingly, at early time points the levels of Ag-specific IL-2 and IFN-\u03b3 were rather comparable between the unmodified and targeted vector groups.", [["DCs", "ANATOMY", 422, 425], ["Ag", "CHEMICAL", 141, 143], ["Ag", "CHEMICAL", 226, 228], ["Ag", "CHEMICAL", 141, 143], ["Ag", "CHEMICAL", 226, 228], ["Ag", "CHEMICAL", 546, 548], ["Ad", "ORGANISM", 54, 56], ["Luc", "GENE_OR_GENE_PRODUCT", 57, 60], ["Ag", "GENE_OR_GENE_PRODUCT", 141, 143], ["Ag", "GENE_OR_GENE_PRODUCT", 226, 228], ["IL-2", "GENE_OR_GENE_PRODUCT", 238, 242], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 247, 252], ["tAd-NP", "GENE_OR_GENE_PRODUCT", 269, 275], ["CD40", "GENE_OR_GENE_PRODUCT", 336, 340], ["DCs", "CELL", 422, 425], ["CD40", "GENE_OR_GENE_PRODUCT", 441, 445], ["Ag", "GENE_OR_GENE_PRODUCT", 546, 548], ["IL-2", "GENE_OR_GENE_PRODUCT", 558, 562], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 567, 572], ["Luc", "PROTEIN", 57, 60], ["Ag", "PROTEIN", 141, 143], ["Ag", "PROTEIN", 226, 228], ["IL-2", "PROTEIN", 238, 242], ["IFN-\u03b3", "PROTEIN", 247, 252], ["tAd", "PROTEIN", 269, 272], ["CD40", "PROTEIN", 336, 340], ["DCs", "CELL_TYPE", 422, 425], ["CD40", "PROTEIN", 441, 445], ["Ag", "PROTEIN", 546, 548], ["IL", "PROTEIN", 558, 560], ["IFN", "PROTEIN", 567, 570], ["local inflammatory reactions", "PROBLEM", 100, 128], ["Ag", "TEST", 226, 228], ["IFN", "TREATMENT", 247, 250], ["tAd-NP", "TREATMENT", 269, 275], ["ligation of CD40", "TREATMENT", 324, 340], ["DCs", "PROBLEM", 422, 425], ["Ag", "TEST", 546, 548], ["specific IL", "TEST", 549, 560], ["IFN", "TEST", 567, 570], ["local", "OBSERVATION_MODIFIER", 100, 105], ["inflammatory", "OBSERVATION", 106, 118]]], ["At later time points, however, the levels of these two cytokines remain elevated with the use of targeted vectors, accompanied by the lower level of IL-4 and the reduced ratio of IgG1/IgG2a.", [["IL-4", "GENE_OR_GENE_PRODUCT", 149, 153], ["IgG1", "GENE_OR_GENE_PRODUCT", 179, 183], ["IgG2a", "GENE_OR_GENE_PRODUCT", 184, 189], ["cytokines", "PROTEIN", 55, 64], ["IL-4", "PROTEIN", 149, 153], ["IgG1", "PROTEIN", 179, 183], ["IgG2a", "PROTEIN", 184, 189], ["targeted vectors", "TREATMENT", 97, 113], ["elevated", "OBSERVATION", 72, 80]]], ["Whether the more sustained IL-2 and IFN-\u03b3 responses with the use of targeted vectors were due to a better development of memory T-cell compartment would require further investigation.", [["memory T-cell compartment", "ANATOMY", 121, 146], ["IL-2", "GENE_OR_GENE_PRODUCT", 27, 31], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 36, 41], ["memory T-cell", "CELL", 121, 134], ["IFN", "PROTEIN", 36, 39], ["memory T-cell compartment", "CELL_TYPE", 121, 146], ["IFN", "TREATMENT", 36, 39], ["targeted vectors", "TREATMENT", 68, 84], ["further investigation", "TEST", 161, 182]]], ["It is of note, however, that CD40 stimulation has been shown to facilitate the development of memory T-cell compartment39, 47, 48, 49 under other experimental conditions.Ag-specific immune responses ::: DiscussionThe markedly delayed Ag-specific mucosal and systemic antibody responses with the use of CFm40L adaptor proteins were somewhat surprising, given the fact that most reports in the literature suggest that CD40L activates both cellular and humoral immune responses against antigens delivered in the form of proteins or DNA constructs.15, 16, 17, 18, 19 However, our findings are in partial agreement with two studies demonstrating CD40L lacks stimulatory effects on the production of Ag-specific antibodies.17, 50 It is unlikely that the biased immune responses reported here were linked to the identity of the transgene as similar observations (more sustained IL-2 and IFN-\u03b3 but reduced antibody titres at later time points) were observed with both tAd-NP and tAd-Luc (Supplementary Figure S3).", [["memory T-cell", "ANATOMY", 94, 107], ["mucosal", "ANATOMY", 246, 253], ["cellular", "ANATOMY", 437, 445], ["Ag", "CHEMICAL", 170, 172], ["Ag", "CHEMICAL", 234, 236], ["Ag", "CHEMICAL", 694, 696], ["Ag", "CHEMICAL", 170, 172], ["Ag", "CHEMICAL", 234, 236], ["Ag", "CHEMICAL", 694, 696], ["CD40", "GENE_OR_GENE_PRODUCT", 29, 33], ["T-cell compartment39", "CELL", 101, 121], ["Ag", "GENE_OR_GENE_PRODUCT", 170, 172], ["Ag", "GENE_OR_GENE_PRODUCT", 234, 236], ["mucosal", "MULTI-TISSUE_STRUCTURE", 246, 253], ["CFm40L", "GENE_OR_GENE_PRODUCT", 302, 308], ["CD40L", "GENE_OR_GENE_PRODUCT", 416, 421], ["cellular", "CELL", 437, 445], ["DNA", "CELLULAR_COMPONENT", 529, 532], ["CD40L", "GENE_OR_GENE_PRODUCT", 641, 646], ["Ag", "GENE_OR_GENE_PRODUCT", 694, 696], ["IL-2", "GENE_OR_GENE_PRODUCT", 871, 875], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 880, 885], ["tAd-Luc", "GENE_OR_GENE_PRODUCT", 971, 978], ["CD40", "PROTEIN", 29, 33], ["Ag", "PROTEIN", 170, 172], ["Ag", "PROTEIN", 234, 236], ["CFm40L adaptor proteins", "PROTEIN", 302, 325], ["CD40L", "PROTEIN", 416, 421], ["antigens", "PROTEIN", 483, 491], ["DNA constructs", "DNA", 529, 543], ["CD40L", "PROTEIN", 641, 646], ["Ag", "PROTEIN", 694, 696], ["specific antibodies", "PROTEIN", 697, 716], ["IL", "PROTEIN", 871, 873], ["IFN", "PROTEIN", 880, 883], ["\u03b3", "PROTEIN", 884, 885], ["tAd", "PROTEIN", 960, 963], ["tAd", "PROTEIN", 971, 974], ["Luc", "PROTEIN", 975, 978], ["CD40 stimulation", "TREATMENT", 29, 45], ["The markedly delayed Ag-specific mucosal and systemic antibody responses", "PROBLEM", 213, 285], ["CFm40L adaptor proteins", "TREATMENT", 302, 325], ["CD40L activates", "PROBLEM", 416, 431], ["DNA constructs", "PROBLEM", 529, 543], ["two studies", "TEST", 615, 626], ["CD40L lacks stimulatory effects", "PROBLEM", 641, 672], ["Ag", "TEST", 694, 696], ["sustained IL", "TEST", 861, 873], ["IFN", "TEST", 880, 883], ["reduced antibody titres", "PROBLEM", 890, 913], ["markedly", "OBSERVATION_MODIFIER", 217, 225], ["delayed", "OBSERVATION_MODIFIER", 226, 233], ["Ag", "OBSERVATION", 234, 236], ["mucosal", "ANATOMY", 246, 253], ["systemic antibody", "OBSERVATION", 258, 275], ["DNA constructs", "OBSERVATION", 529, 543], ["unlikely", "UNCERTAINTY", 730, 738]]], ["In addition, the use of tAd resulted in decreased antibody levels against other adenoviral proteins (Figure 10).", [["tAd", "CHEMICAL", 24, 27], ["tAd", "GENE_OR_GENE_PRODUCT", 24, 27], ["adenoviral", "ORGANISM", 80, 90], ["tAd", "PROTEIN", 24, 27], ["adenoviral proteins", "PROTEIN", 80, 99], ["tAd", "TREATMENT", 24, 27], ["decreased antibody levels", "PROBLEM", 40, 65], ["other adenoviral proteins", "PROBLEM", 74, 99]]], ["However, since both transgenes in this current study (SARS-CoV NP and firefly luciferase) were intracellular proteins, it remains to be determined whether tAd encoding a secreted transgene would result in a similar pattern of immune responses.", [["intracellular", "ANATOMY", 95, 108], ["SARS-CoV NP", "ORGANISM", 54, 65], ["firefly", "GENE_OR_GENE_PRODUCT", 70, 77], ["luciferase", "GENE_OR_GENE_PRODUCT", 78, 88], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 95, 108], ["tAd", "GENE_OR_GENE_PRODUCT", 155, 158], ["firefly luciferase", "PROTEIN", 70, 88], ["intracellular proteins", "PROTEIN", 95, 117], ["tAd", "PROTEIN", 155, 158], ["secreted transgene", "DNA", 170, 188], ["SARS-CoV", "SPECIES", 54, 62], ["this current study", "TEST", 34, 52], ["SARS-CoV NP and firefly luciferase", "TREATMENT", 54, 88], ["intracellular proteins", "PROBLEM", 95, 117]]], ["It is noted, however, others recently reported in a different system (soluble proteins) that CD40-targeted secreted proteins failed to generate a stronger antibody response compared with the untargeted secreted proteins.17 At this time, we think a variety of factors could be ascribed to the differences of results with respect to the patterns of immune responses among various groups.", [["CD40", "GENE_OR_GENE_PRODUCT", 93, 97], ["soluble proteins", "PROTEIN", 70, 86], ["CD40", "PROTEIN", 93, 97], ["secreted proteins", "PROTEIN", 107, 124], ["untargeted secreted proteins", "PROTEIN", 191, 219], ["CD40", "TEST", 93, 97], ["targeted secreted proteins", "PROBLEM", 98, 124], ["a stronger antibody response", "PROBLEM", 144, 172]]], ["One of them might be due to the differences in the vector systems.", [["the differences in the vector systems", "PROBLEM", 28, 65], ["might be due to", "UNCERTAINTY", 12, 27]]], ["It is understood that ours is the only study employing live viral vector in conjunction with CD40L, while other systems were designed to deliver the antigens in the form of DNA plasmid, soluble proteins or virus-like particles.15, 16, 17, 18, 19 Second, the biased immune response might be due to a much lower level of transgene expression with the use of tAd vector at the site of the body receiving the viral vectors.", [["plasmid", "ANATOMY", 177, 184], ["body", "ANATOMY", 386, 390], ["CD40L", "GENE_OR_GENE_PRODUCT", 93, 98], ["DNA", "CELLULAR_COMPONENT", 173, 176], ["tAd", "GENE_OR_GENE_PRODUCT", 356, 359], ["body", "ORGANISM_SUBDIVISION", 386, 390], ["CD40L", "PROTEIN", 93, 98], ["antigens", "PROTEIN", 149, 157], ["DNA plasmid", "DNA", 173, 184], ["soluble proteins", "PROTEIN", 186, 202], ["tAd vector", "DNA", 356, 366], ["CD40L", "TREATMENT", 93, 98], ["DNA plasmid", "PROBLEM", 173, 184], ["soluble proteins", "PROBLEM", 186, 202], ["virus", "PROBLEM", 206, 211], ["tAd vector", "TREATMENT", 356, 366], ["the viral vectors", "TREATMENT", 401, 418], ["transgene expression", "OBSERVATION", 319, 339], ["body", "ANATOMY", 386, 390], ["viral vectors", "OBSERVATION", 405, 418]]], ["For instance, as compared with Ad, \u223c300-fold less transgene expression in the injection site skin (Figures 3a and b) was observed following i.d. injection of tAd, while about 180-fold less in the lungs 3 days after i.n. administration (Figures 4a and b).", [["skin", "ANATOMY", 93, 97], ["lungs", "ANATOMY", 196, 201], ["Ad", "ORGANISM", 31, 33], ["skin", "ORGAN", 93, 97], ["tAd", "GENE_OR_GENE_PRODUCT", 158, 161], ["lungs", "ORGAN", 196, 201], ["tAd", "PROTEIN", 158, 161], ["skin", "ANATOMY", 93, 97], ["lungs", "ANATOMY", 196, 201]]], ["In general, Ag-specific humoral responses are not preferentially elicited in response to smaller amounts of antigens as compared with cellular immune responses.", [["cellular", "ANATOMY", 134, 142], ["Ag", "CHEMICAL", 12, 14], ["Ag", "CHEMICAL", 12, 14], ["Ag", "GENE_OR_GENE_PRODUCT", 12, 14], ["cellular", "CELL", 134, 142], ["Ag", "PROTEIN", 12, 14], ["antigens", "PROTEIN", 108, 116]]], ["Third, the tAd-induced biased immune responses could be tAd interacting with B cells.", [["B cells", "ANATOMY", 77, 84], ["tAd", "CHEMICAL", 11, 14], ["tAd", "GENE_OR_GENE_PRODUCT", 11, 14], ["tAd", "GENE_OR_GENE_PRODUCT", 56, 59], ["B cells", "CELL", 77, 84], ["tAd", "PROTEIN", 11, 14], ["tAd", "PROTEIN", 56, 59], ["B cells", "CELL_TYPE", 77, 84], ["the tAd", "TREATMENT", 7, 14]]], ["There are previous reports documenting that CD40 ligation could lead to largely positive growth outcomes for resting B cells, but inhibited the growth and Ig production of activated B cells which are also known to be CD40(+).39, 51, 52, 53 Given these findings, caution appears to be warranted when considering CD40L as targeting moiety for adenoviral vectors in genetic immunization when induction of humoral immune response is crucial, that is, neutralizing antibodies against pathogens.", [["B cells", "ANATOMY", 117, 124], ["B cells", "ANATOMY", 182, 189], ["CD40", "GENE_OR_GENE_PRODUCT", 44, 48], ["B cells", "CELL", 117, 124], ["Ig", "GENE_OR_GENE_PRODUCT", 155, 157], ["B cells", "CELL", 182, 189], ["CD40", "GENE_OR_GENE_PRODUCT", 217, 221], ["CD40L", "GENE_OR_GENE_PRODUCT", 311, 316], ["adenoviral", "ORGANISM", 341, 351], ["CD40", "PROTEIN", 44, 48], ["resting B cells", "CELL_TYPE", 109, 124], ["activated B cells", "CELL_TYPE", 172, 189], ["CD40", "PROTEIN", 217, 221], ["CD40L", "PROTEIN", 311, 316], ["neutralizing antibodies", "PROTEIN", 447, 470], ["CD40 ligation", "TREATMENT", 44, 57], ["largely positive growth outcomes", "PROBLEM", 72, 104], ["resting B cells", "PROBLEM", 109, 124], ["the growth", "PROBLEM", 140, 150], ["activated B cells", "PROBLEM", 172, 189], ["CD40", "TEST", 217, 221], ["CD40L", "TREATMENT", 311, 316], ["adenoviral vectors", "TREATMENT", 341, 359], ["genetic immunization", "TREATMENT", 363, 383], ["humoral immune response", "PROBLEM", 402, 425], ["neutralizing antibodies", "TEST", 447, 470], ["pathogens", "PROBLEM", 479, 488]]], ["Nevertheless, therapeutic manipulation to facilitate biased or skewed immune responses could be beneficial in clinical applications.", [["therapeutic manipulation", "TREATMENT", 14, 38]]], ["For instance, type 2-biased immune responses (predominant antibody reactions) may be associated with certain immunopathologic complications, such as allergy, asthma and autoimmune diseases.", [["allergy", "DISEASE", 149, 156], ["asthma", "DISEASE", 158, 164], ["autoimmune diseases", "DISEASE", 169, 188], ["type 2-biased immune responses", "PROBLEM", 14, 44], ["predominant antibody reactions", "PROBLEM", 46, 76], ["certain immunopathologic complications", "PROBLEM", 101, 139], ["allergy", "PROBLEM", 149, 156], ["asthma", "PROBLEM", 158, 164], ["autoimmune diseases", "PROBLEM", 169, 188], ["may be associated with", "UNCERTAINTY", 78, 100], ["autoimmune diseases", "OBSERVATION", 169, 188]]], ["Thereby, redirection of the immune response or therapeutic manipulation towards a biased immune response, that is suppression of antibody responses, could help reverse medical conditions related to certain immunopathologic complications.38, 54 Furthermore, enhanced cellular immune responses are well known to play critical roles eliminating or containing certain intracellular pathogens and cancers.10, 11, 12, 28, 41 Finally, as preliminary data presented in this report, the efficient in vitro gene transduction by tAd even in the presence of anti-Ad neutralizing antibodies and lower levels of antibodies against Ad viral proteins in vivo might also help allay one of the major concerns associated with pre-existing immunity against Ad.", [["cellular", "ANATOMY", 266, 274], ["intracellular", "ANATOMY", 364, 377], ["cancers", "ANATOMY", 392, 399], ["cancers", "DISEASE", 392, 399], ["cellular", "CELL", 266, 274], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 364, 377], ["cancers", "CANCER", 392, 399], ["tAd", "GENE_OR_GENE_PRODUCT", 518, 521], ["anti-Ad", "GENE_OR_GENE_PRODUCT", 546, 553], ["Ad", "ORGANISM", 617, 619], ["tAd", "PROTEIN", 518, 521], ["anti-Ad neutralizing antibodies", "PROTEIN", 546, 577], ["antibodies", "PROTEIN", 598, 608], ["Ad viral proteins", "PROTEIN", 617, 634], ["Ad.", "SPECIES", 737, 740], ["the immune response", "TREATMENT", 24, 43], ["therapeutic manipulation", "TREATMENT", 47, 71], ["antibody responses", "PROBLEM", 129, 147], ["reverse medical conditions", "PROBLEM", 160, 186], ["certain immunopathologic complications", "PROBLEM", 198, 236], ["intracellular pathogens", "PROBLEM", 364, 387], ["cancers", "PROBLEM", 392, 399], ["vitro gene transduction", "TREATMENT", 491, 514], ["anti-Ad neutralizing antibodies", "TEST", 546, 577], ["lower levels of antibodies", "PROBLEM", 582, 608], ["Ad viral proteins", "TREATMENT", 617, 634], ["pathogens", "OBSERVATION", 378, 387], ["cancers", "OBSERVATION", 392, 399]]], ["We are currently conducting more in-depth in vivo studies to address these issues.Reagents ::: Materials and methodsAnti-CD40 mAb, rh-IL-4, recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF), the ELISPOT kits with various controls, including IFN-\u03b3 (EL485) and IL-2 (EL402), were purchased from R&D systems, Minneapolis, MN, USA.", [["CD40", "GENE_OR_GENE_PRODUCT", 121, 125], ["rh-IL-4", "GENE_OR_GENE_PRODUCT", 131, 138], ["human", "ORGANISM", 152, 157], ["granulocyte-macrophage colony-stimulating factor", "GENE_OR_GENE_PRODUCT", 158, 206], ["rhGM-CSF", "GENE_OR_GENE_PRODUCT", 208, 216], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 269, 274], ["EL485", "SIMPLE_CHEMICAL", 276, 281], ["IL-2", "GENE_OR_GENE_PRODUCT", 287, 291], ["EL402", "SIMPLE_CHEMICAL", 293, 298], ["CD40 mAb", "PROTEIN", 121, 129], ["rh-IL-4", "PROTEIN", 131, 138], ["recombinant human granulocyte-macrophage colony-stimulating factor", "PROTEIN", 140, 206], ["rhGM", "PROTEIN", 208, 212], ["CSF", "PROTEIN", 213, 216], ["IFN", "PROTEIN", 269, 272], ["\u03b3", "PROTEIN", 273, 274], ["EL485", "PROTEIN", 276, 281], ["IL", "PROTEIN", 287, 289], ["human", "SPECIES", 152, 157], ["human", "SPECIES", 152, 157], ["vivo studies", "TEST", 45, 57], ["these issues", "PROBLEM", 69, 81], ["methods", "TEST", 109, 116], ["CD40 mAb", "TEST", 121, 129], ["rh", "TEST", 131, 133], ["IL", "TEST", 134, 136], ["recombinant human granulocyte", "TEST", 140, 169], ["macrophage colony", "TEST", 170, 187], ["stimulating factor", "PROBLEM", 188, 206], ["rhGM", "TEST", 208, 212], ["the ELISPOT kits", "TEST", 219, 235], ["various controls", "PROBLEM", 241, 257], ["IFN", "TEST", 269, 272], ["IL", "TEST", 287, 289], ["granulocyte", "ANATOMY", 158, 169], ["macrophage colony", "OBSERVATION", 170, 187]]], ["Bright-Glo luciferase assay system was obtained from Promega, Madison, WI, USA.", [["Bright-Glo luciferase", "GENE_OR_GENE_PRODUCT", 0, 21], ["Bright-Glo luciferase assay system", "TEST", 0, 34]]], ["Unless specified, other antibodies and peroxidase-conjugated secondary antibodies were purchased from Cedarlane Labs (Burlington, Ontario, Canada).Production, purification and characterization of CFm40L adaptor protein ::: Materials and methodsThe adaptor protein, CFm40L, is a fusion protein that consists of human Ad receptor CAR fused to mouse CD40L via a trimerization motif.", [["peroxidase", "GENE_OR_GENE_PRODUCT", 39, 49], ["CFm40L", "GENE_OR_GENE_PRODUCT", 265, 271], ["human", "ORGANISM", 310, 315], ["Ad receptor CAR", "GENE_OR_GENE_PRODUCT", 316, 331], ["mouse", "ORGANISM", 341, 346], ["CD40L", "GENE_OR_GENE_PRODUCT", 347, 352], ["antibodies", "PROTEIN", 24, 34], ["peroxidase", "PROTEIN", 39, 49], ["secondary antibodies", "PROTEIN", 61, 81], ["CFm40L adaptor protein", "PROTEIN", 196, 218], ["adaptor protein", "PROTEIN", 248, 263], ["CFm40L", "PROTEIN", 265, 271], ["fusion protein", "PROTEIN", 278, 292], ["human Ad receptor CAR", "PROTEIN", 310, 331], ["mouse CD40L", "PROTEIN", 341, 352], ["trimerization motif", "PROTEIN", 359, 378], ["human", "SPECIES", 310, 315], ["mouse", "SPECIES", 341, 346], ["human", "SPECIES", 310, 315], ["mouse", "SPECIES", 341, 346], ["other antibodies", "TEST", 18, 34], ["peroxidase", "TEST", 39, 49], ["conjugated secondary antibodies", "PROBLEM", 50, 81], ["CFm", "TEST", 265, 268], ["a fusion protein", "TREATMENT", 276, 292], ["human Ad receptor CAR", "TREATMENT", 310, 331], ["a trimerization motif", "TREATMENT", 357, 378]]], ["CFm40L was constructed and used to target Ad vectors to mouse DCs expressing CD40.9 CFm40L was purified from the supernatants in stable HEK293 cells transfected with the expression vector.", [["DCs", "ANATOMY", 62, 65], ["supernatants", "ANATOMY", 113, 125], ["HEK293 cells", "ANATOMY", 136, 148], ["Ad", "ORGANISM", 42, 44], ["mouse", "ORGANISM", 56, 61], ["DCs", "CELL", 62, 65], ["CD40.9", "GENE_OR_GENE_PRODUCT", 77, 83], ["CFm40L", "GENE_OR_GENE_PRODUCT", 84, 90], ["HEK293 cells", "CELL", 136, 148], ["CFm40L", "PROTEIN", 0, 6], ["mouse DCs", "CELL_TYPE", 56, 65], ["CD40.9 CFm40L", "PROTEIN", 77, 90], ["HEK293 cells", "CELL_LINE", 136, 148], ["expression vector", "DNA", 170, 187], ["mouse", "SPECIES", 56, 61], ["mouse", "SPECIES", 56, 61], ["CFm", "TEST", 0, 3], ["Ad vectors", "TREATMENT", 42, 52], ["stable", "OBSERVATION_MODIFIER", 129, 135], ["HEK293 cells", "OBSERVATION", 136, 148]]], ["The production and purification of CFm40L was described previously.9 Briefly, the stable cell line producing CFm40L as a secreted protein was cultured in DMEM:F12 (1:1) medium supplemented with 10% fetal calf serum, 2 mM L-glutamine, 100 \u03bcg ml\u22121 G418 and 40 \u03bcg ml\u22121 gentamicin sulphate.", [["cell line", "ANATOMY", 89, 98], ["CFm40L", "ANATOMY", 109, 115], ["fetal calf serum", "ANATOMY", 198, 214], ["L-glutamine", "CHEMICAL", 221, 232], ["G418", "CHEMICAL", 246, 250], ["gentamicin sulphate", "CHEMICAL", 266, 285], ["CFm40L", "CHEMICAL", 35, 41], ["L-glutamine", "CHEMICAL", 221, 232], ["G418", "CHEMICAL", 246, 250], ["gentamicin sulphate", "CHEMICAL", 266, 285], ["cell line", "CELL", 89, 98], ["CFm40L", "CELL", 109, 115], ["calf", "ORGANISM", 204, 208], ["serum", "ORGANISM_SUBSTANCE", 209, 214], ["L-glutamine", "SIMPLE_CHEMICAL", 221, 232], ["gentamicin sulphate", "SIMPLE_CHEMICAL", 266, 285], ["stable cell line", "CELL_LINE", 82, 98], ["CFm40L", "CELL_LINE", 109, 115], ["secreted protein", "PROTEIN", 121, 137], ["calf", "SPECIES", 204, 208], ["a secreted protein", "TEST", 119, 137], ["fetal calf serum", "TEST", 198, 214], ["2 mM L-glutamine", "TREATMENT", 216, 232], ["gentamicin sulphate", "TREATMENT", 266, 285], ["stable", "OBSERVATION_MODIFIER", 82, 88], ["cell line", "OBSERVATION", 89, 98], ["calf", "ANATOMY", 204, 208]]], ["The medium from the CFm40L-expressing 293 cell cultures were collected and the proteins were precipitated by addition of an equal volume of cold-saturated ammonium sulphate.", [["293 cell cultures", "ANATOMY", 38, 55], ["ammonium sulphate", "CHEMICAL", 155, 172], ["ammonium sulphate", "CHEMICAL", 155, 172], ["CFm40L", "GENE_OR_GENE_PRODUCT", 20, 26], ["293 cell cultures", "CELL", 38, 55], ["ammonium sulphate", "SIMPLE_CHEMICAL", 155, 172], ["CFm40L-expressing 293 cell cultures", "CELL_LINE", 20, 55], ["the CFm40L", "TEST", 16, 26], ["cell cultures", "TEST", 42, 55], ["the proteins", "TEST", 75, 87], ["cold-saturated ammonium sulphate", "TREATMENT", 140, 172], ["medium", "OBSERVATION_MODIFIER", 4, 10]]], ["The precipitates were then collected by centrifugation and dissolved in 1/20 of the original medium volume in phosphate-buffered saline (PBS), followed by dialysis against PBS.", [["phosphate", "CHEMICAL", 110, 119], ["phosphate", "CHEMICAL", 110, 119], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 110, 135], ["the original medium volume in phosphate-buffered saline (PBS)", "TREATMENT", 80, 141], ["dialysis against PBS", "TREATMENT", 155, 175]]], ["The recombinant CFm40L protein was purified from the dialysed protein solution by immobilized metal affinity chromatography using cobalt-immobilized TALON affinity resin (Clontech, Mountain View, CA, USA).", [["cobalt", "CHEMICAL", 130, 136], ["cobalt", "CHEMICAL", 130, 136], ["CFm40L", "GENE_OR_GENE_PRODUCT", 16, 22], ["cobalt", "SIMPLE_CHEMICAL", 130, 136], ["TALON", "SIMPLE_CHEMICAL", 149, 154], ["recombinant CFm40L protein", "PROTEIN", 4, 30], ["The recombinant CFm40L protein", "TEST", 0, 30], ["the dialysed protein solution", "TREATMENT", 49, 78], ["metal affinity chromatography", "TEST", 94, 123], ["cobalt-immobilized TALON affinity resin", "TREATMENT", 130, 169]]], ["The purity of the adaptor protein was confirmed by Coomassie blue staining and western blotting.9Construction and production of recombinant Ads ::: Materials and methodsAll transgenes were cloned into adenoviral transfer vector, Ad5.9 The vector expressing SARS-CoV NP45 was used here as a model antigen.", [["Coomassie blue", "CHEMICAL", 51, 65], ["Coomassie", "SIMPLE_CHEMICAL", 51, 60], ["adenoviral", "ORGANISM", 201, 211], ["Ad", "ORGANISM", 229, 231], ["SARS-CoV NP45", "ORGANISM", 257, 270], ["adaptor protein", "PROTEIN", 18, 33], ["SARS-CoV NP45", "PROTEIN", 257, 270], ["SARS-CoV", "SPECIES", 257, 265], ["the adaptor protein", "TREATMENT", 14, 33], ["CoV NP45", "TREATMENT", 262, 270]]], ["The isogenic control vector expressing the luciferase gene was constructed similarly.", [["luciferase", "GENE_OR_GENE_PRODUCT", 43, 53], ["luciferase gene", "DNA", 43, 58], ["The isogenic control vector", "TREATMENT", 0, 27]]], ["Replication defective recombinant Ads were generated from the constructed transfer vectors as described.9 Transgene expression by recombinant Ads was confirmed by luciferase activity assay or by western blot analysis with anti-SARS N-protein antibody.", [["Ads", "GENE_OR_GENE_PRODUCT", 34, 37], ["Transgene", "GENE_OR_GENE_PRODUCT", 106, 115], ["Ads", "GENE_OR_GENE_PRODUCT", 142, 145], ["luciferase", "GENE_OR_GENE_PRODUCT", 163, 173], ["anti-SARS N-protein antibody", "GENE_OR_GENE_PRODUCT", 222, 250], ["recombinant Ads", "PROTEIN", 130, 145], ["luciferase", "PROTEIN", 163, 173], ["anti-SARS N-protein antibody", "PROTEIN", 222, 250], ["Replication defective", "PROBLEM", 0, 21], ["the constructed transfer vectors", "TREATMENT", 58, 90], ["luciferase activity assay", "TEST", 163, 188], ["blot analysis", "TEST", 203, 216], ["anti-SARS N-protein antibody", "TEST", 222, 250], ["recombinant", "OBSERVATION_MODIFIER", 22, 33]]], ["Ad particles were purified by CsCl gradient centrifugation and titrated as plaque-forming units (PFU) per ml using Adeno-X Rapid Titer kit according to the manufacturer's instructions (BD Biosciences, San Jose, CA, USA).DC culture, Ad infection and luciferase activity assay ::: Materials and methodsMyeloid DCs were obtained from AllCELLS, Emeryville, CA, USA.", [["plaque", "ANATOMY", 75, 81], ["DC", "ANATOMY", 220, 222], ["Myeloid DCs", "ANATOMY", 300, 311], ["CsCl", "CHEMICAL", 30, 34], ["Ad infection", "DISEASE", 232, 244], ["CsCl", "CHEMICAL", 30, 34], ["Ad", "ORGANISM", 0, 2], ["Ad", "ORGANISM", 232, 234], ["luciferase", "GENE_OR_GENE_PRODUCT", 249, 259], ["Myeloid DCs", "CELL", 300, 311], ["DC", "CELL_TYPE", 220, 222], ["luciferase", "PROTEIN", 249, 259], ["Myeloid DCs", "CELL_TYPE", 300, 311], ["Ad", "SPECIES", 232, 234], ["CsCl gradient centrifugation", "TREATMENT", 30, 58], ["Adeno", "TREATMENT", 115, 120], ["DC culture", "TEST", 220, 230], ["Ad infection", "PROBLEM", 232, 244], ["methodsMyeloid DCs", "TEST", 293, 311]]], ["Over 80% of these monocyte-derived cells are CD40(+) in addition to other surface markers including CD1a, CD11c, CD86 and HL-DR.", [["monocyte-derived cells", "ANATOMY", 18, 40], ["surface", "ANATOMY", 74, 81], ["monocyte-derived cells", "CELL", 18, 40], ["CD40", "GENE_OR_GENE_PRODUCT", 45, 49], ["CD1a", "GENE_OR_GENE_PRODUCT", 100, 104], ["CD11c", "GENE_OR_GENE_PRODUCT", 106, 111], ["CD86", "GENE_OR_GENE_PRODUCT", 113, 117], ["monocyte-derived cells", "CELL_TYPE", 18, 40], ["CD40", "PROTEIN", 45, 49], ["surface markers", "PROTEIN", 74, 89], ["CD1a", "PROTEIN", 100, 104], ["CD11c", "PROTEIN", 106, 111], ["CD86", "PROTEIN", 113, 117], ["these monocyte", "TEST", 12, 26], ["CD40", "TEST", 45, 49], ["other surface markers", "TEST", 68, 89], ["CD1a", "TEST", 100, 104], ["CD11c", "TEST", 106, 111], ["CD86", "TEST", 113, 117], ["HL", "TEST", 122, 124]]], ["We previously reported elevated levels of maturation markers (CD11c, CD54, CD40, CD80, CD86) in DCs treated with CFm40L-targeted Ad,9 consistent with other studies which show that CD40 stimulation could facilitate DC maturation.1, 39 The DCs were cultured in RPMI-1640 medium containing rh-IL-4 and rhGM-CSF (1 \u00d7 105 cells per well in 24-well plates) for 4 days prior to being subjected to treatments with Ads.", [["DCs", "ANATOMY", 96, 99], ["DC", "ANATOMY", 214, 216], ["DCs", "ANATOMY", 238, 241], ["cells", "ANATOMY", 317, 322], ["CD11c", "GENE_OR_GENE_PRODUCT", 62, 67], ["CD54", "GENE_OR_GENE_PRODUCT", 69, 73], ["CD40", "GENE_OR_GENE_PRODUCT", 75, 79], ["CD80", "GENE_OR_GENE_PRODUCT", 81, 85], ["CD86", "GENE_OR_GENE_PRODUCT", 87, 91], ["DCs", "CELL", 96, 99], ["CFm40L", "SIMPLE_CHEMICAL", 113, 119], ["Ad", "ORGANISM", 129, 131], ["CD40", "GENE_OR_GENE_PRODUCT", 180, 184], ["DC", "CELL", 214, 216], ["DCs", "CELL", 238, 241], ["rh-IL-4", "GENE_OR_GENE_PRODUCT", 287, 294], ["rhGM-CSF", "GENE_OR_GENE_PRODUCT", 299, 307], ["cells", "CELL", 317, 322], ["Ads", "ORGANISM", 406, 409], ["maturation markers", "PROTEIN", 42, 60], ["CD11c", "PROTEIN", 62, 67], ["CD54", "PROTEIN", 69, 73], ["CD40", "PROTEIN", 75, 79], ["CD80", "PROTEIN", 81, 85], ["CD86", "PROTEIN", 87, 91], ["DCs", "CELL_TYPE", 96, 99], ["CD40", "PROTEIN", 180, 184], ["DC", "CELL_TYPE", 214, 216], ["DCs", "CELL_TYPE", 238, 241], ["rh-IL-4", "PROTEIN", 287, 294], ["rhGM", "PROTEIN", 299, 303], ["CSF", "PROTEIN", 304, 307], ["elevated levels of maturation markers", "PROBLEM", 23, 60], ["CD11c", "TEST", 62, 67], ["CD54", "TEST", 69, 73], ["CD40", "TEST", 75, 79], ["CD80", "TEST", 81, 85], ["CFm", "TEST", 113, 116], ["other studies", "TEST", 150, 163], ["CD40 stimulation", "TREATMENT", 180, 196], ["DC maturation", "TREATMENT", 214, 227], ["RPMI", "TEST", 259, 263], ["rh", "TEST", 287, 289], ["IL", "TEST", 290, 292], ["rhGM", "TEST", 299, 303], ["CSF", "TEST", 304, 307], ["cells", "TEST", 317, 322], ["elevated", "OBSERVATION_MODIFIER", 23, 31]]], ["The preparation of the tAd-Luc (Ad-5 encoding luciferase gene and conjugated with CFm40L) and infection of DCs in vitro were described previously.9 In brief, Ad expressing luciferase genes (Ad-Luc) was pre-mixed with the CFm40L adaptor protein and incubated at 37 \u00b0C for 30 min and then used to infect DCs at 50 PFU per cell.", [["DCs", "ANATOMY", 107, 110], ["DCs", "ANATOMY", 302, 305], ["cell", "ANATOMY", 320, 324], ["infection", "DISEASE", 94, 103], ["tAd-Luc", "GENE_OR_GENE_PRODUCT", 23, 30], ["Ad-5", "GENE_OR_GENE_PRODUCT", 32, 36], ["luciferase", "GENE_OR_GENE_PRODUCT", 46, 56], ["CFm40L", "GENE_OR_GENE_PRODUCT", 82, 88], ["DCs", "CELL", 107, 110], ["Ad", "ORGANISM", 158, 160], ["luciferase", "GENE_OR_GENE_PRODUCT", 172, 182], ["Ad-Luc", "GENE_OR_GENE_PRODUCT", 190, 196], ["CFm40L", "GENE_OR_GENE_PRODUCT", 221, 227], ["DCs", "CELL", 302, 305], ["cell", "CELL", 320, 324], ["tAd-Luc (Ad-5 encoding luciferase gene", "DNA", 23, 61], ["DCs", "CELL_TYPE", 107, 110], ["luciferase genes", "DNA", 172, 188], ["Ad", "DNA", 190, 192], ["Luc", "DNA", 193, 196], ["CFm40L adaptor protein", "PROTEIN", 221, 243], ["DCs", "CELL_TYPE", 302, 305], ["the tAd", "TREATMENT", 19, 26], ["Ad-5 encoding luciferase gene", "TREATMENT", 32, 61], ["CFm", "TREATMENT", 82, 85], ["infection of DCs in vitro", "PROBLEM", 94, 119], ["the CFm40L adaptor protein", "TREATMENT", 217, 243], ["infection", "OBSERVATION", 94, 103]]], ["After 2 days of infection, the cells were harvested to measure luciferase activity using Bright-Glo luciferase assay system.Biodistribution and pathological examination ::: Materials and methodsFemale Balb/c mice were purchased from Charles River Lab, Montreal, Quebec, Canada.", [["cells", "ANATOMY", 31, 36], ["infection", "DISEASE", 16, 25], ["cells", "CELL", 31, 36], ["luciferase", "GENE_OR_GENE_PRODUCT", 63, 73], ["luciferase", "GENE_OR_GENE_PRODUCT", 100, 110], ["Balb/c mice", "ORGANISM", 201, 212], ["luciferase", "PROTEIN", 63, 73], ["mice", "SPECIES", 208, 212], ["mice", "SPECIES", 208, 212], ["infection", "PROBLEM", 16, 25], ["the cells", "TREATMENT", 27, 36], ["luciferase activity", "TEST", 63, 82], ["Bright-Glo luciferase assay system", "TEST", 89, 123], ["pathological examination", "TEST", 144, 168], ["infection", "OBSERVATION", 16, 25]]], ["The mice were maintained in a laminar airflow cabinet under pathogen-free conditions and used at 6\u20137 weeks of age.", [["mice", "ORGANISM", 4, 8], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 4, 8], ["laminar airflow", "OBSERVATION", 30, 45]]], ["A total of 1 \u00d7 109 PFU (\u223c1 \u00d7 1010 viral particles) of Ads suspended in 100 \u03bcl of PBS per mouse was administrated using a syringe with a 29-gauge needle by i.v. (tail veil), intradermal (i.d.) (inguinal) or i.n. routes.", [["tail", "ANATOMY", 161, 165], ["inguinal", "ANATOMY", 193, 201], ["Ads", "ORGANISM", 54, 57], ["mouse", "ORGANISM", 89, 94], ["tail", "ORGANISM_SUBDIVISION", 161, 165], ["veil", "ORGANISM_SUBDIVISION", 166, 170], ["mouse", "SPECIES", 89, 94], ["mouse", "SPECIES", 89, 94], ["viral particles", "TEST", 34, 49], ["a syringe", "TREATMENT", 119, 128], ["a 29-gauge needle", "TREATMENT", 134, 151], ["inguinal", "ANATOMY", 193, 201]]], ["Control mice were injected with 100 \u03bcl of PBS.", [["mice", "ORGANISM", 8, 12], ["mice", "SPECIES", 8, 12], ["mice", "SPECIES", 8, 12], ["PBS", "TREATMENT", 42, 45]]], ["The preparation of Ads complexed with CFm40L was described previously.9 In brief, the same amounts of Ads was mixed with 16 \u03bcg CFm40L (that is 80 ng CFm40L/5 \u00d7 106 PFU Ads) in 100 \u03bcl of PBS and incubated at 37 \u00b0C for 30 min.", [["CFm40L", "CHEMICAL", 38, 44], ["Ads", "ORGANISM", 19, 22], ["Ads", "ORGANISM", 102, 105], ["PBS", "TREATMENT", 186, 189]]], ["The mice were killed on days 3 and 7 after administration of Ads, with tissues collected for subsequent analyses of biodistribution.", [["tissues", "ANATOMY", 71, 78], ["mice", "ORGANISM", 4, 8], ["Ads", "ORGANISM", 61, 64], ["tissues", "TISSUE", 71, 78], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 4, 8]]], ["The levels of luciferase activity, normalized by protein concentration, were determined.", [["luciferase", "GENE_OR_GENE_PRODUCT", 14, 24], ["luciferase", "PROTEIN", 14, 24], ["luciferase activity", "TEST", 14, 33], ["protein concentration", "TEST", 49, 70], ["luciferase activity", "OBSERVATION", 14, 33]]], ["Five mice were used in each group.", [["mice", "ORGANISM", 5, 9], ["mice", "SPECIES", 5, 9], ["mice", "SPECIES", 5, 9]]], ["Pathological examination of tissues using hematoxylin and eosin staining method was conducted using a standard procedure.Isolation of splenocyte and ELISPOT assay for the measurement of cytokines ::: Materials and methodsTo determine the adjuvant effects of CFm40L, non-modified Ad expressing the SARS-CoV NP protein (Ad-NP) was compared with the same virus complexed with CFm40L (tAd-NP) following either i.d. or i.n. administration, with tAd-Luc serving as the baseline control.", [["tissues", "ANATOMY", 28, 35], ["splenocyte", "ANATOMY", 134, 144], ["tAd-NP", "CHEMICAL", 381, 387], ["hematoxylin", "CHEMICAL", 42, 53], ["eosin", "CHEMICAL", 58, 63], ["tissues", "TISSUE", 28, 35], ["hematoxylin", "SIMPLE_CHEMICAL", 42, 53], ["splenocyte", "CELL", 134, 144], ["Ad", "ORGANISM", 279, 281], ["SARS-CoV NP", "ORGANISM", 297, 308], ["Ad-NP", "ORGANISM", 318, 323], ["tAd-NP", "GENE_OR_GENE_PRODUCT", 381, 387], ["tAd-Luc", "GENE_OR_GENE_PRODUCT", 440, 447], ["splenocyte", "CELL_TYPE", 134, 144], ["cytokines", "PROTEIN", 186, 195], ["SARS-CoV NP protein", "PROTEIN", 297, 316], ["NP", "PROTEIN", 321, 323], ["tAd", "PROTEIN", 440, 443], ["Luc", "PROTEIN", 444, 447], ["SARS-CoV", "SPECIES", 297, 305], ["Pathological examination", "TEST", 0, 24], ["hematoxylin", "TREATMENT", 42, 53], ["eosin staining method", "TREATMENT", 58, 79], ["a standard procedure", "TREATMENT", 100, 120], ["ELISPOT assay", "TEST", 149, 162], ["CFm", "TREATMENT", 258, 261], ["the SARS", "TEST", 293, 301], ["CoV NP protein (Ad-NP)", "TREATMENT", 302, 324], ["tAd-NP)", "TREATMENT", 381, 388], ["tissues", "ANATOMY", 28, 35], ["splenocyte", "ANATOMY", 134, 144], ["ELISPOT assay", "OBSERVATION", 149, 162]]], ["We chose the same amount of virus as in the above biodistribution experiments.", [["virus", "PROBLEM", 28, 33], ["virus", "OBSERVATION", 28, 33]]], ["For immunization, five mice were primed with 1 \u00d7 1010 VP of Ad-NP, tAd-NP or tAd-Luc (negative control).", [["Ad-NP", "CHEMICAL", 60, 65], ["mice", "ORGANISM", 23, 27], ["Ad", "ORGANISM", 60, 62], ["-NP", "SIMPLE_CHEMICAL", 62, 65], ["tAd-NP", "SIMPLE_CHEMICAL", 67, 73], ["tAd-Luc", "GENE_OR_GENE_PRODUCT", 77, 84], ["Luc", "PROTEIN", 81, 84], ["mice", "SPECIES", 23, 27], ["mice", "SPECIES", 23, 27], ["immunization", "TREATMENT", 4, 16], ["Ad-NP", "TREATMENT", 60, 65], ["tAd-NP", "TREATMENT", 67, 73]]], ["Thirty days post administration, the mice were boosted once.", [["mice", "ORGANISM", 37, 41], ["mice", "SPECIES", 37, 41], ["mice", "SPECIES", 37, 41], ["the mice", "TREATMENT", 33, 41]]], ["The splenocytes were isolated on days 0, 15 and 30 post boosting for the determination of IFN-\u03b3 and IL-2.", [["splenocytes", "ANATOMY", 4, 15], ["splenocytes", "CELL", 4, 15], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 90, 95], ["IL-2", "GENE_OR_GENE_PRODUCT", 100, 104], ["splenocytes", "CELL_TYPE", 4, 15], ["IFN", "PROTEIN", 90, 93], ["IL", "PROTEIN", 100, 102], ["the determination", "TEST", 69, 86], ["IFN-\u03b3 and IL", "TREATMENT", 90, 102], ["splenocytes", "ANATOMY", 4, 15]]], ["Splenocytes were isolated from mouse spleens by grinding them between the frosted ends of two microscope slides.", [["Splenocytes", "ANATOMY", 0, 11], ["spleens", "ANATOMY", 37, 44], ["Splenocytes", "CELL", 0, 11], ["mouse", "ORGANISM", 31, 36], ["spleens", "ORGAN", 37, 44], ["Splenocytes", "CELL_TYPE", 0, 11], ["mouse", "SPECIES", 31, 36], ["mouse", "SPECIES", 31, 36], ["Splenocytes", "PROBLEM", 0, 11], ["mouse spleens", "OBSERVATION", 31, 44], ["two", "OBSERVATION_MODIFIER", 90, 93], ["microscope slides", "OBSERVATION", 94, 111]]], ["The slides were rinsed with 5 ml of RPMI 1640 medium to collect the cells.", [["cells", "ANATOMY", 68, 73], ["cells", "CELL", 68, 73], ["RPMI", "TREATMENT", 36, 40]]], ["Afterwards, the cell suspension was passed through a fine nylon mesh to obtain a single cell suspension.", [["cell", "ANATOMY", 16, 20], ["cell", "ANATOMY", 88, 92], ["cell", "CELL", 16, 20], ["cell", "CELL", 88, 92], ["the cell suspension", "TREATMENT", 12, 31], ["a fine nylon mesh", "TREATMENT", 51, 68], ["a single cell suspension", "TREATMENT", 79, 103], ["nylon mesh", "OBSERVATION", 58, 68]]], ["The spleen pieces were then gently mashed with the rubber end of a syringe plunger.", [["spleen pieces", "ANATOMY", 4, 17], ["spleen", "ORGAN", 4, 10], ["a syringe plunger", "TREATMENT", 65, 82], ["spleen", "ANATOMY", 4, 10], ["rubber", "OBSERVATION_MODIFIER", 51, 57], ["end", "OBSERVATION_MODIFIER", 58, 61], ["syringe plunger", "OBSERVATION", 67, 82]]], ["A second filtration was then performed by pipetting the 5 ml suspensions of dispersed cells through a fresh 70-\u03bcm nylon mesh cell strainer into a 50-ml conical tube (on ice).", [["cells", "ANATOMY", 86, 91], ["cell", "ANATOMY", 125, 129], ["cells", "CELL", 86, 91], ["tube", "TISSUE", 160, 164], ["dispersed cells", "CELL_TYPE", 76, 91], ["A second filtration", "TREATMENT", 0, 19], ["a fresh 70-\u03bcm nylon mesh cell strainer", "TREATMENT", 100, 138], ["a 50-ml conical tube", "TREATMENT", 144, 164], ["mesh cell", "OBSERVATION", 120, 129], ["tube", "OBSERVATION", 160, 164]]], ["This procedure was repeated with additional washes of 5 ml medium until the splenic capsules turned white (3\u20134 more times).", [["splenic capsules", "ANATOMY", 76, 92], ["This procedure", "TREATMENT", 0, 14], ["additional washes of 5 ml medium", "TREATMENT", 33, 65], ["the splenic capsules", "TREATMENT", 72, 92], ["splenic", "ANATOMY", 76, 83], ["capsules", "ANATOMY_MODIFIER", 84, 92]]], ["The total volume of cell suspension was brought up to 20 ml with medium.", [["cell", "ANATOMY", 20, 24], ["cell", "CELL", 20, 24], ["The total volume of cell suspension", "TREATMENT", 0, 35], ["total", "OBSERVATION_MODIFIER", 4, 9], ["volume", "OBSERVATION_MODIFIER", 10, 16], ["cell suspension", "OBSERVATION", 20, 35]]], ["Cell pellets were then obtained by centrifugation at 400 g for 5 min at 4 \u00b0C. About 1 ml of 0.84% NH4Cl solution was used to lyse the red blood cells.", [["Cell", "ANATOMY", 0, 4], ["red blood cells", "ANATOMY", 134, 149], ["NH4Cl", "CHEMICAL", 98, 103], ["NH4Cl", "CHEMICAL", 98, 103], ["Cell", "CELL", 0, 4], ["NH4Cl", "SIMPLE_CHEMICAL", 98, 103], ["red blood cells", "CELL", 134, 149], ["red blood cells", "CELL_TYPE", 134, 149], ["Cell pellets", "TREATMENT", 0, 12], ["0.84% NH4Cl solution", "TREATMENT", 92, 112], ["the red blood cells", "TEST", 130, 149]]], ["The tubes were gently rolled by hand for 2 min at room temperature, followed by the addition of 30 ml of chilled RPMI medium After passing the cells through another layer of 70-\u03bcm nylon mesh, cells were collected by centrifugation at 400 g for 5 min at 4 \u00b0C. The pellet was then gently resuspended to 2 \u00d7 106 cells per 100 \u03bcl (2 \u00d7 107 cells per ml) in RPMI 1640 containing 10% heat-inactivated fetal bovine serum in the presence of 10 purified SARS-CoV NPs (10 \u03bcg ml\u22121) to stimulate Ag-specific cytokine.43 As stimulation with NP of splenocytes derived from the control animals receiving Ad-Luc did not result in any detectable production of cytokines (background), all subsequent experiments were conducted in the presence of 10 \u03bcg ml\u22121 of NP.", [["tubes", "ANATOMY", 4, 9], ["hand", "ANATOMY", 32, 36], ["cells", "ANATOMY", 143, 148], ["cells", "ANATOMY", 192, 197], ["cells", "ANATOMY", 309, 314], ["cells", "ANATOMY", 335, 340], ["fetal bovine serum", "ANATOMY", 394, 412], ["splenocytes", "ANATOMY", 533, 544], ["Ag", "CHEMICAL", 483, 485], ["Ag", "CHEMICAL", 483, 485], ["tubes", "ORGANISM_SUBSTANCE", 4, 9], ["hand", "ORGANISM_SUBDIVISION", 32, 36], ["cells", "CELL", 143, 148], ["cells", "CELL", 192, 197], ["cells", "CELL", 309, 314], ["cells", "CELL", 335, 340], ["bovine", "ORGANISM", 400, 406], ["serum", "ORGANISM_SUBSTANCE", 407, 412], ["SARS-CoV NPs", "SIMPLE_CHEMICAL", 444, 456], ["Ag", "GENE_OR_GENE_PRODUCT", 483, 485], ["splenocytes", "CELL", 533, 544], ["Ad-Luc", "ORGANISM", 588, 594], ["Ag", "PROTEIN", 483, 485], ["cytokine", "PROTEIN", 495, 503], ["splenocytes", "CELL_TYPE", 533, 544], ["cytokines", "PROTEIN", 642, 651], ["bovine", "SPECIES", 400, 406], ["bovine", "SPECIES", 400, 406], ["The tubes", "TREATMENT", 0, 9], ["chilled RPMI medium", "TREATMENT", 105, 124], ["70-\u03bcm nylon mesh", "TREATMENT", 174, 190], ["The pellet", "TREATMENT", 259, 269], ["fetal bovine serum", "TEST", 394, 412], ["CoV NPs", "TREATMENT", 449, 456], ["Ag", "TEST", 483, 485], ["NP of splenocytes", "TREATMENT", 527, 544], ["NP", "TREATMENT", 741, 743], ["tubes", "OBSERVATION", 4, 9], ["nylon mesh", "OBSERVATION", 180, 190]]], ["These cells were then used at 100 \u03bcl per well for ELISPOT assays using procedures as provided by the supplier, R&D system.Determination of Ag-specific antibody responses and IgG 1/IgG 2a ratio ::: Materials and methodsELISA was conducted to determine the titre of antibodies against the SARS-CoV NP protein.", [["cells", "ANATOMY", 6, 11], ["cells", "CELL", 6, 11], ["Ag-", "GENE_OR_GENE_PRODUCT", 139, 142], ["IgG 1", "GENE_OR_GENE_PRODUCT", 174, 179], ["IgG 2a", "GENE_OR_GENE_PRODUCT", 180, 186], ["SARS-CoV NP", "GENE_OR_GENE_PRODUCT", 287, 298], ["Ag-specific antibody", "PROTEIN", 139, 159], ["IgG 1", "PROTEIN", 174, 179], ["IgG 2a", "PROTEIN", 180, 186], ["antibodies", "PROTEIN", 264, 274], ["SARS-CoV NP protein", "PROTEIN", 287, 306], ["SARS-CoV", "SPECIES", 287, 295], ["ELISPOT assays", "TEST", 50, 64], ["procedures", "TREATMENT", 71, 81], ["Ag-specific antibody responses", "TEST", 139, 169], ["IgG", "TEST", 174, 177], ["methodsELISA", "TREATMENT", 211, 223], ["antibodies", "TREATMENT", 264, 274], ["the SARS", "PROBLEM", 283, 291], ["CoV NP protein", "TREATMENT", 292, 306]]], ["To this end, the Nunc 96-well plates were coated with the 100 \u03bcl of NP protein at 5 \u03bcg ml\u22121 in 50 mM carbonate buffer (pH 8.6) and incubated at 4 \u00b0C overnight.", [["carbonate", "CHEMICAL", 101, 110], ["carbonate", "SIMPLE_CHEMICAL", 101, 110], ["Nunc 96-well plates", "DNA", 17, 36], ["NP protein", "PROTEIN", 68, 78], ["the Nunc", "TEST", 13, 21], ["NP protein", "TREATMENT", 68, 78], ["50 mM carbonate buffer", "TREATMENT", 95, 117], ["pH", "TEST", 119, 121]]], ["The wells were then washed five times with PBS, 0.05% Tween-20, followed by the addition of blocking buffer comprised of PBS, 0.05% Tween-20 and 5% BSA.", [["Tween-20", "CHEMICAL", 54, 62], ["Tween-20", "CHEMICAL", 54, 62], ["Tween-20", "CHEMICAL", 132, 140], ["Tween-20", "SIMPLE_CHEMICAL", 54, 62], ["PBS", "SIMPLE_CHEMICAL", 121, 124], ["Tween-20", "SIMPLE_CHEMICAL", 132, 140], ["BSA", "SIMPLE_CHEMICAL", 148, 151], ["PBS", "TREATMENT", 43, 46], ["blocking buffer", "TREATMENT", 92, 107], ["PBS", "TREATMENT", 121, 124]]], ["After incubation at 37 \u00b0C for 1 h, the blocking buffer was removed, followed by the addition of samples of serum or washing fluids of the lung from the mice.", [["samples", "ANATOMY", 96, 103], ["serum", "ANATOMY", 107, 112], ["lung", "ANATOMY", 138, 142], ["serum", "ORGANISM_SUBSTANCE", 107, 112], ["lung", "ORGAN", 138, 142], ["mice", "ORGANISM", 152, 156], ["mice", "SPECIES", 152, 156], ["mice", "SPECIES", 152, 156], ["the blocking buffer", "TREATMENT", 35, 54], ["samples of serum", "TEST", 96, 112], ["washing fluids of the lung", "TREATMENT", 116, 142], ["lung", "ANATOMY", 138, 142]]], ["Afterwards, secondary antibodies (peroxidase-conjugated goat anti-mouse IgG, IgM or IgA) were added at concentrations recommended by the supplier (Cedarlane Labs).", [["peroxidase", "GENE_OR_GENE_PRODUCT", 34, 44], ["IgM", "GENE_OR_GENE_PRODUCT", 77, 80], ["IgA", "GENE_OR_GENE_PRODUCT", 84, 87], ["secondary antibodies", "PROTEIN", 12, 32], ["peroxidase", "PROTEIN", 34, 44], ["conjugated goat anti-mouse IgG", "PROTEIN", 45, 75], ["IgM", "PROTEIN", 77, 80], ["IgA", "PROTEIN", 84, 87], ["goat", "SPECIES", 56, 60], ["anti-mouse", "SPECIES", 61, 71], ["goat", "SPECIES", 56, 60], ["secondary antibodies", "TEST", 12, 32], ["peroxidase-conjugated goat anti-mouse IgG", "TREATMENT", 34, 75], ["IgM", "TREATMENT", 77, 80], ["IgA)", "TREATMENT", 84, 88]]], ["Following an additional incubation at 37 \u00b0C for 1 h, the plates were washed five times before o-phenylenediamine dihydrochloride (OPD) was added for colorimetric development.", [["o-phenylenediamine dihydrochloride", "CHEMICAL", 94, 128], ["o-phenylenediamine dihydrochloride", "CHEMICAL", 94, 128], ["OPD", "CHEMICAL", 130, 133], ["o-phenylenediamine dihydrochloride", "SIMPLE_CHEMICAL", 94, 128], ["OPD", "SIMPLE_CHEMICAL", 130, 133], ["an additional incubation", "TREATMENT", 10, 34], ["the plates", "TREATMENT", 53, 63], ["o-phenylenediamine dihydrochloride (OPD)", "TREATMENT", 94, 134]]], ["The positive controls (mouse anti-SARS monoclonal antibodies) were purchased from BD Pharmingen, San Diego, CA, USA).", [["mouse", "ORGANISM", 23, 28], ["mouse anti-SARS monoclonal antibodies", "PROTEIN", 23, 60], ["mouse", "SPECIES", 23, 28], ["mouse", "SPECIES", 23, 28], ["The positive controls (mouse anti-SARS monoclonal antibodies", "PROBLEM", 0, 60], ["positive controls", "OBSERVATION", 4, 21]]], ["The cut-off was defined as mean of five negative samples (from un-immunized control) plus two s.d.", [["samples", "ANATOMY", 49, 56], ["un-immunized control", "TREATMENT", 63, 83]]], ["For the determination of relative levels of transgene (NP)-specific IgG subclasses, anti-mouse IgG1 and IgG2a conjugated with HRP (Cedarlane Labs) were substituted for anti-mouse IgG-HRP prior to the addition of OPD for colorimetric development.26Statistical analysis ::: Materials and methodsResults are presented with the means\u00b1s.d.", [["transgene (NP)", "GENE_OR_GENE_PRODUCT", 44, 58], ["IgG", "GENE_OR_GENE_PRODUCT", 68, 71], ["IgG1", "GENE_OR_GENE_PRODUCT", 95, 99], ["IgG2a", "GENE_OR_GENE_PRODUCT", 104, 109], ["HRP", "SIMPLE_CHEMICAL", 126, 129], ["Cedarlane Labs", "SIMPLE_CHEMICAL", 131, 145], ["HRP", "GENE_OR_GENE_PRODUCT", 183, 186], ["OPD", "SIMPLE_CHEMICAL", 212, 215], ["transgene (NP)-specific IgG subclasses", "PROTEIN", 44, 82], ["anti-mouse IgG1", "PROTEIN", 84, 99], ["IgG2a", "PROTEIN", 104, 109], ["HRP", "PROTEIN", 126, 129], ["Cedarlane Labs", "PROTEIN", 131, 145], ["anti-mouse IgG", "PROTEIN", 168, 182], ["HRP", "PROTEIN", 183, 186], ["anti-mouse", "SPECIES", 84, 94], ["anti-mouse", "SPECIES", 168, 178], ["anti-mouse", "SPECIES", 84, 94], ["transgene (NP)", "TEST", 44, 58], ["specific IgG subclasses", "TEST", 59, 82], ["anti-mouse IgG1", "TEST", 84, 99], ["IgG2a", "TEST", 104, 109], ["HRP (Cedarlane Labs", "TEST", 126, 145], ["anti-mouse IgG", "TREATMENT", 168, 182]]]], "PMC7232519": [], "91c05988b14f0eb6feec0d60cba27db392c6a0a2": [["S1.1 X-ray structure determinationFor the structural determination of 1, a single-crystal of the compound was mounted on a Bruker Kappa APEX II diffractometer, equipped with a triumph monochromator at ambient temperature.", [["the structural determination", "TEST", 38, 66], ["a triumph monochromator at ambient temperature", "TREATMENT", 174, 220]]], ["Diffraction measurements were recorded using Mo K\u03b1 radiation.", [["K\u03b1", "CHEMICAL", 48, 50], ["Diffraction measurements", "TEST", 0, 24], ["Mo K\u03b1 radiation", "TREATMENT", 45, 60]]], ["Unit cell dimensions were determined using 169 reflections in the range 15<\u03b8<20 o .", [["cell", "ANATOMY", 5, 9], ["Unit cell", "CELL", 0, 9], ["Unit cell dimensions", "TEST", 0, 20]]], ["Intensity data were collected using \u03c6 and \u03c9 scan mode.", [["Intensity data", "TEST", 0, 14], ["\u03c9 scan mode", "TEST", 42, 53]]], ["The frames collected were integrated with the Bruker SAINT software packageS1.1 X-ray structure determination[1] using a narrow-frame algorithm.", [["a narrow-frame algorithm", "TREATMENT", 119, 143]]], ["Data were corrected for absorption using the numerical method (SADABS) based on crystal dimensions [2] .", [["the numerical method (SADABS)", "TREATMENT", 41, 70]]], ["The structure was solved using the SUPERFLIP package [3] and refined by full-matrix least-squares method on F 2 using the CRYSTALS package version 14.61_build_6236 [4] .", [["the SUPERFLIP package", "TREATMENT", 31, 52]]], ["All non-hydrogen atoms were refined anisotropically.", [["non-hydrogen", "CHEMICAL", 4, 16], ["non-hydrogen atoms", "SIMPLE_CHEMICAL", 4, 22]]], ["All hydrogen atoms were found at their expected positions and refined using soft constraints.", [["hydrogen", "CHEMICAL", 4, 12], ["hydrogen", "CHEMICAL", 4, 12], ["hydrogen atoms", "SIMPLE_CHEMICAL", 4, 18], ["All hydrogen atoms", "PROBLEM", 0, 18], ["soft constraints", "TREATMENT", 76, 92], ["hydrogen atoms", "OBSERVATION", 4, 18], ["soft constraints", "OBSERVATION", 76, 92]]], ["Illustrations were drawn by CAMERON [5] .S1.1 X-ray structure determinationSingle-crystal X-ray diffraction data for complexes 2\u00b73.3MeOH and 3\u00b70.9MeOH\u00b70.2H 2 O were collected on a Nonius Kappa CCD diffractometer using Mo-K\u03b1 radiation (\u03bb = 0.71073 \u00c5) at 150 K. The data were processed using DENZO [6] .", [["2\u00b73.3MeOH", "CHEMICAL", 127, 136], ["Mo-K\u03b1", "CHEMICAL", 218, 223], ["MeOH", "CHEMICAL", 132, 136], ["MeOH", "CHEMICAL", 146, 150], ["0.2H 2 O", "CHEMICAL", 151, 159], ["2\u00b73.3MeOH", "SIMPLE_CHEMICAL", 127, 136], ["0.2H 2 O", "SIMPLE_CHEMICAL", 151, 159], ["ray structure determination", "TEST", 48, 75], ["Single-crystal X-ray diffraction data", "TEST", 75, 112], ["complexes", "TEST", 117, 126], ["MeOH", "TEST", 132, 136], ["MeOH", "TEST", 146, 150], ["Mo-K\u03b1 radiation", "TREATMENT", 218, 233]]], ["Structures were solved by direct methods implemented in SIR97 [7] or SIR2004 [8] and refined by a full-matrix least-squares procedure based on F 2 with SHELXL-2018 [9] .", [["direct methods", "TEST", 26, 40], ["a full-matrix least-squares procedure", "TREATMENT", 96, 133]]], ["All the non-hydrogen atoms were refined anisotropically.S1.1 X-ray structure determinationHydrogen atoms were readily located in difference Fourier maps and were subsequently treated as riding atoms in geometrically idealized positions with U iso (H) = kU eq (C,N or O), where k = 1.5 for OH and methyl groups, which were permitted to rotate but not to tilt, and 1.2 for all other H atoms unless otherwise noted.S1.1 X-ray structure determinationIn the crystal structure of 2\u00b73.3MeOH, carbonyl oxygen atoms O7 and O9 of monodentately bonded indomethacin ligands are disordered over two positions with a refined occupancy ratio 0.54:0.46 and O7A-C39, O7B-C39, O9B-C58 distances were refined restraining the bond distances with U iso (H) = 1.5U eq (O).", [["Hydrogen atoms", "CHEMICAL", 90, 104], ["OH", "CHEMICAL", 289, 291], ["methyl", "CHEMICAL", 296, 302], ["2\u00b73.3MeOH", "CHEMICAL", 474, 483], ["carbonyl", "CHEMICAL", 485, 493], ["oxygen", "CHEMICAL", 494, 500], ["O7", "CHEMICAL", 507, 509], ["O9", "CHEMICAL", 514, 516], ["indomethacin", "CHEMICAL", 541, 553], ["O7B-C39", "CHEMICAL", 650, 657], ["non-hydrogen", "CHEMICAL", 8, 20], ["Hydrogen", "CHEMICAL", 90, 98], ["H", "CHEMICAL", 248, 249], ["C", "CHEMICAL", 260, 261], ["N", "CHEMICAL", 262, 263], ["O", "CHEMICAL", 267, 268], ["OH", "CHEMICAL", 289, 291], ["methyl", "CHEMICAL", 296, 302], ["H", "CHEMICAL", 381, 382], ["MeOH", "CHEMICAL", 479, 483], ["carbonyl", "CHEMICAL", 485, 493], ["oxygen", "CHEMICAL", 494, 500], ["O7", "CHEMICAL", 507, 509], ["O9", "CHEMICAL", 514, 516], ["indomethacin", "CHEMICAL", 541, 553], ["O7A-C39, O7B-C39, O9B-C58", "CHEMICAL", 641, 666], ["non-hydrogen atoms", "SIMPLE_CHEMICAL", 8, 26], ["Hydrogen atoms", "SIMPLE_CHEMICAL", 90, 104], ["OH", "SIMPLE_CHEMICAL", 289, 291], ["methyl groups", "SIMPLE_CHEMICAL", 296, 309], ["H atoms", "SIMPLE_CHEMICAL", 381, 388], ["2\u00b73.3MeOH", "SIMPLE_CHEMICAL", 474, 483], ["carbonyl oxygen atoms O7", "SIMPLE_CHEMICAL", 485, 509], ["O9", "SIMPLE_CHEMICAL", 514, 516], ["indomethacin ligands", "SIMPLE_CHEMICAL", 541, 561], ["O7A-C39", "SIMPLE_CHEMICAL", 641, 648], ["O7B-C39", "SIMPLE_CHEMICAL", 650, 657], ["O9B-C58", "SIMPLE_CHEMICAL", 659, 666], ["H atoms", "PROTEIN", 381, 388], ["O9B", "PROTEIN", 659, 662], ["Hydrogen atoms", "PROBLEM", 90, 104], ["Fourier maps", "TEST", 140, 152], ["U iso", "TEST", 241, 246], ["k", "TEST", 277, 278], ["carbonyl oxygen atoms O7", "TREATMENT", 485, 509], ["O9 of monodentately bonded indomethacin ligands", "TREATMENT", 514, 561], ["a refined occupancy ratio", "TEST", 601, 626], ["O7A", "TEST", 641, 644], ["O7B", "TEST", 650, 653], ["U iso", "TEST", 726, 731], ["Hydrogen atoms", "OBSERVATION", 90, 104]]], ["Hydrogen atoms bonded to coordinated water molecule O1 were refined restraining the bonding distances.", [["Hydrogen atoms", "CHEMICAL", 0, 14], ["Hydrogen", "CHEMICAL", 0, 8], ["O1", "CHEMICAL", 52, 54], ["Hydrogen atoms", "SIMPLE_CHEMICAL", 0, 14], ["water molecule O1", "SIMPLE_CHEMICAL", 37, 54], ["Hydrogen atoms", "PROBLEM", 0, 14], ["atoms bonded", "OBSERVATION", 9, 21], ["coordinated", "OBSERVATION_MODIFIER", 25, 36], ["water molecule", "OBSERVATION", 37, 51]]], ["One methanol solvate molecule was refined restraining the O23-C101 bond distance.", [["methanol solvate", "CHEMICAL", 4, 20], ["methanol", "CHEMICAL", 4, 12], ["O23-C101", "CHEMICAL", 58, 66], ["methanol solvate molecule", "SIMPLE_CHEMICAL", 4, 29], ["O23", "SIMPLE_CHEMICAL", 58, 61], ["O23", "PROTEIN", 58, 61], ["One methanol solvate molecule", "TREATMENT", 0, 29]]], ["Three methanol solvate molecules were refined with fixed occupancy factor of 0.65 and one methanol solvate molecule with fixed occupancy factor of 0.70.S1.1 X-ray structure determinationOne methanol solvate molecule was refined disordered over two positions with refined occupancy factor 0.401 and 0.250, respectively, with the same coordinates used for C10A and C10B atoms as well as anisotropic displacement parameters.S1.1 X-ray structure determinationIn the crystal structure 3\u00b70.9MeOH\u00b70.2H 2 O methanol solvate molecule is disordered over 2fold rotation axis with refined partial occupancy factor in 0.45:0.45 ratio.", [["methanol solvate", "CHEMICAL", 6, 22], ["methanol solvate", "CHEMICAL", 190, 206], ["0.2H 2 O methanol solvate", "CHEMICAL", 490, 515], ["methanol", "CHEMICAL", 6, 14], ["methanol", "CHEMICAL", 90, 98], ["methanol", "CHEMICAL", 190, 198], ["C10A", "CHEMICAL", 354, 358], ["C10B", "CHEMICAL", 363, 367], ["MeOH", "CHEMICAL", 485, 489], ["0.2H", "CHEMICAL", 490, 494], ["O", "CHEMICAL", 497, 498], ["methanol", "CHEMICAL", 499, 507], ["methanol solvate molecules", "SIMPLE_CHEMICAL", 6, 32], ["methanol solvate molecule", "SIMPLE_CHEMICAL", 90, 115], ["methanol solvate molecule", "SIMPLE_CHEMICAL", 190, 215], ["C10A", "SIMPLE_CHEMICAL", 354, 358], ["C10B atoms", "SIMPLE_CHEMICAL", 363, 373], ["0.2H 2 O methanol solvate molecule", "SIMPLE_CHEMICAL", 490, 524], ["occupancy factor", "PROTEIN", 271, 287], ["C10A", "PROTEIN", 354, 358], ["refined partial occupancy factor", "PROTEIN", 569, 601], ["Three methanol solvate molecules", "TREATMENT", 0, 32], ["fixed occupancy factor", "PROBLEM", 51, 73], ["one methanol solvate molecule", "TREATMENT", 86, 115], ["fixed occupancy factor", "PROBLEM", 121, 143], ["One methanol solvate molecule", "TREATMENT", 186, 215], ["C10A and C10B atoms", "TREATMENT", 354, 373], ["anisotropic displacement parameters", "TEST", 385, 420], ["MeOH", "TEST", 485, 489], ["2 O methanol solvate molecule", "TREATMENT", 495, 524], ["refined partial occupancy factor", "PROBLEM", 569, 601], ["partial", "OBSERVATION_MODIFIER", 577, 584], ["occupancy", "OBSERVATION_MODIFIER", 585, 594]]], ["Water solvate molecule O6 is disordered over the inversion center with refined partial occupancy factor in 0.10:0.10 ratio.S1.1 X-ray structure determinationHydrogen atoms on water oxygen atom O6 were not found in difference Fourier maps and were not included in the refinement.S1.1 X-ray structure determinationThe crystal data, details of data collection and structure refinement are listed in Table S1 .S1.1 X-ray structure determinationFurther details on the crystallographic studies as well as atomic displacement parameters are given as Supporting Information in the form of cif files.S1.2 Calculation of valence-bond sumThe bond valence sum value for the Co atom was calculated by the Pauling equation [10, 11] :S1.2 Calculation of valence-bond sumwhere R ij is the length and S ij the valence of the bond between atoms i and j, and R 0 and b are the empirically determined bond valence parameters (R 0 = 1.69 for Co-O, 2.04 for Co-Cl, and 1.84 for Co-N; b = 0.37) [12] .S2.1 Antioxidant activityThe in vitro antioxidant activity of 1-5 was evaluated via their ability to scavenge the free radicals DPPH and ABTS.", [["O6", "CHEMICAL", 23, 25], ["Hydrogen atoms", "CHEMICAL", 157, 171], ["oxygen", "CHEMICAL", 181, 187], ["Co", "CHEMICAL", 662, 664], ["1-5", "CHEMICAL", 1040, 1043], ["DPPH", "CHEMICAL", 1106, 1110], ["ABTS", "CHEMICAL", 1115, 1119], ["O6", "CHEMICAL", 23, 25], ["Hydrogen", "CHEMICAL", 157, 165], ["oxygen", "CHEMICAL", 181, 187], ["O6", "CHEMICAL", 193, 195], ["Co", "CHEMICAL", 662, 664], ["Co", "CHEMICAL", 921, 923], ["O", "CHEMICAL", 924, 925], ["Co-Cl", "CHEMICAL", 936, 941], ["Co-N", "CHEMICAL", 956, 960], ["DPPH", "CHEMICAL", 1106, 1110], ["ABTS", "CHEMICAL", 1115, 1119], ["Water solvate molecule O6", "SIMPLE_CHEMICAL", 0, 25], ["Hydrogen atoms", "SIMPLE_CHEMICAL", 157, 171], ["water oxygen atom O6", "SIMPLE_CHEMICAL", 175, 195], ["Co atom", "SIMPLE_CHEMICAL", 662, 669], ["Co-O", "SIMPLE_CHEMICAL", 921, 925], ["Co-Cl", "SIMPLE_CHEMICAL", 936, 941], ["S2.1", "SIMPLE_CHEMICAL", 978, 982], ["1-5", "SIMPLE_CHEMICAL", 1040, 1043], ["DPPH", "SIMPLE_CHEMICAL", 1106, 1110], ["ABTS", "SIMPLE_CHEMICAL", 1115, 1119], ["refined partial occupancy factor", "PROTEIN", 71, 103], ["S1.1 X", "DNA", 406, 412], ["Water solvate molecule O6", "TREATMENT", 0, 25], ["Hydrogen atoms", "PROBLEM", 157, 171], ["water oxygen atom O6", "TREATMENT", 175, 195], ["Fourier maps", "TEST", 225, 237], ["The crystal data", "TEST", 312, 328], ["data collection", "TEST", 341, 356], ["the crystallographic studies", "TEST", 459, 487], ["atomic displacement parameters", "TEST", 499, 529], ["the Co atom", "TEST", 658, 669], ["valence-bond sumwhere R ij", "TREATMENT", 739, 765], ["bond valence parameters", "TEST", 881, 904], ["Co", "TEST", 921, 923], ["Co-Cl", "TEST", 936, 941], ["Co", "TEST", 956, 958], ["b", "TEST", 962, 963], ["Antioxidant activity", "TREATMENT", 983, 1003], ["partial", "OBSERVATION_MODIFIER", 79, 86], ["occupancy", "OBSERVATION_MODIFIER", 87, 96], ["Hydrogen atoms", "OBSERVATION", 157, 171], ["ij", "ANATOMY", 763, 765], ["ij", "ANATOMY", 786, 788], ["activity", "OBSERVATION_MODIFIER", 995, 1003]]], ["These experiments were carried out in triplicate and the standard deviation of absorbance was < 10% of the mean.DPPH scavenging activityThe absorbance of a methanolic solution containing DPPH (0.5 mM) and the corresponding compound (0.1 mM) or standard at 517 nm was measured at room temperature after 30 and 60 min in order to examine the possible time-dependence of the DPPH radical scavenging activity [13] .DPPH scavenging activityEvery measurement was repeated in triplicate and a solution of each compound in methanol was used as control solution.", [["DPPH", "CHEMICAL", 112, 116], ["DPPH", "CHEMICAL", 187, 191], ["DPPH", "CHEMICAL", 372, 376], ["methanol", "CHEMICAL", 515, 523], ["DPPH", "CHEMICAL", 112, 116], ["DPPH", "CHEMICAL", 187, 191], ["DPPH", "CHEMICAL", 372, 376], ["[13] .DPPH", "CHEMICAL", 405, 415], ["methanol", "CHEMICAL", 515, 523], ["DPPH", "SIMPLE_CHEMICAL", 112, 116], ["DPPH", "SIMPLE_CHEMICAL", 187, 191], ["DPPH", "SIMPLE_CHEMICAL", 372, 376], ["[13] .DPPH", "SIMPLE_CHEMICAL", 405, 415], ["methanol", "SIMPLE_CHEMICAL", 515, 523], ["These experiments", "TEST", 0, 17], ["absorbance", "TEST", 79, 89], ["DPPH", "TREATMENT", 112, 116], ["a methanolic solution containing DPPH", "TREATMENT", 154, 191], ["the DPPH radical scavenging activity", "TREATMENT", 368, 404], ["scavenging activity", "TEST", 416, 435], ["Every measurement", "TEST", 435, 452], ["a solution of each compound in methanol", "TREATMENT", 484, 523], ["activity", "OBSERVATION_MODIFIER", 128, 136], ["absorbance", "OBSERVATION_MODIFIER", 140, 150]]], ["The DPPH scavenging activity of the complexes was expressed as the percentage reduction of the absorbance values of the initial DPPH solution (DPPH%).", [["DPPH", "CHEMICAL", 4, 8], ["DPPH", "CHEMICAL", 128, 132], ["DPPH", "CHEMICAL", 143, 147], ["DPPH", "CHEMICAL", 4, 8], ["DPPH", "CHEMICAL", 128, 132], ["DPPH", "CHEMICAL", 143, 147], ["DPPH", "SIMPLE_CHEMICAL", 4, 8], ["DPPH", "SIMPLE_CHEMICAL", 128, 132], ["DPPH", "SIMPLE_CHEMICAL", 143, 147], ["The DPPH scavenging", "TEST", 0, 19], ["the initial DPPH solution", "TREATMENT", 116, 141], ["DPPH", "OBSERVATION", 4, 8], ["scavenging activity", "OBSERVATION", 9, 28], ["percentage", "OBSERVATION_MODIFIER", 67, 77], ["reduction", "OBSERVATION_MODIFIER", 78, 87]]], ["The natural antioxidant NDGA and the well-known for its antioxidant properties compound BHT were used as reference compounds.ABTS scavenging activityABTS radical cation (ABTS + \u2022 ) was produced by the reaction of an ABTS solution (2mM) in DMSO and potassium persulfate (0.17mM).", [["NDGA", "CHEMICAL", 24, 28], ["BHT", "CHEMICAL", 88, 91], ["ABTS", "CHEMICAL", 125, 129], ["ABTS", "CHEMICAL", 170, 174], ["ABTS", "CHEMICAL", 216, 220], ["DMSO", "CHEMICAL", 239, 243], ["potassium persulfate", "CHEMICAL", 248, 268], ["NDGA", "CHEMICAL", 24, 28], ["BHT", "CHEMICAL", 88, 91], ["ABTS", "CHEMICAL", 125, 129], ["ABTS", "CHEMICAL", 170, 174], ["ABTS", "CHEMICAL", 216, 220], ["DMSO", "CHEMICAL", 239, 243], ["potassium persulfate", "CHEMICAL", 248, 268], ["NDGA", "SIMPLE_CHEMICAL", 24, 28], ["BHT", "SIMPLE_CHEMICAL", 88, 91], ["ABTS", "SIMPLE_CHEMICAL", 125, 129], ["activityABTS radical cation", "SIMPLE_CHEMICAL", 141, 168], ["ABTS + \u2022", "SIMPLE_CHEMICAL", 170, 178], ["ABTS", "SIMPLE_CHEMICAL", 216, 220], ["DMSO", "SIMPLE_CHEMICAL", 239, 243], ["potassium persulfate", "SIMPLE_CHEMICAL", 248, 268], ["The natural antioxidant NDGA", "TREATMENT", 0, 28], ["its antioxidant properties compound BHT", "TREATMENT", 52, 91], ["ABTS", "TEST", 125, 129], ["radical cation (ABTS", "TEST", 154, 174], ["an ABTS solution", "TREATMENT", 213, 229], ["DMSO", "TREATMENT", 239, 243], ["potassium persulfate", "TREATMENT", 248, 268]]], ["The reaction mixture was stored in dark at room temperature for 12-16 h before its use.", [["The reaction mixture", "PROBLEM", 0, 20]]], ["The ABTS was oxidized incompletely because the stoichiometric reaction ratio of ABTS and potassium persulfate is 1:0.5.", [["ABTS", "CHEMICAL", 4, 8], ["ABTS", "CHEMICAL", 80, 84], ["potassium persulfate", "CHEMICAL", 89, 109], ["ABTS", "CHEMICAL", 4, 8], ["ABTS", "CHEMICAL", 80, 84], ["potassium persulfate", "CHEMICAL", 89, 109], ["ABTS", "SIMPLE_CHEMICAL", 4, 8], ["ABTS", "SIMPLE_CHEMICAL", 80, 84], ["potassium persulfate", "SIMPLE_CHEMICAL", 89, 109], ["The ABTS", "TREATMENT", 0, 8], ["the stoichiometric reaction", "TEST", 43, 70], ["ABTS", "TEST", 80, 84], ["potassium persulfate", "TREATMENT", 89, 109]]], ["The absorbance became maximal and stable only after 6 h of reaction although the oxidation of the ABTS started immediately.", [["ABTS", "CHEMICAL", 98, 102], ["ABTS", "CHEMICAL", 98, 102], ["ABTS", "SIMPLE_CHEMICAL", 98, 102], ["The absorbance", "TEST", 0, 14], ["reaction", "PROBLEM", 59, 67], ["the ABTS", "TREATMENT", 94, 102], ["absorbance", "OBSERVATION_MODIFIER", 4, 14], ["maximal", "OBSERVATION_MODIFIER", 22, 29], ["stable", "OBSERVATION_MODIFIER", 34, 40]]], ["The radical was stable in this form for two days when allowed to stand in the dark at room temperature.", [["radical", "OBSERVATION_MODIFIER", 4, 11], ["stable", "OBSERVATION_MODIFIER", 16, 22]]], ["Then a dilution of ABTS + \u2022 in DMSO followed, in order to obtain an absorbance of 0.70 at 734nm.", [["ABTS", "CHEMICAL", 19, 23], ["DMSO", "CHEMICAL", 31, 35], ["ABTS", "CHEMICAL", 19, 23], ["DMSO", "CHEMICAL", 31, 35], ["ABTS + \u2022", "SIMPLE_CHEMICAL", 19, 27], ["DMSO", "SIMPLE_CHEMICAL", 31, 35], ["a dilution of ABTS", "TREATMENT", 5, 23], ["DMSO", "TREATMENT", 31, 35], ["an absorbance", "TEST", 65, 78]]], ["The DMSO solution (0.1 mM) of the compounds or standards was added and the absorbance at 734 nm was recorded immediately [13] .", [["DMSO", "CHEMICAL", 4, 8], ["DMSO", "CHEMICAL", 4, 8], ["DMSO", "SIMPLE_CHEMICAL", 4, 8], ["The DMSO solution", "TREATMENT", 0, 17], ["the compounds", "TREATMENT", 30, 43]]], ["The radical scavenging activity of the complexes was expressed as the percentage inhibition of the absorbance of the initial ABTS solution (ABTS%).", [["ABTS", "CHEMICAL", 125, 129], ["ABTS", "CHEMICAL", 125, 129], ["ABTS", "CHEMICAL", 140, 144], ["ABTS", "SIMPLE_CHEMICAL", 125, 129], ["ABTS", "SIMPLE_CHEMICAL", 140, 144], ["the initial ABTS solution", "TREATMENT", 113, 138], ["radical", "OBSERVATION_MODIFIER", 4, 11], ["scavenging activity", "OBSERVATION", 12, 31]]], ["As a standard compound we used trolox which is a water-soluble analog of vitamin E.Binding study with CT DNA by UV spectroscopyUV-vis spectroscopy was used to study the interaction of complexes 1-5 with CT DNA in order to estimate their possible binding mode to CT DNA and calculate the corresponding binding :Binding study with CT DNA by UV spectroscopywhere [DNA] is the concentration of DNA in base pairs, \u03b5 A = A obsd /[compound], \u03b5 f = the extinction coefficient for the free compound and \u03b5 b = the extinction coefficient for the compound in the fully bound form.CT DNA binding studies by cyclic voltammetryThe interaction of 1-5 with CT DNA was also investigated via monitoring the changes observed in the cyclic voltammogram of a 0.40 mM 1:2 DMSO:buffer solution of the complex upon addition of DNA solution at diverse r values.", [["trolox", "CHEMICAL", 31, 37], ["vitamin E.Binding", "CHEMICAL", 73, 90], ["cyclic voltammetry", "CHEMICAL", 594, 612], ["DMSO", "CHEMICAL", 749, 753], ["trolox", "CHEMICAL", 31, 37], ["vitamin E.Binding", "CHEMICAL", 73, 90], ["DMSO", "CHEMICAL", 749, 753], ["trolox", "SIMPLE_CHEMICAL", 31, 37], ["vitamin", "SIMPLE_CHEMICAL", 73, 80], ["DNA", "CELLULAR_COMPONENT", 105, 108], ["DNA", "CELLULAR_COMPONENT", 206, 209], ["DNA", "CELLULAR_COMPONENT", 265, 268], ["DNA", "CELLULAR_COMPONENT", 332, 335], ["DNA", "CELLULAR_COMPONENT", 361, 364], ["DNA", "CELLULAR_COMPONENT", 390, 393], ["DNA", "CELLULAR_COMPONENT", 571, 574], ["1-5", "SIMPLE_CHEMICAL", 631, 634], ["DNA", "CELLULAR_COMPONENT", 643, 646], ["DMSO", "SIMPLE_CHEMICAL", 749, 753], ["DNA", "CELLULAR_COMPONENT", 802, 805], ["CT DNA", "DNA", 102, 108], ["CT DNA", "DNA", 203, 209], ["CT DNA", "DNA", 262, 268], ["CT DNA", "DNA", 329, 335], ["CT DNA", "DNA", 640, 646], ["trolox", "TREATMENT", 31, 37], ["a water-soluble analog", "TREATMENT", 47, 69], ["vitamin E.Binding study", "TEST", 73, 96], ["CT DNA", "TEST", 102, 108], ["vis spectroscopy", "TEST", 130, 146], ["CT DNA", "TEST", 203, 209], ["CT DNA", "TEST", 262, 268], ["Binding study", "TEST", 310, 323], ["CT DNA", "TEST", 329, 335], ["DNA", "PROBLEM", 361, 364], ["DNA in base pairs", "TEST", 390, 407], ["the free compound", "PROBLEM", 472, 489], ["CT DNA binding studies", "TEST", 568, 590], ["cyclic voltammetry", "TEST", 594, 612], ["CT DNA", "TEST", 640, 646], ["the cyclic voltammogram", "TEST", 708, 731], ["buffer solution", "TREATMENT", 754, 769], ["DNA solution", "TREATMENT", 802, 814], ["base", "ANATOMY_MODIFIER", 397, 401]]], ["The buffer was also used as the supporting electrolyte and the cyclic voltammograms were recorded at \u03bd = 100 mV s \u22121 .CT DNA binding studies by cyclic voltammetryCyclic voltammetry can be also used in order to calculate the corresponding equilibrium constant for the redox process.", [["cyclic voltammetry", "CHEMICAL", 144, 162], ["DNA", "CELLULAR_COMPONENT", 121, 124], ["The buffer", "TREATMENT", 0, 10], ["the cyclic voltammograms", "TEST", 59, 83], ["DNA binding studies", "TEST", 121, 140], ["cyclic voltammetry", "TEST", 144, 162], ["Cyclic voltammetry", "TREATMENT", 162, 180], ["the redox process", "PROBLEM", 263, 280]]], ["The ratio of the DNA-binding constants for the reduced (K r ) andCT DNA binding studies by cyclic voltammetryoxidized forms (K ox ) of the complexes (K r /K ox ) was calculated according to equation S3 [15] :CT DNA-binding studies by viscosity measurementsThe viscosity of DNA solution in buffer solution (150mM NaCl and 15mM trisodium citrate at pH 7.0) was measured upon increasing amounts of complexes 1-5 (up to the value of r=0.35).CT DNA-binding studies by viscosity measurementsAll measurements were performed at room temperature and the obtained data are presented as (\u03b7/\u03b7 0 ) 1/3 versus r, where \u03b7 is the viscosity of DNA in the presence of the compound and \u03b7 0 is the viscosity of DNA alone in buffer solution.EB-displacement studiesFluorescence emission spectroscopy was used to investigate the competitive studies of The EB-displacement studies involved the calculation of the Stern-Volmer constant (K SV, in M -1 ) in order to evaluate the quenching efficiency of each compound according to the Stern-Volmer equation (eq.", [["K", "CHEMICAL", 56, 57], ["K", "CHEMICAL", 125, 126], ["NaCl", "CHEMICAL", 312, 316], ["trisodium citrate", "CHEMICAL", 326, 343], ["EB", "CHEMICAL", 833, 835], ["NaCl", "CHEMICAL", 312, 316], ["trisodium citrate", "CHEMICAL", 326, 343], ["DNA", "CELLULAR_COMPONENT", 17, 20], ["DNA", "CELLULAR_COMPONENT", 68, 71], ["DNA", "CELLULAR_COMPONENT", 211, 214], ["DNA", "CELLULAR_COMPONENT", 273, 276], ["trisodium citrate", "SIMPLE_CHEMICAL", 326, 343], ["DNA", "CELLULAR_COMPONENT", 440, 443], ["DNA", "CELLULAR_COMPONENT", 627, 630], ["DNA", "CELLULAR_COMPONENT", 691, 694], ["EB", "SIMPLE_CHEMICAL", 833, 835], ["K ox", "PROTEIN", 155, 159], ["The ratio", "TEST", 0, 9], ["the DNA", "TEST", 13, 20], ["binding constants", "TEST", 21, 38], ["K r ) andCT DNA binding studies", "TEST", 56, 87], ["cyclic voltammetryoxidized forms", "TEST", 91, 123], ["K ox", "TEST", 125, 129], ["the complexes", "TEST", 135, 148], ["K r /K ox", "TEST", 150, 159], ["CT DNA-binding studies", "TEST", 208, 230], ["viscosity measurements", "TEST", 234, 256], ["The viscosity of DNA solution in buffer solution", "TREATMENT", 256, 304], ["150mM NaCl", "TREATMENT", 306, 316], ["15mM trisodium citrate", "TREATMENT", 321, 343], ["pH", "TEST", 347, 349], ["CT DNA-binding studies", "TEST", 437, 459], ["viscosity measurements", "TEST", 463, 485], ["All measurements", "TEST", 485, 501], ["DNA", "PROBLEM", 627, 630], ["displacement studies", "TEST", 723, 743], ["Fluorescence emission spectroscopy", "TEST", 743, 777], ["The EB-displacement studies", "TEST", 829, 856]]], ["S4) [17, 18] :EB-displacement studieswhere Io and I are the emission intensities of the EB-DNA solution in the absence and the presence of the compound-quencher, respectively, [Q] is the concentration of the quencher (i.e. complexes 1-5), \u03c4 o = the average lifetime of the emitting system without the quencher and k q = the quenching constant.", [["EB", "CHEMICAL", 88, 90], ["[17, 18] :EB", "SIMPLE_CHEMICAL", 4, 16], ["DNA", "CELLULAR_COMPONENT", 91, 94], ["the EB-DNA solution", "TREATMENT", 84, 103]]], ["K SV was obtained from the Stern-Volmer plots by the slope of the diagram Io/I versus [Q]EB-displacement studies( Fig. S5 ).", [["K", "CHEMICAL", 0, 1], ["K SV", "GENE_OR_GENE_PRODUCT", 0, 4], ["K SV", "TEST", 0, 4], ["displacement studies", "TEST", 92, 112]]], ["Taking \u03c4 o = 23 ns as the fluorescence lifetime of the EB-DNA system [18] , the quenching constants (k q , in M -1 s -1 ) of the complexes can be determined according to eq.", [["DNA", "CELLULAR_COMPONENT", 58, 61], ["the quenching constants", "TEST", 76, 99], ["k q", "TEST", 101, 104]]], ["S5 [16] :S2.3 Albumin binding studiesThe albumin binding studies were performed by performing tryptophan fluorescence quenching experiments using bovine (BSA, 3 \u03bcM) or human serum albumin (HSA, 3 \u03bcM) in buffer solution.", [["serum", "ANATOMY", 174, 179], ["tryptophan", "CHEMICAL", 94, 104], ["tryptophan", "CHEMICAL", 94, 104], ["Albumin", "GENE_OR_GENE_PRODUCT", 14, 21], ["albumin", "GENE_OR_GENE_PRODUCT", 41, 48], ["tryptophan", "SIMPLE_CHEMICAL", 94, 104], ["bovine", "ORGANISM", 146, 152], ["BSA", "SIMPLE_CHEMICAL", 154, 157], ["human", "ORGANISM", 168, 173], ["serum", "ORGANISM_SUBSTANCE", 174, 179], ["albumin", "SIMPLE_CHEMICAL", 180, 187], ["HSA", "SIMPLE_CHEMICAL", 189, 192], ["bovine", "SPECIES", 146, 152], ["human", "SPECIES", 168, 173], ["human", "SPECIES", 168, 173], ["Albumin binding studies", "TEST", 14, 37], ["The albumin binding studies", "TEST", 37, 64], ["tryptophan fluorescence quenching experiments", "TREATMENT", 94, 139], ["bovine (BSA", "TREATMENT", 146, 157], ["human serum albumin (HSA", "TREATMENT", 168, 192]]], ["The quenching of the emission intensity of tryptophan residues of BSA at 345 nm or HSA at 340 nm was monitored using complexes 1-5 as quenchers with gradually increasing concentration and the fluorescence emission spectra were recorded in the range of 300-500 nm with excitation wavelength of 295 nm [16] .", [["tryptophan", "CHEMICAL", 43, 53], ["BSA", "CHEMICAL", 66, 69], ["tryptophan", "CHEMICAL", 43, 53], ["tryptophan", "AMINO_ACID", 43, 53], ["BSA", "SIMPLE_CHEMICAL", 66, 69], ["HSA", "SIMPLE_CHEMICAL", 83, 86], ["BSA", "TEST", 66, 69], ["HSA", "TEST", 83, 86], ["gradually increasing concentration", "PROBLEM", 149, 183], ["the fluorescence emission spectra", "TEST", 188, 221], ["excitation wavelength", "TEST", 268, 289], ["tryptophan residues", "OBSERVATION", 43, 62]]], ["Indomethacin and its complexes 1-5 exhibited in buffer solution a low-intensity emission band at ~365 nm under the same experimental conditions (excitation at 295 nm) [19] .", [["Indomethacin", "CHEMICAL", 0, 12], ["1-5", "CHEMICAL", 31, 34], ["Indomethacin", "CHEMICAL", 0, 12], ["Indomethacin", "SIMPLE_CHEMICAL", 0, 12], ["1-5", "SIMPLE_CHEMICAL", 31, 34], ["Indomethacin", "TREATMENT", 0, 12], ["a low-intensity emission band", "TREATMENT", 64, 93]]], ["Therefore, the quantitative studies of the serum albumin fluorescence spectra were performed after their correction by subtracting the spectra of the compounds.S2.3 Albumin binding studiesThe extent of the inner-filter effect can be roughly estimated with the following formula: where I corr = corrected intensity, I meas = the measured intensity, c = the concentration of the quencher, d = the cuvette (1 cm), \u03b5(\u03bb exc ) and \u03b5(\u03bb em ) = the \u03b5 of the quencher at the excitation and the emission wavelength, respectively, as calculated from the UV-vis spectra of the complexes [20] .S2.3 Albumin binding studiesThe Stern-Volmer and Scatchard graphs are used in order to study the interaction of a quencher with serum albumins.", [["serum", "ANATOMY", 43, 48], ["serum", "ANATOMY", 708, 713], ["serum", "ORGANISM_SUBSTANCE", 43, 48], ["albumin", "SIMPLE_CHEMICAL", 49, 56], ["Albumin", "GENE_OR_GENE_PRODUCT", 165, 172], ["Albumin", "GENE_OR_GENE_PRODUCT", 585, 592], ["Stern-Volmer", "SIMPLE_CHEMICAL", 612, 624], ["serum", "ORGANISM_SUBSTANCE", 708, 713], ["albumins", "ORGANISM_SUBSTANCE", 714, 722], ["the quantitative studies", "TEST", 11, 35], ["the serum albumin fluorescence spectra", "TEST", 39, 77], ["Albumin binding studies", "TEST", 165, 188], ["the inner-filter effect", "PROBLEM", 202, 225], ["the cuvette", "TEST", 391, 402], ["Albumin binding studies", "TEST", 585, 608], ["Scatchard graphs", "TEST", 629, 645], ["a quencher with serum albumins", "TEST", 692, 722], ["extent", "OBSERVATION_MODIFIER", 192, 198], ["inner-filter", "OBSERVATION", 206, 218], ["emission wavelength", "OBSERVATION", 484, 503]]], ["S4) [21] , The SA-binding constant K (in M -1 ) is calculated from the slope in plots (\u0394I/Io)/[Q] versus \u0394I/Io (Figs.", [["The SA-binding constant K", "TEST", 11, 36], ["plots", "TEST", 80, 85], ["\u0394I", "TEST", 87, 89], ["\u0394I", "TEST", 105, 107]]], ["S8 and S9) and n (the number of binding sites per albumin) is given by the ratio of y intercept to the slope all coming from the Scatchard equation [16, 21] :Competitive studies with warfarin and ibuprofenThese experiments were carried out by titration of a two mL solution of SA (3 \u03bc\u039c) and the corresponding site probe warfarin or ibuprofen (each of 0.3 mM) by complexes 1-5 (0.1 mM) at increasing amounts.", [["warfarin", "CHEMICAL", 183, 191], ["ibuprofenThese", "CHEMICAL", 196, 210], ["SA", "CHEMICAL", 277, 279], ["warfarin", "CHEMICAL", 320, 328], ["ibuprofen", "CHEMICAL", 332, 341], ["complexes 1-5", "CHEMICAL", 362, 375], ["warfarin", "CHEMICAL", 183, 191], ["ibuprofenThese", "CHEMICAL", 196, 210], ["warfarin", "CHEMICAL", 320, 328], ["ibuprofen", "CHEMICAL", 332, 341], ["albumin", "GENE_OR_GENE_PRODUCT", 50, 57], ["warfarin", "SIMPLE_CHEMICAL", 183, 191], ["ibuprofenThese", "SIMPLE_CHEMICAL", 196, 210], ["SA", "SIMPLE_CHEMICAL", 277, 279], ["warfarin", "SIMPLE_CHEMICAL", 320, 328], ["ibuprofen", "SIMPLE_CHEMICAL", 332, 341], ["1-5", "SIMPLE_CHEMICAL", 372, 375], ["S8", "PROTEIN", 0, 2], ["S9", "PROTEIN", 7, 9], ["binding sites", "PROTEIN", 32, 45], ["albumin", "PROTEIN", 50, 57], ["the Scatchard equation", "TEST", 125, 147], ["Competitive studies", "TEST", 158, 177], ["warfarin", "TREATMENT", 183, 191], ["ibuprofenThese experiments", "TREATMENT", 196, 222], ["a two mL solution of SA", "TREATMENT", 256, 279], ["the corresponding site probe warfarin", "TREATMENT", 291, 328], ["ibuprofen", "TREATMENT", 332, 341]]], ["The fluorescence emission spectra were recorded in the range of 300-500 nm with excitation wavelength of 295 nm [22] .", [["The fluorescence emission spectra", "TEST", 0, 33], ["excitation wavelength", "TEST", 80, 101]]], ["Also, the quantitative studies were performed after their correction by subtracting the spectra of the SA-compound mixture.", [["SA-compound", "CHEMICAL", 103, 114], ["the quantitative studies", "TEST", 6, 30]]], ["The Scatchard equation (eq.", [["The Scatchard equation", "TEST", 0, 22]]], ["S6) and the corresponding plots (Figs.", [["S6", "PROTEIN", 0, 2]]], ["S10-S13) were used to calculate the SA-binding constants K (in M -1 ) of complex-SA systems in the presence of warfarin and ibuprofen for sites I and II.S3.", [["warfarin", "CHEMICAL", 111, 119], ["ibuprofen", "CHEMICAL", 124, 133], ["warfarin", "CHEMICAL", 111, 119], ["ibuprofen", "CHEMICAL", 124, 133], ["S10-S13", "GENE_OR_GENE_PRODUCT", 0, 7], ["warfarin", "SIMPLE_CHEMICAL", 111, 119], ["ibuprofen", "SIMPLE_CHEMICAL", 124, 133], ["S3", "GENE_OR_GENE_PRODUCT", 153, 155], ["S10", "PROTEIN", 0, 3], ["the SA", "TEST", 32, 38], ["K", "TEST", 57, 58], ["complex-SA systems", "PROBLEM", 73, 91], ["warfarin", "TREATMENT", 111, 119], ["ibuprofen", "TREATMENT", 124, 133], ["warfarin", "OBSERVATION", 111, 119]]], ["In silico computational methods (molecular modeling and docking calculations)The in silico predictive tools that have been employed to study the interaction of the compounds with the selected macromolecules, are Spartan \u203214, Schr\u00f6dinger and Biovia Discovery respectively), to investigate the effect of the studied complexes on these targets.", [["docking calculations)", "TREATMENT", 56, 77]]], ["X-ray crystal structures of HSA in complex with bound co-crystallized drug ibuprofen (IBP, 2-(4isobutylphenyl)propionic acid) [25] , BSA in complex with bound co-crystallized drug naproxen (NPS, (S)-2-(6-methoxynaphthalen-2-yl)propanoic acid) [26] , and synthetic CT DNA dodecamer [27] were obtained from the Brookhaven Protein Data Bank (operated by the Research Collaboratory for Structural Bioinformatics, RCSB) [28] [29] [30] .", [["ibuprofen", "CHEMICAL", 75, 84], ["IBP, 2-(4isobutylphenyl)propionic acid", "CHEMICAL", 86, 124], ["BSA", "CHEMICAL", 133, 136], ["naproxen", "CHEMICAL", 180, 188], ["NPS", "CHEMICAL", 190, 193], ["(S)-2-(6-methoxynaphthalen-2-yl)propanoic acid", "CHEMICAL", 195, 241], ["ibuprofen", "CHEMICAL", 75, 84], ["IBP", "CHEMICAL", 86, 89], ["2-(4isobutylphenyl)propionic acid", "CHEMICAL", 91, 124], ["naproxen", "CHEMICAL", 180, 188], ["NPS", "CHEMICAL", 190, 193], ["(S)-2-(6-methoxynaphthalen-2-yl)propanoic acid", "CHEMICAL", 195, 241], ["HSA", "SIMPLE_CHEMICAL", 28, 31], ["ibuprofen", "SIMPLE_CHEMICAL", 75, 84], ["IBP, 2-(4isobutylphenyl)propionic acid) [25]", "SIMPLE_CHEMICAL", 86, 130], ["BSA", "SIMPLE_CHEMICAL", 133, 136], ["naproxen", "SIMPLE_CHEMICAL", 180, 188], ["NPS, (S)-2-(6-methoxynaphthalen-2-yl)propanoic acid", "SIMPLE_CHEMICAL", 190, 241], ["HSA", "PROTEIN", 28, 31], ["HSA in complex", "TREATMENT", 28, 42], ["bound co-crystallized drug ibuprofen (IBP", "TREATMENT", 48, 89], ["(4isobutylphenyl)propionic acid)", "TREATMENT", 93, 125], ["bound co-crystallized drug naproxen (NPS", "TREATMENT", 153, 193], ["methoxynaphthalen", "TREATMENT", 204, 221], ["propanoic acid)", "TREATMENT", 227, 242], ["synthetic CT DNA dodecamer", "TEST", 254, 280]]], ["The chosen crystal structures of HSA and BSA have been refined at 2.70 \u00c5 and 2.58 \u00c5 resolution, conjugated with IBP and NPS, respectively, while the crystal structure of the synthetic DNA-dodecamer has been refined at 1.9 \u00c5 resolution.", [["HSA", "SIMPLE_CHEMICAL", 33, 36], ["BSA", "SIMPLE_CHEMICAL", 41, 44], ["DNA", "CELLULAR_COMPONENT", 184, 187], ["HSA", "PROTEIN", 33, 36], ["BSA", "PROTEIN", 41, 44], ["IBP", "PROTEIN", 112, 115], ["NPS", "PROTEIN", 120, 123], ["BSA", "TEST", 41, 44], ["IBP", "TEST", 112, 115], ["NPS", "TREATMENT", 120, 123], ["HSA", "ANATOMY", 33, 36]]], ["For the docking calculations on HSA and BSA, it was used only the A chain of the protein since chain B is replicate, with IBP and NPS bound at the same ligand binding site among the chains.", [["HSA", "SIMPLE_CHEMICAL", 32, 35], ["BSA", "SIMPLE_CHEMICAL", 40, 43], ["NPS", "SIMPLE_CHEMICAL", 130, 133], ["HSA", "PROTEIN", 32, 35], ["A chain", "PROTEIN", 66, 73], ["chain B", "PROTEIN", 95, 102], ["IBP", "PROTEIN", 122, 125], ["NPS", "PROTEIN", 130, 133], ["ligand binding site", "PROTEIN", 152, 171], ["HSA and BSA", "TREATMENT", 32, 43], ["IBP", "TREATMENT", 122, 125], ["NPS bound", "PROBLEM", 130, 139], ["chains", "OBSERVATION_MODIFIER", 182, 188]]], ["For this reason, from corresponding PDB files the data for chain B and the data of the drugs referring to this chain were deleted.S3.", [["S3", "GENE_OR_GENE_PRODUCT", 130, 132], ["chain B", "PROTEIN", 59, 66], ["the data", "TEST", 46, 54], ["chain B", "PROBLEM", 59, 66], ["the drugs", "TREATMENT", 83, 92]]], ["In silico computational methods (molecular modeling and docking calculations)In our studies, molecular docking calculations were performed with two different modeling packages Schr\u00f6dinger suite and BioMedCAChe, both having the ability for accurate calculations. the actual docking procedure [33] .", [["docking calculations)", "TREATMENT", 56, 77], ["our studies", "TEST", 80, 91], ["molecular docking calculations", "TEST", 93, 123], ["BioMedCAChe", "TREATMENT", 198, 209], ["the actual docking procedure", "TREATMENT", 262, 290]]], ["The crystal structures of the proteins were prepared using the Protein Preparation Wizard [33] , in Schr\u00f6dinger Suite 2015-2 (Schr\u00f6dinger, LLC, New York, NY) [34, 35] .", [["LLC", "ANATOMY", 139, 142]]], ["Protein was prepared by adding the hydrogen atoms, optimizing hydrogen bonds, removing atomic clashes, adding formal charges to the hetero groups and then optimizing at neutral pH.S3.", [["hydrogen", "CHEMICAL", 35, 43], ["hydrogen", "CHEMICAL", 62, 70], ["S3", "GENE_OR_GENE_PRODUCT", 180, 182], ["the hydrogen atoms", "TREATMENT", 31, 49], ["optimizing hydrogen bonds", "TREATMENT", 51, 76], ["atomic clashes", "PROBLEM", 87, 101], ["formal charges to the hetero groups", "TREATMENT", 110, 145], ["hydrogen bonds", "OBSERVATION", 62, 76]]], ["In silico computational methods (molecular modeling and docking calculations)Missing loops and side chains were prepared using Prime version 3.2 [36, 37] .", [["docking calculations)", "TREATMENT", 56, 77], ["Missing loops and side chains", "PROBLEM", 77, 106], ["loops", "ANATOMY_MODIFIER", 85, 90], ["side chains", "OBSERVATION_MODIFIER", 95, 106]]], ["Finally, the structure was minimized using OPLS3 force field.", [["OPLS3 force field", "TREATMENT", 43, 60]]], ["Active site of studied proteins was obtained using SiteMap tool [38, 39] , which provides a fast and effective means of identifying potential binding pockets of proteins.", [["studied proteins", "TEST", 15, 31], ["SiteMap tool", "TEST", 51, 63], ["potential binding pockets of proteins", "PROBLEM", 132, 169]]], ["SiteMap identifies the character of binding sites using novel search and assesses each site by calculating various properties like size, volume, amino acid exposure, enclosure, contact, hydrophobicity, hydrophilicity and donor/acceptor ratio.", [["amino acid", "CHEMICAL", 145, 155], ["amino acid", "CHEMICAL", 145, 155], ["amino acid", "AMINO_ACID", 145, 155], ["binding sites", "DNA", 36, 49], ["binding sites", "PROBLEM", 36, 49], ["novel search", "TREATMENT", 56, 68], ["amino acid exposure", "TREATMENT", 145, 164], ["donor/acceptor ratio", "TREATMENT", 221, 241], ["binding sites", "OBSERVATION", 36, 49], ["size", "OBSERVATION_MODIFIER", 131, 135], ["amino acid", "OBSERVATION", 145, 155]]], ["Receptor grid was generated around the active site for effective binding using Receptor grid generation in the Glide (version 5.9) application of Maestro.", [["Receptor grid", "PROBLEM", 0, 13], ["effective binding", "PROBLEM", 55, 72], ["Receptor grid generation in the Glide (version", "TREATMENT", 79, 125], ["Maestro", "TREATMENT", 146, 153]]], ["Once the receptor grid is generated, the ligands are docked to the proteins using Glide (Grid based Ligand Docking with Energetics) docking tool of Schr\u00f6dinger [35, 40] , Compounds were docked in the binding site of the proteins using Induced-Fit Docking (IFD) protocol 2015-2 [41] [42] [43] .", [["[41] [42] [43]", "SIMPLE_CHEMICAL", 277, 291], ["Glide (Grid based Ligand Docking with Energetics", "TREATMENT", 82, 130]]], ["The ligand interactions are shown in Ligand interaction tool of Maestro (Schr\u00f6dinger).S3.", [["S3", "GENE_OR_GENE_PRODUCT", 86, 88]]], ["In silico computational methods (molecular modeling and docking calculations)Water molecules were deleted with Maestro, the graphical user interface (GUI) of Schr\u00f6dinger software, prior to docking.", [["docking calculations)", "TREATMENT", 56, 77], ["Maestro", "TREATMENT", 111, 118]]], ["Molecular docking studies were carried out for the best fitted compounds to the model, while the final selection criteria were compounds docking scores and the presence of crucial interactions for binding to the studied proteins [44] .", [["Molecular docking studies", "TEST", 0, 25]]], ["The resulting poses were examined manually and the most promising ones were redocked with IFD calculations.", [["IFD calculations", "TEST", 90, 106]]], ["Poses that pass the initial screens enter the final stage of the algorithm, which involves evaluation and minimization of a grid approximation to the OPLS-AA non-bonded ligand-receptor interaction energy.", [["AA", "CHEMICAL", 155, 157], ["OPLS", "PROTEIN", 150, 154], ["the algorithm", "TEST", 61, 74], ["evaluation", "TEST", 91, 101], ["the OPLS", "TEST", 146, 154]]], ["By default, Schr\u00f6dinger's proprietary GlideScore [40] multi-ligand scoring function is used to score the poses.", [["Schr\u00f6dinger's proprietary GlideScore", "TREATMENT", 12, 48]]], ["All complexes showed good docking scores reflecting drug-binding affinities with the studied proteins.S3.", [["S3", "GENE_OR_GENE_PRODUCT", 102, 104], ["drug-binding affinities", "PROBLEM", 52, 75], ["the studied proteins", "PROBLEM", 81, 101], ["good", "OBSERVATION_MODIFIER", 21, 25]]], ["In silico computational methods (molecular modeling and docking calculations)Molecular docking simulation was also performed in project leader of BioMedCAChe 7.5 computer-aided chemistry software package, which is part of the CAChe package (CACheWorkSystem Pro version 7.5.0.85, Fujitsu Co. Ltd., Tokyo, Japan), according to previously published paper [45] .", [["docking calculations)", "TREATMENT", 56, 77]]], ["Docking was carried out at full rotation allowing full flexibility for the ligand while keeping the target protein and DNA positions fixed in space.", [["DNA", "CELLULAR_COMPONENT", 119, 122]]], ["The produced compound-protein conjugates were ranked by the energy score, including their binding conformations.", [["compound-protein conjugates", "TREATMENT", 13, 40], ["protein conjugates", "OBSERVATION", 22, 40]]], ["All molecules were docked individually.S3.", [["S3", "GENE_OR_GENE_PRODUCT", 39, 41]]], ["In silico computational methods (molecular modeling and docking calculations)PyMol Molecular Graphics System (Schr\u00f6dinger, LLC. version 1.8.2.0, www.pymol.org), was used to visualize the molecules and analyze the results of the docking and to construct the molecular models [46] .References [1]Bruker Analytical X-ray Systems, Inc. Apex2, Version 2 User Manual, M86-E01078, Madison, WI, (2006).", [["silico computational methods", "TREATMENT", 3, 31], ["docking calculations)", "TREATMENT", 56, 77], ["version", "TEST", 128, 135], ["Bruker Analytical X-ray Systems", "TEST", 294, 325], ["LLC", "ANATOMY", 123, 126]]], ["Table S2 .", [["S2", "ANATOMY", 6, 8]]], ["Hydrogen-bonding interactions in complex 1.", [["Hydrogen", "CHEMICAL", 0, 8], ["Hydrogen", "CHEMICAL", 0, 8], ["Hydrogen", "SIMPLE_CHEMICAL", 0, 8], ["complex 1", "GENE_OR_GENE_PRODUCT", 33, 42], ["complex 1", "PROTEIN", 33, 42]]], ["Hydrogen-bonding interactions in complex 3.", [["Hydrogen", "CHEMICAL", 0, 8], ["Hydrogen", "CHEMICAL", 0, 8], ["Hydrogen", "SIMPLE_CHEMICAL", 0, 8], ["complex 3", "GENE_OR_GENE_PRODUCT", 33, 42], ["complex 3", "PROTEIN", 33, 42]]], ["Symmetry codes: (i) x, -y + 1, z + \u00bd; (ii) -x+2, -y+1, -z+1; (iii) -x+2, y, -z+3/2. .", [["(i) x, -y + 1, z + \u00bd; (ii) -x+2, -y+1, -z+1; (iii) -x+2, y, -z+3/2", "CHEMICAL", 16, 82], ["z + \u00bd; (ii) -x+2", "SIMPLE_CHEMICAL", 31, 47], ["-z+1; (iii) -x+2", "SIMPLE_CHEMICAL", 55, 71], ["z", "TEST", 31, 32]]], ["Target protein is illustrated as opaque surface with sub-domains color-coded according to chainbow.", [["surface", "ANATOMY", 40, 47], ["surface", "CELLULAR_COMPONENT", 40, 47], ["Target protein", "TEST", 0, 14]]], ["Co-crystallized drug naproxen (NPS) (depicted in stick model and colored according to atom type in hot pink, yellow and light pink C atoms, for BSs III, IV and II, respectively) is also illustrated.", [["naproxen", "CHEMICAL", 21, 29], ["NPS", "CHEMICAL", 31, 34], ["naproxen", "CHEMICAL", 21, 29], ["NPS", "CHEMICAL", 31, 34], ["C", "CHEMICAL", 131, 132], ["naproxen", "SIMPLE_CHEMICAL", 21, 29], ["NPS", "SIMPLE_CHEMICAL", 31, 34], ["BSs III, IV and II", "PROTEIN", 144, 162], ["Co-crystallized drug naproxen (NPS)", "TREATMENT", 0, 35], ["yellow and light pink C atoms", "PROBLEM", 109, 138]]], ["In the crystal structure of the protein is depicted the binding sites I, II, III, and IV with notation of their relatively narrow entries (for bulk molecules), as well as the binding site between BSs II, III and IV.", [["BSs II", "GENE_OR_GENE_PRODUCT", 196, 202], ["binding sites", "PROTEIN", 56, 69], ["I, II, III, and IV", "PROTEIN", 70, 88], ["binding site", "PROTEIN", 175, 187], ["BSs II, III and IV", "PROTEIN", 196, 214], ["crystal", "OBSERVATION_MODIFIER", 7, 14], ["protein", "OBSERVATION", 32, 39], ["binding sites", "OBSERVATION", 56, 69], ["narrow", "OBSERVATION_MODIFIER", 123, 129]]], ["S19.", [["S19", "GENE_OR_GENE_PRODUCT", 0, 3]]], ["Docking poses of complexes 2, 3 and 5 in the crystal structure of HSA (PDB entry code 2BXG) (chain A) depicting the best (lower energy ranking) pose.", [["HSA", "SIMPLE_CHEMICAL", 66, 69], ["complexes 2, 3 and 5", "PROTEIN", 17, 37], ["HSA", "PROTEIN", 66, 69], ["PDB entry code 2BXG", "PROTEIN", 71, 90], ["chain A", "PROTEIN", 93, 100], ["HSA", "ANATOMY", 66, 69]]], ["In the upper left part are shown the drug-binding sites of the protein superimposed with the co-crystallized drug IBP.", [["drug-binding sites", "PROTEIN", 37, 55], ["the co-crystallized drug IBP", "TREATMENT", 89, 117], ["upper", "ANATOMY_MODIFIER", 7, 12], ["left", "ANATOMY_MODIFIER", 13, 17], ["binding sites", "OBSERVATION", 42, 55], ["drug IBP", "OBSERVATION", 109, 117]]], ["Target protein is illustrated as cartoon with sub-domains color-coded according to chainbow and additional depiction of semitransparent surface colored also by chainbow (in the upper left part).", [["surface", "ANATOMY", 136, 143], ["left part", "ANATOMY", 183, 192], ["Target protein", "TEST", 0, 14], ["semitransparent surface colored", "TREATMENT", 120, 151], ["semitransparent surface", "OBSERVATION", 120, 143], ["upper", "ANATOMY_MODIFIER", 177, 182], ["left", "ANATOMY_MODIFIER", 183, 187]]], ["All complexes are illustrated in sphere representation, while co-crystallized IBP is depicted in stick model.", [["co-crystallized IBP", "TEST", 62, 81], ["complexes", "OBSERVATION", 4, 13], ["sphere", "OBSERVATION_MODIFIER", 33, 39]]], ["Docked molecules are colored according to atom type: violet purple, hotpink, and splitpea green C atoms for complexes 2, 3 and 5, respectively, and NPS in hot pink C atoms.", [["C", "CHEMICAL", 96, 97], ["NPS", "CHEMICAL", 148, 151], ["C", "CHEMICAL", 164, 165], ["violet purple", "SIMPLE_CHEMICAL", 53, 66], ["splitpea green C atoms", "SIMPLE_CHEMICAL", 81, 103], ["NPS", "SIMPLE_CHEMICAL", 148, 151], ["pink C atoms", "SIMPLE_CHEMICAL", 159, 171], ["violet purple", "OBSERVATION", 53, 66]]], ["For complexes 3 and 5 it is also depicted a higher energy pose accommodated in binding site V (C atoms of the molecules are rendered in slate blues spheres).", [["C", "CHEMICAL", 95, 96], ["binding site V", "PROTEIN", 79, 93], ["C atoms", "PROTEIN", 95, 102]]], ["Hydrogen atoms are omitted for clarity.", [["Hydrogen", "CHEMICAL", 0, 8], ["Hydrogen", "CHEMICAL", 0, 8], ["Hydrogen atoms", "SIMPLE_CHEMICAL", 0, 14], ["Hydrogen atoms", "PROBLEM", 0, 14]]], ["Drug-binding sites (BSs) of HSA (PDB entry code 2BXG).", [["HSA", "SIMPLE_CHEMICAL", 28, 31], ["Drug-binding sites", "PROTEIN", 0, 18], ["HSA", "PROTEIN", 28, 31], ["PDB entry code 2BXG", "PROTEIN", 33, 52]]], ["Target protein is illustrated as opaque surface with sub-domains color-coded according to chainbow.", [["surface", "ANATOMY", 40, 47], ["surface", "CELLULAR_COMPONENT", 40, 47], ["Target protein", "TEST", 0, 14]]], ["Co-crystallized drug ibuprofen (IBP) (depicted in stick model and colored according to atom type in hot pink, and yellow C atoms, for BSs III and IV, respectively) is also illustrated.", [["ibuprofen", "CHEMICAL", 21, 30], ["ibuprofen", "CHEMICAL", 21, 30], ["IBP", "CHEMICAL", 32, 35], ["C", "CHEMICAL", 121, 122], ["ibuprofen", "SIMPLE_CHEMICAL", 21, 30], ["yellow C atoms", "SIMPLE_CHEMICAL", 114, 128], ["BSs III", "GENE_OR_GENE_PRODUCT", 134, 141], ["IV", "PROTEIN", 146, 148], ["Co-crystallized drug ibuprofen (IBP)", "TREATMENT", 0, 36], ["hot pink", "PROBLEM", 100, 108], ["yellow C atoms", "PROBLEM", 114, 128], ["BSs III and IV", "TREATMENT", 134, 148]]], ["In the crystal structure of the protein is depicted the binding sites III, IV and V with notation of their relatively narrow entries (for bulk molecules), as well as the binding site between BSs II, III and IV.", [["BSs II", "GENE_OR_GENE_PRODUCT", 191, 197], ["binding sites III, IV and V", "PROTEIN", 56, 83], ["binding site", "PROTEIN", 170, 182], ["BSs II, III and IV", "PROTEIN", 191, 209], ["crystal", "OBSERVATION_MODIFIER", 7, 14], ["protein", "OBSERVATION", 32, 39], ["binding sites", "OBSERVATION", 56, 69], ["relatively", "OBSERVATION_MODIFIER", 107, 117], ["narrow", "OBSERVATION_MODIFIER", 118, 124]]]], "62f9e16ec9022120f56d329998a012ff21c952cb": [["Older adults and those at any age with hypertension, coronary heart disease and diabetes are at higher risk of SARS-CoV-2 infection and severe disease course (1, 2) .", [["coronary", "ANATOMY", 53, 61], ["heart", "ANATOMY", 62, 67], ["hypertension", "DISEASE", 39, 51], ["coronary heart disease", "DISEASE", 53, 75], ["diabetes", "DISEASE", 80, 88], ["SARS-CoV-2 infection", "DISEASE", 111, 131], ["heart", "ORGAN", 62, 67], ["SARS-CoV", "SPECIES", 111, 119], ["hypertension", "PROBLEM", 39, 51], ["coronary heart disease", "PROBLEM", 53, 75], ["diabetes", "PROBLEM", 80, 88], ["SARS", "PROBLEM", 111, 115], ["CoV", "PROBLEM", 116, 119], ["2 infection", "PROBLEM", 120, 131], ["severe disease course", "PROBLEM", 136, 157], ["hypertension", "OBSERVATION", 39, 51], ["coronary heart", "ANATOMY", 53, 67], ["disease", "OBSERVATION", 68, 75], ["diabetes", "OBSERVATION", 80, 88], ["SARS", "OBSERVATION", 111, 115], ["infection", "OBSERVATION", 122, 131], ["severe", "OBSERVATION_MODIFIER", 136, 142], ["disease", "OBSERVATION", 143, 150]]], ["Although the lung is the main target organ of SARS-CoV-2 infection; damage can occur in multiple organs.", [["lung", "ANATOMY", 13, 17], ["organ", "ANATOMY", 37, 42], ["organs", "ANATOMY", 97, 103], ["SARS", "DISEASE", 46, 50], ["infection", "DISEASE", 57, 66], ["lung", "ORGAN", 13, 17], ["organ", "ORGAN", 37, 42], ["SARS-CoV-2", "ORGANISM", 46, 56], ["organs", "ORGAN", 97, 103], ["SARS-CoV-2", "SPECIES", 46, 56], ["SARS", "PROBLEM", 46, 50], ["CoV-2 infection", "PROBLEM", 51, 66], ["damage", "PROBLEM", 68, 74], ["lung", "ANATOMY", 13, 17], ["main", "OBSERVATION_MODIFIER", 25, 29], ["SARS", "OBSERVATION", 46, 50], ["CoV", "OBSERVATION_MODIFIER", 51, 54], ["infection", "OBSERVATION", 57, 66]]], ["The liver is the vital organ in the human body and its exposure to the viral particles might be an additional concern for CVID-19 patients.", [["liver", "ANATOMY", 4, 9], ["organ", "ANATOMY", 23, 28], ["body", "ANATOMY", 42, 46], ["CVID", "DISEASE", 122, 126], ["liver", "ORGAN", 4, 9], ["organ", "ORGAN", 23, 28], ["human", "ORGANISM", 36, 41], ["body", "ORGANISM_SUBDIVISION", 42, 46], ["patients", "ORGANISM", 130, 138], ["human", "SPECIES", 36, 41], ["patients", "SPECIES", 130, 138], ["human", "SPECIES", 36, 41], ["the viral particles", "PROBLEM", 67, 86], ["CVID", "PROBLEM", 122, 126], ["liver", "ANATOMY", 4, 9], ["vital organ", "OBSERVATION", 17, 28], ["human body", "ANATOMY_MODIFIER", 36, 46], ["viral particles", "OBSERVATION", 71, 86]]], ["Up to now, there is no strong evidence that the liver cells are exposed to SARS-CoV-2 in severe cases.", [["liver cells", "ANATOMY", 48, 59], ["SARS", "DISEASE", 75, 79], ["liver cells", "CELL", 48, 59], ["liver cells", "CELL_TYPE", 48, 59], ["SARS-CoV", "SPECIES", 75, 83], ["the liver cells", "PROBLEM", 44, 59], ["SARS", "TEST", 75, 79], ["CoV", "TEST", 80, 83], ["no strong evidence", "UNCERTAINTY", 20, 38], ["liver", "ANATOMY", 48, 53], ["severe", "OBSERVATION_MODIFIER", 89, 95]]], ["Moreover, it remains unclear yet to what extent liver diseases are considerable risk factors of COVID-19 severity and mortality.INTRODUCTIONLiver impairment is an emerging concern with COVID-19, as it was observed with the similar coronavirus SARS.", [["liver", "ANATOMY", 48, 53], ["liver diseases", "DISEASE", 48, 62], ["SARS", "DISEASE", 243, 247], ["COVID-19", "CHEMICAL", 185, 193], ["liver", "ORGAN", 48, 53], ["coronavirus", "ORGANISM", 231, 242], ["liver diseases", "PROBLEM", 48, 62], ["COVID", "TEST", 96, 101], ["COVID", "TEST", 185, 190], ["the similar coronavirus SARS", "PROBLEM", 219, 247], ["liver", "ANATOMY", 48, 53], ["diseases", "OBSERVATION", 54, 62]]], ["According to previous studies, up to 60% of patients had a liver impairment, with liver biopsy specimens suggesting viral nucleic acid and damage (3) (4) (5) .", [["liver", "ANATOMY", 59, 64], ["liver biopsy specimens", "ANATOMY", 82, 104], ["liver impairment", "DISEASE", 59, 75], ["nucleic acid", "CHEMICAL", 122, 134], ["patients", "ORGANISM", 44, 52], ["liver", "ORGAN", 59, 64], ["liver biopsy specimens", "CANCER", 82, 104], ["patients", "SPECIES", 44, 52], ["previous studies", "TEST", 13, 29], ["a liver impairment", "PROBLEM", 57, 75], ["liver biopsy specimens", "TEST", 82, 104], ["viral nucleic acid and damage", "PROBLEM", 116, 145], ["liver", "ANATOMY", 59, 64], ["impairment", "OBSERVATION", 65, 75], ["liver", "ANATOMY", 82, 87], ["viral nucleic acid", "OBSERVATION", 116, 134]]], ["In these studies authors noted that this might have been the result of drug-induced liver damage, given that the majority of the patients were treated with high doses of antibiotics, hepatotoxic antiviral drugs and steroids.INTRODUCTIONSome studies have reported the clinical features and laboratory test results associated with liver dysfunction in patients with COVID-19 infection (6) (7) (8) (9) (10) (11) (12) (13) .", [["liver", "ANATOMY", 84, 89], ["liver", "ANATOMY", 329, 334], ["liver damage", "DISEASE", 84, 96], ["steroids", "CHEMICAL", 215, 223], ["liver dysfunction", "DISEASE", 329, 346], ["COVID-19", "CHEMICAL", 364, 372], ["infection", "DISEASE", 373, 382], ["steroids", "CHEMICAL", 215, 223], ["COVID-19", "CHEMICAL", 364, 372], ["liver", "ORGAN", 84, 89], ["patients", "ORGANISM", 129, 137], ["steroids", "SIMPLE_CHEMICAL", 215, 223], ["liver", "ORGAN", 329, 334], ["patients", "ORGANISM", 350, 358], ["patients", "SPECIES", 129, 137], ["patients", "SPECIES", 350, 358], ["drug-induced liver damage", "PROBLEM", 71, 96], ["antibiotics", "TREATMENT", 170, 181], ["hepatotoxic antiviral drugs", "TREATMENT", 183, 210], ["steroids", "TREATMENT", 215, 223], ["INTRODUCTIONSome studies", "TEST", 224, 248], ["laboratory test", "TEST", 289, 304], ["liver dysfunction", "PROBLEM", 329, 346], ["COVID", "TEST", 364, 369], ["19 infection", "PROBLEM", 370, 382], ["liver", "ANATOMY", 84, 89], ["damage", "OBSERVATION", 90, 96], ["liver", "ANATOMY", 329, 334], ["dysfunction", "OBSERVATION", 335, 346], ["infection", "OBSERVATION", 373, 382]]], ["Although, pre-existing liver conditions have not been listed in most of these studies and the interaction of pre-existing liver disease with COVID-19 has not been investigated, which are major limitations in evaluating the underlying causes of liver injury in the severe disease course.", [["liver", "ANATOMY", 23, 28], ["liver", "ANATOMY", 122, 127], ["liver", "ANATOMY", 244, 249], ["liver disease", "DISEASE", 122, 135], ["COVID-19", "CHEMICAL", 141, 149], ["liver injury", "DISEASE", 244, 256], ["COVID-19", "CHEMICAL", 141, 149], ["liver", "ORGAN", 23, 28], ["liver", "ORGAN", 122, 127], ["COVID-19", "GENE_OR_GENE_PRODUCT", 141, 149], ["liver", "ORGAN", 244, 249], ["pre-existing liver conditions", "PROBLEM", 10, 39], ["these studies", "TEST", 72, 85], ["pre-existing liver disease", "PROBLEM", 109, 135], ["COVID", "TEST", 141, 146], ["liver injury", "PROBLEM", 244, 256], ["the severe disease course", "PROBLEM", 260, 285], ["liver", "ANATOMY", 23, 28], ["liver", "ANATOMY", 122, 127], ["disease", "OBSERVATION", 128, 135], ["liver", "ANATOMY", 244, 249], ["injury", "OBSERVATION", 250, 256], ["severe", "OBSERVATION_MODIFIER", 264, 270], ["disease", "OBSERVATION", 271, 278]]], ["However, the elevated levels of alanine aminotransferase and reduced platelet counts and reduced levels of albumin showed an association with higher fatality in COVID-19 patients (2).", [["platelet", "ANATOMY", 69, 77], ["alanine", "CHEMICAL", 32, 39], ["alanine", "CHEMICAL", 32, 39], ["alanine", "AMINO_ACID", 32, 39], ["aminotransferase", "GENE_OR_GENE_PRODUCT", 40, 56], ["platelet", "CELL", 69, 77], ["albumin", "GENE_OR_GENE_PRODUCT", 107, 114], ["patients", "ORGANISM", 170, 178], ["alanine aminotransferase", "PROTEIN", 32, 56], ["albumin", "PROTEIN", 107, 114], ["patients", "SPECIES", 170, 178], ["the elevated levels", "PROBLEM", 9, 28], ["alanine aminotransferase", "TEST", 32, 56], ["reduced platelet counts", "TEST", 61, 84], ["reduced levels of albumin", "PROBLEM", 89, 114], ["COVID", "TEST", 161, 166], ["elevated", "OBSERVATION_MODIFIER", 13, 21], ["platelet counts", "OBSERVATION", 69, 84]]], ["It is still unknown whether these laboratory analyses are an indicator of pre-existing hepatic diseases in severe patients, whether they rather mirror liver failure caused by the SARS-CoV-2 itself (14) .", [["hepatic", "ANATOMY", 87, 94], ["liver", "ANATOMY", 151, 156], ["hepatic diseases", "DISEASE", 87, 103], ["liver failure", "DISEASE", 151, 164], ["hepatic", "ORGAN", 87, 94], ["patients", "ORGANISM", 114, 122], ["liver", "ORGAN", 151, 156], ["patients", "SPECIES", 114, 122], ["SARS-CoV", "SPECIES", 179, 187], ["these laboratory analyses", "TEST", 28, 53], ["pre-existing hepatic diseases", "PROBLEM", 74, 103], ["mirror liver failure", "PROBLEM", 144, 164], ["the SARS", "TEST", 175, 183], ["CoV", "TEST", 184, 187], ["hepatic", "ANATOMY", 87, 94], ["diseases", "OBSERVATION", 95, 103], ["severe", "OBSERVATION_MODIFIER", 107, 113], ["liver", "ANATOMY", 151, 156], ["failure", "OBSERVATION", 157, 164]]], ["Overreaction of the immune system may also contribute to disease progression and can lead to liver injury (15) .", [["immune system", "ANATOMY", 20, 33], ["liver", "ANATOMY", 93, 98], ["liver injury", "DISEASE", 93, 105], ["liver", "ORGAN", 93, 98], ["the immune system", "TREATMENT", 16, 33], ["disease progression", "PROBLEM", 57, 76], ["liver injury", "PROBLEM", 93, 105], ["may also contribute to", "UNCERTAINTY", 34, 56], ["disease", "OBSERVATION", 57, 64], ["liver", "ANATOMY", 93, 98], ["injury", "OBSERVATION", 99, 105]]], ["Serum concentrations of pro-inflammatory cytokines, including C-reactive protein (CRP) TNF-\u03b1, IL-1\u03b2, and IL-6 were seen at elevated levels in most of the severe cases, indicating cytokine storm syndrome might be associated with the disease severity (16, 17) .", [["Serum", "ANATOMY", 0, 5], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 62, 80], ["CRP", "GENE_OR_GENE_PRODUCT", 82, 85], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 87, 92], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 94, 99], ["IL-6", "GENE_OR_GENE_PRODUCT", 105, 109], ["pro-inflammatory cytokines", "PROTEIN", 24, 50], ["C-reactive protein", "PROTEIN", 62, 80], ["CRP", "PROTEIN", 82, 85], ["TNF", "PROTEIN", 87, 90], ["IL-1\u03b2", "PROTEIN", 94, 99], ["IL-6", "PROTEIN", 105, 109], ["cytokine", "PROTEIN", 179, 187], ["Serum concentrations", "TEST", 0, 20], ["pro-inflammatory cytokines", "TEST", 24, 50], ["C", "TEST", 62, 63], ["reactive protein", "TEST", 64, 80], ["CRP", "TEST", 82, 85], ["TNF", "TEST", 87, 90], ["IL", "TEST", 94, 96], ["IL", "TEST", 105, 107], ["elevated levels", "PROBLEM", 123, 138], ["the severe cases", "PROBLEM", 150, 166], ["cytokine storm syndrome", "PROBLEM", 179, 202], ["the disease severity", "PROBLEM", 228, 248], ["pro-inflammatory cytokines", "OBSERVATION", 24, 50], ["cytokine storm syndrome", "OBSERVATION", 179, 202], ["disease", "OBSERVATION", 232, 239]]], ["It is also considered that systemic infections might influence liver functions in a severe disease course.", [["liver", "ANATOMY", 63, 68], ["infections", "DISEASE", 36, 46], ["liver", "ORGAN", 63, 68], ["systemic infections", "PROBLEM", 27, 46], ["a severe disease course", "PROBLEM", 82, 105], ["systemic", "OBSERVATION_MODIFIER", 27, 35], ["infections", "OBSERVATION", 36, 46], ["liver", "ANATOMY", 63, 68], ["severe", "OBSERVATION_MODIFIER", 84, 90], ["disease", "OBSERVATION", 91, 98]]], ["Further clinical studies can provide a better insight on liver damage in severe patients with SARS-CoV-2 infection.", [["liver", "ANATOMY", 57, 62], ["liver damage", "DISEASE", 57, 69], ["SARS-CoV-2 infection", "DISEASE", 94, 114], ["liver", "ORGAN", 57, 62], ["patients", "ORGANISM", 80, 88], ["SARS-CoV-2", "ORGANISM", 94, 104], ["patients", "SPECIES", 80, 88], ["Further clinical studies", "TEST", 0, 24], ["liver damage", "PROBLEM", 57, 69], ["SARS", "PROBLEM", 94, 98], ["CoV-2 infection", "PROBLEM", 99, 114], ["liver", "ANATOMY", 57, 62], ["severe", "OBSERVATION_MODIFIER", 73, 79], ["infection", "OBSERVATION", 105, 114]]], ["This review summarizes the available data on liver test abnormalities in COVID-19 patients; critically evaluates the possible causes of liver injury and provides recommendations for clinicians.", [["liver", "ANATOMY", 45, 50], ["liver", "ANATOMY", 136, 141], ["liver test abnormalities", "DISEASE", 45, 69], ["liver injury", "DISEASE", 136, 148], ["liver", "ORGAN", 45, 50], ["patients", "ORGANISM", 82, 90], ["liver", "ORGAN", 136, 141], ["patients", "SPECIES", 82, 90], ["liver test abnormalities", "TEST", 45, 69], ["COVID", "TEST", 73, 78], ["liver injury", "PROBLEM", 136, 148], ["liver", "ANATOMY", 45, 50], ["liver", "ANATOMY", 136, 141], ["injury", "OBSERVATION", 142, 148]]], ["Online databases including Google Scholar, PubMed, Scopus, and medRxiv were searched to identify relevant publications using relevant keywords.PREVALENCE OF LIVER FUNCTION TEST ABNORMALITIES IN COVID-19 PATIENTSSeveral studies have demonstrated the different degrees of elevated liver test markers in COVID-19 patients, mainly reported by alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT) levels accompanied by moderately elevated prothrombin time (PT), and total bilirubin (TB) levels (6) (7) (8) (9) (10) (11) (12) (13) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) .", [["liver", "ANATOMY", 279, 284], ["alanine", "CHEMICAL", 339, 346], ["aspartate", "CHEMICAL", 371, 380], ["bilirubin", "CHEMICAL", 513, 522], ["alanine", "CHEMICAL", 339, 346], ["aspartate", "CHEMICAL", 371, 380], ["bilirubin", "CHEMICAL", 513, 522], ["liver", "ORGAN", 279, 284], ["patients", "ORGANISM", 310, 318], ["alanine aminotransferase", "GENE_OR_GENE_PRODUCT", 339, 363], ["ALT", "SIMPLE_CHEMICAL", 365, 368], ["aspartate aminotransferase", "GENE_OR_GENE_PRODUCT", 371, 397], ["AST", "SIMPLE_CHEMICAL", 399, 402], ["gamma-glutamyl transferase", "GENE_OR_GENE_PRODUCT", 405, 431], ["GGT", "SIMPLE_CHEMICAL", 433, 436], ["prothrombin", "GENE_OR_GENE_PRODUCT", 480, 491], ["bilirubin", "SIMPLE_CHEMICAL", 513, 522], ["8) (9) (10) (11) (12) (13) (17) (18) (19) (20) (21) (22) (23) (24) (25", "SIMPLE_CHEMICAL", 544, 614], ["alanine aminotransferase", "PROTEIN", 339, 363], ["ALT", "PROTEIN", 365, 368], ["aspartate aminotransferase", "PROTEIN", 371, 397], ["AST", "PROTEIN", 399, 402], ["gamma-glutamyl transferase", "PROTEIN", 405, 431], ["GGT", "PROTEIN", 433, 436], ["prothrombin", "PROTEIN", 480, 491], ["patients", "SPECIES", 310, 318], ["medRxiv", "TREATMENT", 63, 70], ["LIVER FUNCTION TEST ABNORMALITIES", "TEST", 157, 190], ["PATIENTSSeveral studies", "TEST", 203, 226], ["elevated liver test markers", "PROBLEM", 270, 297], ["COVID", "TEST", 301, 306], ["alanine aminotransferase", "TEST", 339, 363], ["ALT", "TEST", 365, 368], ["aspartate aminotransferase", "TEST", 371, 397], ["AST", "TEST", 399, 402], ["gamma", "TEST", 405, 410], ["glutamyl transferase", "TEST", 411, 431], ["GGT) levels", "TEST", 433, 444], ["moderately elevated prothrombin time", "PROBLEM", 460, 496], ["PT", "TEST", 498, 500], ["total bilirubin", "TEST", 507, 522], ["levels", "TEST", 528, 534], ["LIVER", "ANATOMY", 157, 162], ["elevated", "OBSERVATION", 270, 278], ["liver", "ANATOMY", 279, 284], ["moderately", "OBSERVATION_MODIFIER", 460, 470], ["elevated", "OBSERVATION", 471, 479], ["prothrombin time", "OBSERVATION", 480, 496]]], ["However, there are limited numbers of studies that have specifically investigated the clinical characteristics of liver failure in COVID-19 patients.", [["liver", "ANATOMY", 114, 119], ["liver failure", "DISEASE", 114, 127], ["liver", "ORGAN", 114, 119], ["patients", "ORGANISM", 140, 148], ["patients", "SPECIES", 140, 148], ["studies", "TEST", 38, 45], ["liver failure", "PROBLEM", 114, 127], ["liver", "ANATOMY", 114, 119], ["failure", "OBSERVATION", 120, 127]]], ["The available reports on liver function tests in COVID-19 patients are listed in Table 1 .", [["liver", "ANATOMY", 25, 30], ["liver", "ORGAN", 25, 30], ["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66], ["liver function tests", "TEST", 25, 45], ["liver", "ANATOMY", 25, 30]]], ["Of these studies, an increasing trend for liver enzymes has been observed in severe/non-survivor patients.", [["liver", "ANATOMY", 42, 47], ["liver", "ORGAN", 42, 47], ["patients", "ORGANISM", 97, 105], ["liver enzymes", "PROTEIN", 42, 55], ["patients", "SPECIES", 97, 105], ["these studies", "TEST", 3, 16], ["liver enzymes", "TEST", 42, 55], ["increasing", "OBSERVATION_MODIFIER", 21, 31], ["liver", "ANATOMY", 42, 47]]], ["The prevalence of elevated ALT, AST, and GGT were up to 82, 75, and 72%, respectively.", [["ALT", "GENE_OR_GENE_PRODUCT", 27, 30], ["AST", "SIMPLE_CHEMICAL", 32, 35], ["GGT", "SIMPLE_CHEMICAL", 41, 44], ["ALT", "PROTEIN", 27, 30], ["AST", "PROTEIN", 32, 35], ["GGT", "PROTEIN", 41, 44], ["elevated ALT", "PROBLEM", 18, 30], ["AST", "TEST", 32, 35], ["GGT", "TEST", 41, 44], ["elevated", "OBSERVATION_MODIFIER", 18, 26], ["ALT", "OBSERVATION_MODIFIER", 27, 30]]], ["A recent study reported 76.3% of liver test abnormalities and 21.5% of liver injury among hospitalized COVID-19 patients (6) .", [["liver", "ANATOMY", 33, 38], ["liver", "ANATOMY", 71, 76], ["liver test abnormalities", "DISEASE", 33, 57], ["liver injury", "DISEASE", 71, 83], ["liver", "ORGAN", 33, 38], ["liver", "ORGAN", 71, 76], ["patients", "ORGANISM", 112, 120], ["patients", "SPECIES", 112, 120], ["A recent study", "TEST", 0, 14], ["liver test abnormalities", "TEST", 33, 57], ["liver injury", "PROBLEM", 71, 83], ["liver", "ANATOMY", 33, 38], ["liver", "ANATOMY", 71, 76], ["injury", "OBSERVATION", 77, 83]]], ["Serum levels of ALT, AST, GGT and TB were significantly higher (p < 0.01) in ICU admitted severe patients than non-severe patients (6) .", [["Serum", "ANATOMY", 0, 5], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["ALT", "GENE_OR_GENE_PRODUCT", 16, 19], ["AST", "SIMPLE_CHEMICAL", 21, 24], ["GGT", "SIMPLE_CHEMICAL", 26, 29], ["patients", "ORGANISM", 97, 105], ["patients", "ORGANISM", 122, 130], ["ALT", "PROTEIN", 16, 19], ["AST", "PROTEIN", 21, 24], ["GGT", "PROTEIN", 26, 29], ["patients", "SPECIES", 97, 105], ["patients", "SPECIES", 122, 130], ["Serum levels", "TEST", 0, 12], ["ALT", "TEST", 16, 19], ["AST", "TEST", 21, 24], ["GGT", "TEST", 26, 29], ["TB", "TEST", 34, 36], ["ALT", "ANATOMY", 16, 19]]], ["In that study, 26.7% of patients with liver test abnormalities showed a progression to severe pneumonia.", [["liver", "ANATOMY", 38, 43], ["liver test abnormalities", "DISEASE", 38, 62], ["pneumonia", "DISEASE", 94, 103], ["patients", "ORGANISM", 24, 32], ["liver", "ORGAN", 38, 43], ["patients", "SPECIES", 24, 32], ["that study", "TEST", 3, 13], ["liver test abnormalities", "TEST", 38, 62], ["severe pneumonia", "PROBLEM", 87, 103], ["liver", "ANATOMY", 38, 43], ["progression", "OBSERVATION_MODIFIER", 72, 83], ["severe", "OBSERVATION_MODIFIER", 87, 93], ["pneumonia", "OBSERVATION", 94, 103]]], ["The abnormal liver tests were more pronounced in patients within 2 weeks of hospitalization.", [["liver", "ANATOMY", 13, 18], ["liver", "ORGAN", 13, 18], ["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57], ["The abnormal liver tests", "PROBLEM", 0, 24], ["abnormal", "OBSERVATION_MODIFIER", 4, 12], ["liver", "ANATOMY", 13, 18], ["more pronounced", "OBSERVATION_MODIFIER", 30, 45]]], ["The liver injury was significantly higher in severe patients than non-severe patients.", [["liver", "ANATOMY", 4, 9], ["liver injury", "DISEASE", 4, 16], ["liver", "ORGAN", 4, 9], ["patients", "ORGANISM", 52, 60], ["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 52, 60], ["patients", "SPECIES", 77, 85], ["The liver injury", "PROBLEM", 0, 16], ["liver", "ANATOMY", 4, 9], ["injury", "OBSERVATION", 10, 16], ["significantly", "OBSERVATION_MODIFIER", 21, 34], ["higher", "OBSERVATION_MODIFIER", 35, 41], ["severe", "OBSERVATION_MODIFIER", 45, 51]]], ["The authors also noted that patients in hepatocyte type had significantly higher odds for progression to severe COVID-19.", [["hepatocyte", "ANATOMY", 40, 50], ["COVID", "DISEASE", 112, 117], ["COVID-19", "CHEMICAL", 112, 120], ["patients", "ORGANISM", 28, 36], ["hepatocyte type", "CELL", 40, 55], ["patients", "SPECIES", 28, 36], ["severe COVID", "PROBLEM", 105, 117], ["hepatocyte", "ANATOMY", 40, 50], ["severe", "OBSERVATION_MODIFIER", 105, 111]]], ["In another study, concentrations of ALT, AST, GGT, ALP, and TB were markedly higher in deceased patients than in recovered patients (19) .", [["ALT", "SIMPLE_CHEMICAL", 36, 39], ["AST", "SIMPLE_CHEMICAL", 41, 44], ["GGT", "SIMPLE_CHEMICAL", 46, 49], ["ALP", "GENE_OR_GENE_PRODUCT", 51, 54], ["patients", "ORGANISM", 96, 104], ["patients", "ORGANISM", 123, 131], ["ALT", "PROTEIN", 36, 39], ["AST", "PROTEIN", 41, 44], ["GGT", "PROTEIN", 46, 49], ["ALP", "PROTEIN", 51, 54], ["patients", "SPECIES", 96, 104], ["patients", "SPECIES", 123, 131], ["another study", "TEST", 3, 16], ["ALT", "TEST", 36, 39], ["AST", "TEST", 41, 44], ["GGT", "TEST", 46, 49], ["ALP", "TEST", 51, 54], ["TB", "TEST", 60, 62], ["higher", "OBSERVATION_MODIFIER", 77, 83]]], ["About 52% of deceased patients and 16% who recovered had elevated AST levels (19) .", [["patients", "ORGANISM", 22, 30], ["AST", "SIMPLE_CHEMICAL", 66, 69], ["AST", "PROTEIN", 66, 69], ["patients", "SPECIES", 22, 30], ["elevated AST levels", "PROBLEM", 57, 76]]], ["In a retrospective study, the levels of ALT, AST, GGT, and TB, showed statistically significant elevation in severe COVID-19 patients compared with that in mild patients (27) .", [["TB", "DISEASE", 59, 61], ["ALT", "GENE_OR_GENE_PRODUCT", 40, 43], ["AST", "SIMPLE_CHEMICAL", 45, 48], ["GGT", "SIMPLE_CHEMICAL", 50, 53], ["patients", "ORGANISM", 125, 133], ["patients", "ORGANISM", 161, 169], ["ALT", "PROTEIN", 40, 43], ["AST", "PROTEIN", 45, 48], ["GGT", "PROTEIN", 50, 53], ["patients", "SPECIES", 125, 133], ["patients", "SPECIES", 161, 169], ["a retrospective study", "TEST", 3, 24], ["the levels", "TEST", 26, 36], ["ALT", "TEST", 40, 43], ["AST", "TEST", 45, 48], ["GGT", "TEST", 50, 53], ["TB", "TEST", 59, 61], ["statistically significant elevation in severe COVID", "PROBLEM", 70, 121], ["ALT", "ANATOMY", 40, 43], ["significant", "OBSERVATION_MODIFIER", 84, 95], ["elevation", "OBSERVATION", 96, 105], ["severe", "OBSERVATION_MODIFIER", 109, 115], ["mild", "OBSERVATION_MODIFIER", 156, 160]]], ["ALT and AST abnormalities were also found at least two times higher in severe patients than non-severe patients (13) .", [["ALT", "SIMPLE_CHEMICAL", 0, 3], ["AST", "SIMPLE_CHEMICAL", 8, 11], ["patients", "ORGANISM", 78, 86], ["patients", "ORGANISM", 103, 111], ["ALT", "PROTEIN", 0, 3], ["AST", "PROTEIN", 8, 11], ["patients", "SPECIES", 78, 86], ["patients", "SPECIES", 103, 111], ["ALT", "TEST", 0, 3], ["AST abnormalities", "TEST", 8, 25], ["severe", "OBSERVATION_MODIFIER", 71, 77]]], ["Moreover, a large cohort study including 1,099 patients, reported an elevated level of ALT and AST (28.1 and 39.4%, respectively) in severe patients than non-severe patients (19.8 and 18.2%, respectively) (8) .", [["patients", "ORGANISM", 47, 55], ["ALT", "GENE_OR_GENE_PRODUCT", 87, 90], ["patients", "ORGANISM", 140, 148], ["patients", "ORGANISM", 165, 173], ["ALT", "PROTEIN", 87, 90], ["AST", "PROTEIN", 95, 98], ["patients", "SPECIES", 47, 55], ["patients", "SPECIES", 140, 148], ["patients", "SPECIES", 165, 173], ["a large cohort study", "TEST", 10, 30], ["an elevated level", "PROBLEM", 66, 83], ["ALT", "TEST", 87, 90], ["AST", "TEST", 95, 98], ["non-severe patients", "PROBLEM", 154, 173], ["large", "OBSERVATION_MODIFIER", 12, 17], ["elevated", "OBSERVATION", 69, 77], ["severe", "OBSERVATION_MODIFIER", 133, 139]]], ["Similarly, the prevalence of elevated AST in ICU patients (62%) was higher than non-ICU patients (25%) (28) .", [["AST", "SIMPLE_CHEMICAL", 38, 41], ["patients", "ORGANISM", 49, 57], ["patients", "ORGANISM", 88, 96], ["AST", "PROTEIN", 38, 41], ["patients", "SPECIES", 49, 57], ["patients", "SPECIES", 88, 96], ["elevated AST", "PROBLEM", 29, 41], ["elevated", "OBSERVATION_MODIFIER", 29, 37], ["AST", "OBSERVATION_MODIFIER", 38, 41]]], ["Furthermore, in another publication, AST abnormalities were found lower in patients before the onset of symptoms than the patients did diagnose after the onset of symptoms (9) .", [["AST", "SIMPLE_CHEMICAL", 37, 40], ["patients", "ORGANISM", 75, 83], ["patients", "ORGANISM", 122, 130], ["AST", "PROTEIN", 37, 40], ["patients", "SPECIES", 75, 83], ["patients", "SPECIES", 122, 130], ["AST abnormalities", "PROBLEM", 37, 54], ["symptoms", "PROBLEM", 104, 112], ["symptoms", "PROBLEM", 163, 171], ["lower", "OBSERVATION_MODIFIER", 66, 71]]], ["Other studies, however, reported different results.", [["Other studies", "TEST", 0, 13]]], ["For example, Wu et al. did not find significant differences in liver function tests when compared to mild cases with severe cases (26) .", [["liver", "ANATOMY", 63, 68], ["liver", "ORGAN", 63, 68], ["liver function tests", "TEST", 63, 83], ["severe cases", "PROBLEM", 117, 129], ["significant", "OBSERVATION_MODIFIER", 36, 47], ["differences", "OBSERVATION", 48, 59], ["liver", "ANATOMY", 63, 68]]], ["Another study consisted of 339 elderly COVID-19 patients and reported no evident differences in ALT levels between death and survival (25) .", [["death", "DISEASE", 115, 120], ["patients", "ORGANISM", 48, 56], ["ALT", "SIMPLE_CHEMICAL", 96, 99], ["ALT", "PROTEIN", 96, 99], ["patients", "SPECIES", 48, 56], ["Another study", "TEST", 0, 13], ["evident differences in ALT levels", "PROBLEM", 73, 106], ["no evident", "UNCERTAINTY", 70, 80]]], ["Therefore, researchers also argue that though liver function tests abnormalities are common in COVID-19 patients, liver functions impairment maybe not a prominent feature of COVID-19 (27) .", [["liver", "ANATOMY", 46, 51], ["liver", "ANATOMY", 114, 119], ["liver functions impairment", "DISEASE", 114, 140], ["COVID-19", "CHEMICAL", 174, 182], ["liver", "ORGAN", 46, 51], ["patients", "ORGANISM", 104, 112], ["liver", "ORGAN", 114, 119], ["patients", "SPECIES", 104, 112], ["liver function tests abnormalities", "TEST", 46, 80], ["COVID", "TEST", 95, 100], ["liver functions impairment", "PROBLEM", 114, 140], ["COVID", "TEST", 174, 179], ["liver", "ANATOMY", 46, 51], ["liver", "ANATOMY", 114, 119]]], ["However, the major studies clearly indicated increased liver dysfunctions in severe COVID-19 patients, though clinically significant liver failure has rarely been described.POSSIBLE EFFECTS OF DRUGS ON LIVER FUNCTION IN COVID-19 PATIENTSIt is also possible that the drugs used in the treatment are associated with liver injury in COVI19 patients.", [["liver", "ANATOMY", 55, 60], ["liver", "ANATOMY", 133, 138], ["liver", "ANATOMY", 314, 319], ["liver dysfunctions", "DISEASE", 55, 73], ["COVID", "DISEASE", 84, 89], ["liver failure", "DISEASE", 133, 146], ["liver injury", "DISEASE", 314, 326], ["liver", "ORGAN", 55, 60], ["patients", "ORGANISM", 93, 101], ["liver", "ORGAN", 133, 138], ["liver", "ORGAN", 314, 319], ["patients", "ORGANISM", 337, 345], ["patients", "SPECIES", 93, 101], ["patients", "SPECIES", 337, 345], ["the major studies", "TEST", 9, 26], ["increased liver dysfunctions", "PROBLEM", 45, 73], ["clinically significant liver failure", "PROBLEM", 110, 146], ["the drugs", "TREATMENT", 262, 271], ["the treatment", "TREATMENT", 280, 293], ["liver injury", "PROBLEM", 314, 326], ["increased", "OBSERVATION_MODIFIER", 45, 54], ["liver", "ANATOMY", 55, 60], ["dysfunctions", "OBSERVATION", 61, 73], ["severe", "OBSERVATION_MODIFIER", 77, 83], ["significant", "OBSERVATION_MODIFIER", 121, 132], ["liver", "ANATOMY", 133, 138], ["failure", "OBSERVATION", 139, 146], ["LIVER", "ANATOMY", 202, 207], ["liver", "ANATOMY", 314, 319], ["injury", "OBSERVATION", 320, 326]]], ["For example, the use of multiple drugs, such as antibiotics, antivirals, antipyretics and analgesics, and traditional Chinese medicine may cause liver injury in COVID-19 patients (30) .", [["liver", "ANATOMY", 145, 150], ["liver injury", "DISEASE", 145, 157], ["liver", "ORGAN", 145, 150], ["patients", "ORGANISM", 170, 178], ["patients", "SPECIES", 170, 178], ["multiple drugs", "TREATMENT", 24, 38], ["antibiotics", "TREATMENT", 48, 59], ["antivirals", "TREATMENT", 61, 71], ["antipyretics", "TREATMENT", 73, 85], ["analgesics", "TREATMENT", 90, 100], ["traditional Chinese medicine", "TREATMENT", 106, 134], ["liver injury", "PROBLEM", 145, 157], ["liver", "ANATOMY", 145, 150], ["injury", "OBSERVATION", 151, 157]]], ["Yet, there is no clear evidence that the liver dysfunctions during hospitalization are completely drug-induced in severe patients with COVI-19 infection.", [["liver", "ANATOMY", 41, 46], ["liver dysfunctions", "DISEASE", 41, 59], ["COVI-19", "CHEMICAL", 135, 142], ["infection", "DISEASE", 143, 152], ["liver", "ORGAN", 41, 46], ["patients", "ORGANISM", 121, 129], ["patients", "SPECIES", 121, 129], ["the liver dysfunctions", "PROBLEM", 37, 59], ["COVI-19 infection", "PROBLEM", 135, 152], ["no clear evidence", "UNCERTAINTY", 14, 31], ["liver", "ANATOMY", 41, 46], ["dysfunctions", "OBSERVATION", 47, 59], ["severe", "OBSERVATION_MODIFIER", 114, 120], ["infection", "OBSERVATION", 143, 152]]], ["In a recent study, the liver biopsy specimen of a patient who died from COVID-19 showed elevated liver enzymes that could be the partial effects of drugs used in the treatment, and the liver dysfunction may be occurred because of sepsis and shock (6) .", [["liver biopsy specimen", "ANATOMY", 23, 44], ["liver", "ANATOMY", 97, 102], ["liver", "ANATOMY", 185, 190], ["elevated liver enzymes", "DISEASE", 88, 110], ["liver dysfunction", "DISEASE", 185, 202], ["sepsis", "DISEASE", 230, 236], ["shock", "DISEASE", 241, 246], ["COVID-19", "CHEMICAL", 72, 80], ["liver biopsy specimen", "MULTI-TISSUE_STRUCTURE", 23, 44], ["patient", "ORGANISM", 50, 57], ["liver", "ORGAN", 97, 102], ["liver", "ORGAN", 185, 190], ["liver enzymes", "PROTEIN", 97, 110], ["patient", "SPECIES", 50, 57], ["a recent study", "TEST", 3, 17], ["the liver biopsy specimen", "TEST", 19, 44], ["COVID", "TEST", 72, 77], ["elevated liver enzymes", "PROBLEM", 88, 110], ["drugs", "TREATMENT", 148, 153], ["the treatment", "TREATMENT", 162, 175], ["the liver dysfunction", "PROBLEM", 181, 202], ["sepsis", "PROBLEM", 230, 236], ["shock", "PROBLEM", 241, 246], ["liver", "ANATOMY", 23, 28], ["liver", "ANATOMY", 97, 102], ["liver", "ANATOMY", 185, 190], ["dysfunction", "OBSERVATION", 191, 202], ["sepsis", "OBSERVATION", 230, 236], ["shock", "OBSERVATION", 241, 246]]], ["It has been indicated that angiotensin II receptor blockers and ACE-inhibitors drugs may inhibit liver functions in COVID-19 patients (6) .", [["liver", "ANATOMY", 97, 102], ["angiotensin II", "CHEMICAL", 27, 41], ["ACE-inhibitors", "CHEMICAL", 64, 78], ["liver functions", "DISEASE", 97, 112], ["angiotensin II receptor blockers", "GENE_OR_GENE_PRODUCT", 27, 59], ["ACE", "GENE_OR_GENE_PRODUCT", 64, 67], ["liver", "ORGAN", 97, 102], ["patients", "ORGANISM", 125, 133], ["patients", "SPECIES", 125, 133], ["angiotensin II receptor blockers", "TREATMENT", 27, 59], ["ACE-inhibitors drugs", "TREATMENT", 64, 84], ["liver functions", "TEST", 97, 112], ["COVID", "TEST", 116, 121], ["liver", "ANATOMY", 97, 102]]], ["In that study, elevated levels of liver enzymes were observed among participants who used ACE-Is/ARBs drugs during hospitalization, though; the elevation was not significant with those who did not use these drugs (6) .", [["liver", "ANATOMY", 34, 39], ["ACE-Is/ARBs", "CHEMICAL", 90, 101], ["liver", "ORGAN", 34, 39], ["ACE-Is", "SIMPLE_CHEMICAL", 90, 96], ["ARBs", "SIMPLE_CHEMICAL", 97, 101], ["liver enzymes", "PROTEIN", 34, 47], ["participants", "SPECIES", 68, 80], ["that study", "TEST", 3, 13], ["elevated levels of liver enzymes", "PROBLEM", 15, 47], ["ACE", "TREATMENT", 90, 93], ["ARBs drugs", "TREATMENT", 97, 107], ["the elevation", "PROBLEM", 140, 153], ["these drugs", "TREATMENT", 201, 212], ["elevated", "OBSERVATION", 15, 23], ["liver", "ANATOMY", 34, 39]]], ["The authors also observed that the drugs lopinavir and ritonavir contributed significantly to liver test abnormalities and liver injury.", [["liver", "ANATOMY", 94, 99], ["liver", "ANATOMY", 123, 128], ["lopinavir", "CHEMICAL", 41, 50], ["ritonavir", "CHEMICAL", 55, 64], ["liver test abnormalities", "DISEASE", 94, 118], ["liver injury", "DISEASE", 123, 135], ["lopinavir", "CHEMICAL", 41, 50], ["ritonavir", "CHEMICAL", 55, 64], ["lopinavir", "SIMPLE_CHEMICAL", 41, 50], ["ritonavir", "SIMPLE_CHEMICAL", 55, 64], ["liver", "ORGAN", 94, 99], ["liver", "ORGAN", 123, 128], ["the drugs lopinavir", "TREATMENT", 31, 50], ["ritonavir", "TREATMENT", 55, 64], ["liver test abnormalities", "PROBLEM", 94, 118], ["liver injury", "PROBLEM", 123, 135], ["liver", "ANATOMY", 94, 99], ["liver", "ANATOMY", 123, 128], ["injury", "OBSERVATION", 129, 135]]], ["These drugs increased the odds of liver injury by fourfold (p < 0.001).", [["liver", "ANATOMY", 34, 39], ["liver injury", "DISEASE", 34, 46], ["liver", "ORGAN", 34, 39], ["These drugs", "TREATMENT", 0, 11], ["liver injury", "PROBLEM", 34, 46], ["liver", "ANATOMY", 34, 39], ["injury", "OBSERVATION", 40, 46]]], ["Moreover, using antibiotics in the treatment also showed an association with the increased prevalence of liver test abnormalities in the regression model; however in other models this association was not significant (6) .", [["liver", "ANATOMY", 105, 110], ["liver test abnormalities", "DISEASE", 105, 129], ["liver", "ORGAN", 105, 110], ["antibiotics", "TREATMENT", 16, 27], ["the treatment", "TREATMENT", 31, 44], ["liver test abnormalities", "PROBLEM", 105, 129], ["increased", "OBSERVATION_MODIFIER", 81, 90], ["liver", "ANATOMY", 105, 110], ["significant", "OBSERVATION_MODIFIER", 204, 215]]], ["Another study showed 55.4% of liver injuries after treatment with lopinavir and ritonavir, suggesting possible drug-induced liver damage in COVID-19 patients (30) .", [["liver", "ANATOMY", 30, 35], ["liver", "ANATOMY", 124, 129], ["liver injuries", "DISEASE", 30, 44], ["lopinavir", "CHEMICAL", 66, 75], ["ritonavir", "CHEMICAL", 80, 89], ["liver damage", "DISEASE", 124, 136], ["lopinavir", "CHEMICAL", 66, 75], ["ritonavir", "CHEMICAL", 80, 89], ["liver", "ORGAN", 30, 35], ["lopinavir", "SIMPLE_CHEMICAL", 66, 75], ["ritonavir", "SIMPLE_CHEMICAL", 80, 89], ["liver", "ORGAN", 124, 129], ["patients", "ORGANISM", 149, 157], ["patients", "SPECIES", 149, 157], ["Another study", "TEST", 0, 13], ["liver injuries", "PROBLEM", 30, 44], ["treatment", "TREATMENT", 51, 60], ["lopinavir", "TREATMENT", 66, 75], ["ritonavir", "TREATMENT", 80, 89], ["drug-induced liver damage", "PROBLEM", 111, 136], ["COVID", "TEST", 140, 145], ["liver", "ANATOMY", 30, 35], ["injuries", "OBSERVATION", 36, 44], ["suggesting possible", "UNCERTAINTY", 91, 110], ["liver", "ANATOMY", 124, 129], ["damage", "OBSERVATION", 130, 136]]], ["A randomized controlled trial reported gastrointestinal adverse events in COVID-19 patients, who received lopinavir-ritonavir in the treatment (31) .", [["gastrointestinal", "ANATOMY", 39, 55], ["lopinavir-ritonavir", "CHEMICAL", 106, 125], ["lopinavir", "CHEMICAL", 106, 115], ["ritonavir", "CHEMICAL", 116, 125], ["gastrointestinal", "ORGANISM_SUBDIVISION", 39, 55], ["patients", "ORGANISM", 83, 91], ["lopinavir-ritonavir", "SIMPLE_CHEMICAL", 106, 125], ["patients", "SPECIES", 83, 91], ["A randomized controlled trial", "TREATMENT", 0, 29], ["gastrointestinal adverse events", "PROBLEM", 39, 70], ["lopinavir", "TREATMENT", 106, 115], ["ritonavir", "TREATMENT", 116, 125], ["gastrointestinal", "ANATOMY", 39, 55]]], ["However, no remarkable differences were observed in the levels of liver test markers (ALT and AST) between the lopinavir-ritonavir group and standard care group of COVID-19 patients.", [["liver", "ANATOMY", 66, 71], ["lopinavir-ritonavir", "CHEMICAL", 111, 130], ["lopinavir", "CHEMICAL", 111, 120], ["ritonavir", "CHEMICAL", 121, 130], ["liver", "ORGAN", 66, 71], ["ALT", "SIMPLE_CHEMICAL", 86, 89], ["AST", "SIMPLE_CHEMICAL", 94, 97], ["lopinavir", "SIMPLE_CHEMICAL", 111, 120], ["ritonavir", "SIMPLE_CHEMICAL", 121, 130], ["patients", "ORGANISM", 173, 181], ["liver test markers", "PROTEIN", 66, 84], ["ALT", "PROTEIN", 86, 89], ["AST", "PROTEIN", 94, 97], ["patients", "SPECIES", 173, 181], ["remarkable differences", "PROBLEM", 12, 34], ["liver test markers", "TEST", 66, 84], ["ALT", "TEST", 86, 89], ["AST", "TEST", 94, 97], ["the lopinavir-ritonavir group", "TREATMENT", 107, 136], ["no", "UNCERTAINTY", 9, 11], ["remarkable", "OBSERVATION_MODIFIER", 12, 22], ["differences", "OBSERVATION", 23, 34], ["liver", "ANATOMY", 66, 71]]], ["Hydroxychloroquine, an antimalarial agent has not been associated with liver injury in COVID-19; however, it should be used with caution to avoid any harmful effects.", [["liver", "ANATOMY", 71, 76], ["Hydroxychloroquine", "CHEMICAL", 0, 18], ["liver injury", "DISEASE", 71, 83], ["Hydroxychloroquine", "CHEMICAL", 0, 18], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 0, 18], ["liver", "ORGAN", 71, 76], ["Hydroxychloroquine", "TREATMENT", 0, 18], ["an antimalarial agent", "TREATMENT", 20, 41], ["liver injury", "PROBLEM", 71, 83], ["COVID", "TEST", 87, 92], ["any harmful effects", "PROBLEM", 146, 165], ["liver", "ANATOMY", 71, 76], ["injury", "OBSERVATION", 77, 83]]], ["Future studies would be worth conducting in determining the possible effects of drugs on liver function in COVID-19 patients.POSSIBLE MECHANISMS OF LIVER INJURY IN COVID-19 INFECTIONIt is speculated that liver injury in patients with SARS-CoV-2 infection may have occurred by directly the virus itself (32) .", [["liver", "ANATOMY", 89, 94], ["liver", "ANATOMY", 204, 209], ["liver injury", "DISEASE", 204, 216], ["SARS", "DISEASE", 234, 238], ["infection", "DISEASE", 245, 254], ["liver", "ORGAN", 89, 94], ["patients", "ORGANISM", 116, 124], ["liver", "ORGAN", 204, 209], ["patients", "ORGANISM", 220, 228], ["SARS-CoV-2", "ORGANISM", 234, 244], ["patients", "SPECIES", 116, 124], ["patients", "SPECIES", 220, 228], ["Future studies", "TEST", 0, 14], ["drugs", "TREATMENT", 80, 85], ["liver function", "TEST", 89, 103], ["LIVER INJURY", "PROBLEM", 148, 160], ["liver injury", "PROBLEM", 204, 216], ["SARS", "PROBLEM", 234, 238], ["CoV-2 infection", "PROBLEM", 239, 254], ["liver", "ANATOMY", 89, 94], ["LIVER", "ANATOMY", 148, 153], ["INJURY", "OBSERVATION", 154, 160], ["liver", "ANATOMY", 204, 209], ["injury", "OBSERVATION", 210, 216], ["infection", "OBSERVATION", 245, 254]]], ["Presence of diarrhea in 2-10% of patients, and SARS-CoV-2 RNA in blood and stools of patients with COVID-19 (33), indicating a possible viral inclusion in the liver (15) .", [["blood", "ANATOMY", 65, 70], ["stools", "ANATOMY", 75, 81], ["liver", "ANATOMY", 159, 164], ["diarrhea", "DISEASE", 12, 20], ["SARS", "DISEASE", 47, 51], ["COVID-19", "CHEMICAL", 99, 107], ["patients", "ORGANISM", 33, 41], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 47, 57], ["blood", "ORGANISM_SUBSTANCE", 65, 70], ["stools", "ORGANISM_SUBSTANCE", 75, 81], ["patients", "ORGANISM", 85, 93], ["liver", "ORGAN", 159, 164], ["SARS-CoV-2 RNA", "RNA", 47, 61], ["patients", "SPECIES", 33, 41], ["patients", "SPECIES", 85, 93], ["SARS-CoV", "SPECIES", 47, 55], ["diarrhea", "PROBLEM", 12, 20], ["SARS", "PROBLEM", 47, 51], ["CoV", "TEST", 52, 55], ["COVID", "TEST", 99, 104], ["viral inclusion in the liver", "PROBLEM", 136, 164], ["diarrhea", "OBSERVATION", 12, 20], ["blood", "ANATOMY", 65, 70], ["stools", "ANATOMY", 75, 81], ["possible", "UNCERTAINTY", 127, 135], ["viral", "OBSERVATION_MODIFIER", 136, 141], ["inclusion", "OBSERVATION", 142, 151], ["liver", "ANATOMY", 159, 164]]], ["A recent review demonstrated that both SARS-CoV-2 and SARS-CoV use angiotensin-converting enzyme 2 (ACE2) receptor to enter the target host cell (10), which then subsequently infects the upper respiratory tract and lung cells.", [["cell", "ANATOMY", 140, 144], ["upper respiratory tract", "ANATOMY", 187, 210], ["lung cells", "ANATOMY", 215, 225], ["angiotensin", "CHEMICAL", 67, 78], ["SARS-CoV-2", "ORGANISM", 39, 49], ["SARS-CoV", "ORGANISM", 54, 62], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 67, 98], ["ACE2", "GENE_OR_GENE_PRODUCT", 100, 104], ["host cell", "CELL", 135, 144], ["lung cells", "CELL", 215, 225], ["angiotensin-converting enzyme 2 (ACE2) receptor", "PROTEIN", 67, 114], ["lung cells", "CELL_TYPE", 215, 225], ["SARS-CoV", "SPECIES", 39, 47], ["SARS-CoV", "SPECIES", 54, 62], ["A recent review", "TEST", 0, 15], ["both SARS", "TEST", 34, 43], ["CoV", "TEST", 44, 47], ["SARS", "PROBLEM", 54, 58], ["angiotensin", "TREATMENT", 67, 78], ["converting enzyme 2 (ACE2) receptor", "TREATMENT", 79, 114], ["host cell", "OBSERVATION", 135, 144], ["upper", "ANATOMY_MODIFIER", 187, 192], ["respiratory tract", "ANATOMY", 193, 210], ["lung", "ANATOMY", 215, 219], ["cells", "OBSERVATION", 220, 225]]], ["In pathological studies, patients with SARS showed the viral presence in their liver tissue at a low level (34) , however, patients with MERS, virus were not detected in their liver tissue (35) .", [["liver tissue", "ANATOMY", 79, 91], ["liver tissue", "ANATOMY", 176, 188], ["SARS", "DISEASE", 39, 43], ["patients", "ORGANISM", 25, 33], ["liver tissue", "TISSUE", 79, 91], ["patients", "ORGANISM", 123, 131], ["MERS", "GENE_OR_GENE_PRODUCT", 137, 141], ["liver tissue", "TISSUE", 176, 188], ["patients", "SPECIES", 25, 33], ["patients", "SPECIES", 123, 131], ["pathological studies", "TEST", 3, 23], ["SARS", "PROBLEM", 39, 43], ["the viral presence in their liver tissue", "PROBLEM", 51, 91], ["MERS", "PROBLEM", 137, 141], ["virus", "PROBLEM", 143, 148], ["viral", "OBSERVATION", 55, 60], ["liver", "ANATOMY", 79, 84], ["liver", "ANATOMY", 176, 181]]], ["Serum GGT, a potential diagnostic marker for cholangiocyte injury has been found at increased levels up to 72% in severe COVID-19 patients (6, 15) .", [["Serum", "ANATOMY", 0, 5], ["cholangiocyte", "ANATOMY", 45, 58], ["cholangiocyte injury", "DISEASE", 45, 65], ["COVID", "DISEASE", 121, 126], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["GGT", "GENE_OR_GENE_PRODUCT", 6, 9], ["cholangiocyte", "CANCER", 45, 58], ["patients", "ORGANISM", 130, 138], ["Serum GGT", "PROTEIN", 0, 9], ["patients", "SPECIES", 130, 138], ["Serum GGT", "TEST", 0, 9], ["cholangiocyte injury", "PROBLEM", 45, 65], ["increased levels", "PROBLEM", 84, 100], ["cholangiocyte", "ANATOMY", 45, 58], ["injury", "OBSERVATION", 59, 65], ["increased", "OBSERVATION_MODIFIER", 84, 93], ["severe", "OBSERVATION_MODIFIER", 114, 120]]], ["A preliminary study reported that the ACE2 receptor is abundantly expressed in cholangiocytes (36) ; suggesting that SARS-CoV-2 might bind to ACE2-positive cholangiocytes and cause liver dysfunction (15) .", [["cholangiocytes", "ANATOMY", 79, 93], ["cholangiocytes", "ANATOMY", 156, 170], ["liver", "ANATOMY", 181, 186], ["liver dysfunction", "DISEASE", 181, 198], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 38, 51], ["cholangiocytes", "CELL", 79, 93], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 117, 127], ["ACE2", "GENE_OR_GENE_PRODUCT", 142, 146], ["liver", "ORGAN", 181, 186], ["ACE2 receptor", "PROTEIN", 38, 51], ["ACE2", "PROTEIN", 142, 146], ["A preliminary study", "TEST", 0, 19], ["the ACE2 receptor", "TEST", 34, 51], ["SARS", "PROBLEM", 117, 121], ["CoV", "TEST", 122, 125], ["ACE2", "TEST", 142, 146], ["positive cholangiocytes", "PROBLEM", 147, 170], ["liver dysfunction", "PROBLEM", 181, 198], ["cholangiocytes", "ANATOMY", 79, 93], ["positive cholangiocytes", "OBSERVATION", 147, 170], ["liver", "ANATOMY", 181, 186], ["dysfunction", "OBSERVATION", 187, 198]]], ["Nonetheless, viral inclusions were not identified in the liver tissue of a patient who died from COVID-19 (37) .", [["liver tissue", "ANATOMY", 57, 69], ["COVID-19", "CHEMICAL", 97, 105], ["liver tissue", "TISSUE", 57, 69], ["patient", "ORGANISM", 75, 82], ["patient", "SPECIES", 75, 82], ["viral inclusions", "PROBLEM", 13, 29], ["COVID", "TEST", 97, 102], ["viral inclusions", "OBSERVATION", 13, 29], ["liver", "ANATOMY", 57, 62]]], ["Apart from these observations, it is also assumed that antiviral drugs used for the treatment might be linked with liver damage in COVID-19 patients (6, 15) .", [["liver", "ANATOMY", 115, 120], ["liver damage", "DISEASE", 115, 127], ["liver", "ORGAN", 115, 120], ["patients", "ORGANISM", 140, 148], ["patients", "SPECIES", 140, 148], ["antiviral drugs", "TREATMENT", 55, 70], ["the treatment", "TREATMENT", 80, 93], ["liver damage", "PROBLEM", 115, 127], ["antiviral drugs", "OBSERVATION", 55, 70], ["liver", "ANATOMY", 115, 120], ["damage", "OBSERVATION", 121, 127]]], ["Although, it remains unclear to what extent viruses or drugs are associated with liver injury in severe disease courses.", [["liver", "ANATOMY", 81, 86], ["liver injury", "DISEASE", 81, 93], ["liver", "ORGAN", 81, 86], ["drugs", "TREATMENT", 55, 60], ["liver injury", "PROBLEM", 81, 93], ["severe disease courses", "PROBLEM", 97, 119], ["associated with", "UNCERTAINTY", 65, 80], ["liver", "ANATOMY", 81, 86], ["injury", "OBSERVATION", 87, 93], ["severe", "OBSERVATION_MODIFIER", 97, 103], ["disease", "OBSERVATION", 104, 111]]], ["Dysregulation of the innate immune response may be another important aspect of liver injury in COVID-19.", [["liver", "ANATOMY", 79, 84], ["liver injury", "DISEASE", 79, 91], ["liver", "ORGAN", 79, 84], ["COVID-19", "CELL", 95, 103], ["liver injury", "PROBLEM", 79, 91], ["COVID", "TEST", 95, 100], ["liver", "ANATOMY", 79, 84], ["injury", "OBSERVATION", 85, 91]]], ["So, the possible pathways that can be associated with liver damage in COVID-19 patients are (i) immune-mediated inflammation, such as cytokines storm and pneumonia-related hypoxia, (ii) Direct cytotoxicity because of active viral replication in the liver cells, (iii) Drug-induced liver damage: initially recommend antiviral drugs including lopinavir/ritonavir, chloroquine, remdesivir, tocilizumab, uminefovir, being potentially hepatotoxic in severe patients, (iv) Reactivation of pre-existing hepatic disease: patients with previous chronic hepatic disease are more vulnerable to hepatic damage from this viral infection, (v) Possible reactivation of hepatitis B virus with some biological drugs such as tocilizumab and baricitinib that may lead to liver dysfunction.", [["liver", "ANATOMY", 54, 59], ["liver cells", "ANATOMY", 249, 260], ["liver", "ANATOMY", 281, 286], ["hepatic", "ANATOMY", 496, 503], ["hepatic", "ANATOMY", 544, 551], ["hepatic", "ANATOMY", 583, 590], ["liver", "ANATOMY", 752, 757], ["liver damage", "DISEASE", 54, 66], ["inflammation", "DISEASE", 112, 124], ["pneumonia", "DISEASE", 154, 163], ["hypoxia", "DISEASE", 172, 179], ["liver damage", "DISEASE", 281, 293], ["lopinavir/ritonavir", "CHEMICAL", 341, 360], ["chloroquine", "CHEMICAL", 362, 373], ["remdesivir", "CHEMICAL", 375, 385], ["tocilizumab", "CHEMICAL", 387, 398], ["uminefovir", "CHEMICAL", 400, 410], ["hepatotoxic", "DISEASE", 430, 441], ["hepatic disease", "DISEASE", 496, 511], ["chronic hepatic disease", "DISEASE", 536, 559], ["hepatic damage", "DISEASE", 583, 597], ["viral infection", "DISEASE", 608, 623], ["hepatitis B", "DISEASE", 654, 665], ["tocilizumab", "CHEMICAL", 707, 718], ["baricitinib", "CHEMICAL", 723, 734], ["liver dysfunction", "DISEASE", 752, 769], ["lopinavir", "CHEMICAL", 341, 350], ["ritonavir", "CHEMICAL", 351, 360], ["chloroquine", "CHEMICAL", 362, 373], ["remdesivir", "CHEMICAL", 375, 385], ["uminefovir", "CHEMICAL", 400, 410], ["baricitinib", "CHEMICAL", 723, 734], ["liver", "ORGAN", 54, 59], ["patients", "ORGANISM", 79, 87], ["liver cells", "CELL", 249, 260], ["liver", "ORGAN", 281, 286], ["lopinavir", "SIMPLE_CHEMICAL", 341, 350], ["ritonavir", "SIMPLE_CHEMICAL", 351, 360], ["chloroquine", "SIMPLE_CHEMICAL", 362, 373], ["remdesivir", "SIMPLE_CHEMICAL", 375, 385], ["tocilizumab", "SIMPLE_CHEMICAL", 387, 398], ["uminefovir", "SIMPLE_CHEMICAL", 400, 410], ["patients", "ORGANISM", 452, 460], ["hepatic", "ORGAN", 496, 503], ["patients", "ORGANISM", 513, 521], ["hepatic", "ORGAN", 544, 551], ["hepatic", "ORGAN", 583, 590], ["hepatitis B virus", "ORGANISM", 654, 671], ["tocilizumab", "SIMPLE_CHEMICAL", 707, 718], ["baricitinib", "SIMPLE_CHEMICAL", 723, 734], ["liver", "ORGAN", 752, 757], ["cytokines", "PROTEIN", 134, 143], ["liver cells", "CELL_TYPE", 249, 260], ["patients", "SPECIES", 79, 87], ["patients", "SPECIES", 452, 460], ["patients", "SPECIES", 513, 521], ["hepatitis B virus", "SPECIES", 654, 671], ["hepatitis B virus", "SPECIES", 654, 671], ["liver damage", "PROBLEM", 54, 66], ["COVID", "TEST", 70, 75], ["immune-mediated inflammation", "PROBLEM", 96, 124], ["cytokines storm", "PROBLEM", 134, 149], ["pneumonia", "PROBLEM", 154, 163], ["hypoxia", "PROBLEM", 172, 179], ["Direct cytotoxicity", "PROBLEM", 186, 205], ["active viral replication in the liver cells", "PROBLEM", 217, 260], ["liver damage", "PROBLEM", 281, 293], ["antiviral drugs", "TREATMENT", 315, 330], ["lopinavir", "TREATMENT", 341, 350], ["ritonavir", "TREATMENT", 351, 360], ["chloroquine", "TREATMENT", 362, 373], ["remdesivir", "TREATMENT", 375, 385], ["tocilizumab", "TREATMENT", 387, 398], ["uminefovir", "TREATMENT", 400, 410], ["pre-existing hepatic disease", "PROBLEM", 483, 511], ["previous chronic hepatic disease", "PROBLEM", 527, 559], ["hepatic damage", "PROBLEM", 583, 597], ["this viral infection", "PROBLEM", 603, 623], ["hepatitis B virus", "PROBLEM", 654, 671], ["some biological drugs", "TREATMENT", 677, 698], ["tocilizumab", "TREATMENT", 707, 718], ["baricitinib", "TREATMENT", 723, 734], ["liver dysfunction", "PROBLEM", 752, 769], ["liver", "ANATOMY", 54, 59], ["damage", "OBSERVATION", 60, 66], ["inflammation", "OBSERVATION", 112, 124], ["pneumonia", "OBSERVATION", 154, 163], ["hypoxia", "OBSERVATION", 172, 179], ["active", "OBSERVATION_MODIFIER", 217, 223], ["viral replication", "OBSERVATION", 224, 241], ["liver", "ANATOMY", 249, 254], ["liver", "ANATOMY", 281, 286], ["hepatic", "ANATOMY", 496, 503], ["disease", "OBSERVATION", 504, 511], ["chronic", "OBSERVATION_MODIFIER", 536, 543], ["hepatic", "ANATOMY", 544, 551], ["disease", "OBSERVATION", 552, 559], ["hepatic", "ANATOMY", 583, 590], ["damage", "OBSERVATION", 591, 597], ["viral", "OBSERVATION_MODIFIER", 608, 613], ["infection", "OBSERVATION", 614, 623], ["hepatitis", "OBSERVATION", 654, 663], ["liver", "ANATOMY", 752, 757], ["dysfunction", "OBSERVATION", 758, 769]]], ["Moreover, it is also unknown whether SARS -CoV\u22122 infection enhances cholestasis in patients with underlying cholestatic hepatic diseases.", [["hepatic", "ANATOMY", 120, 127], ["infection", "DISEASE", 49, 58], ["cholestasis", "DISEASE", 68, 79], ["cholestatic hepatic diseases", "DISEASE", 108, 136], ["SARS -CoV\u22122", "ORGANISM", 37, 48], ["patients", "ORGANISM", 83, 91], ["hepatic", "ORGAN", 120, 127], ["patients", "SPECIES", 83, 91], ["SARS", "PROBLEM", 37, 41], ["CoV\u22122 infection", "PROBLEM", 43, 58], ["cholestasis", "PROBLEM", 68, 79], ["underlying cholestatic hepatic diseases", "PROBLEM", 97, 136], ["infection", "OBSERVATION", 49, 58], ["cholestasis", "OBSERVATION", 68, 79], ["cholestatic", "OBSERVATION_MODIFIER", 108, 119], ["hepatic", "ANATOMY", 120, 127], ["diseases", "OBSERVATION", 128, 136]]], ["More mechanistic studies regarding virus entry and replication in liver cells and the potential consequences of drugs in the liver are required.COVID-19 PATIENTS WITH PRE-EXISTING LIVER DISEASEData on pre-existing liver disease in COVID-19 would be worth in evaluating the underlying causes of liver damage in severe disease courses.", [["liver cells", "ANATOMY", 66, 77], ["liver", "ANATOMY", 125, 130], ["liver", "ANATOMY", 214, 219], ["liver", "ANATOMY", 294, 299], ["liver disease", "DISEASE", 214, 227], ["liver damage", "DISEASE", 294, 306], ["liver cells", "CELL", 66, 77], ["liver", "ORGAN", 125, 130], ["liver", "ORGAN", 214, 219], ["liver", "ORGAN", 294, 299], ["liver cells", "CELL_TYPE", 66, 77], ["More mechanistic studies", "TEST", 0, 24], ["virus entry", "PROBLEM", 35, 46], ["replication in liver cells", "PROBLEM", 51, 77], ["drugs in the liver", "PROBLEM", 112, 130], ["pre-existing liver disease", "PROBLEM", 201, 227], ["COVID", "TEST", 231, 236], ["liver damage", "PROBLEM", 294, 306], ["severe disease courses", "PROBLEM", 310, 332], ["liver", "ANATOMY", 66, 71], ["liver", "ANATOMY", 125, 130], ["LIVER", "ANATOMY", 180, 185], ["DISEASEData", "OBSERVATION", 186, 197], ["liver", "ANATOMY", 214, 219], ["disease", "OBSERVATION", 220, 227], ["liver", "ANATOMY", 294, 299], ["damage", "OBSERVATION", 300, 306], ["severe", "OBSERVATION_MODIFIER", 310, 316], ["disease", "OBSERVATION", 317, 324]]], ["However, limited information is available on the interaction between pre-existing liver disease and COVID-19.", [["liver", "ANATOMY", 82, 87], ["liver disease", "DISEASE", 82, 95], ["liver", "ORGAN", 82, 87], ["pre-existing liver disease", "PROBLEM", 69, 95], ["COVID", "TEST", 100, 105], ["liver", "ANATOMY", 82, 87], ["disease", "OBSERVATION", 88, 95]]], ["A recent study examined the effects of pre-existing liver disease on outcomes in a large cohort of COVID-19 patients (n = 2,780) in the USA (38) .", [["liver", "ANATOMY", 52, 57], ["liver disease", "DISEASE", 52, 65], ["liver", "ORGAN", 52, 57], ["patients", "ORGANISM", 108, 116], ["patients", "SPECIES", 108, 116], ["A recent study", "TEST", 0, 14], ["pre-existing liver disease", "PROBLEM", 39, 65], ["COVID", "TEST", 99, 104], ["liver", "ANATOMY", 52, 57], ["disease", "OBSERVATION", 58, 65], ["large", "OBSERVATION_MODIFIER", 83, 88]]], ["The authors observed a higher proportion of comorbidities (diabetes 48% and hypertension 68%) in patients with liver disease.", [["liver", "ANATOMY", 111, 116], ["diabetes", "DISEASE", 59, 67], ["hypertension", "DISEASE", 76, 88], ["liver disease", "DISEASE", 111, 124], ["patients", "ORGANISM", 97, 105], ["liver", "ORGAN", 111, 116], ["patients", "SPECIES", 97, 105], ["diabetes", "TEST", 59, 67], ["hypertension", "PROBLEM", 76, 88], ["liver disease", "PROBLEM", 111, 124], ["liver", "ANATOMY", 111, 116], ["disease", "OBSERVATION", 117, 124]]], ["Fatty liver disease and non-alcoholic steatohepatitis (42%) were more frequent among patients with pre-existing liver disease.", [["Fatty liver", "ANATOMY", 0, 11], ["liver", "ANATOMY", 112, 117], ["Fatty liver disease", "DISEASE", 0, 19], ["non-alcoholic steatohepatitis", "DISEASE", 24, 53], ["liver disease", "DISEASE", 112, 125], ["liver", "ORGAN", 6, 11], ["patients", "ORGANISM", 85, 93], ["liver", "ORGAN", 112, 117], ["patients", "SPECIES", 85, 93], ["Fatty liver disease", "PROBLEM", 0, 19], ["non-alcoholic steatohepatitis", "PROBLEM", 24, 53], ["pre-existing liver disease", "PROBLEM", 99, 125], ["liver", "ANATOMY", 6, 11], ["non-alcoholic steatohepatitis", "OBSERVATION", 24, 53], ["liver", "ANATOMY", 112, 117], ["disease", "OBSERVATION", 118, 125]]], ["Importantly, the mortality rate was significantly higher (p < 0.001) in patients with pre-existing liver disease than patients without liver disease and the relative risk was markedly higher in patients with cirrhosis (p < 0.001) (38) .", [["liver", "ANATOMY", 99, 104], ["liver", "ANATOMY", 135, 140], ["liver disease", "DISEASE", 99, 112], ["liver disease", "DISEASE", 135, 148], ["cirrhosis", "DISEASE", 208, 217], ["patients", "ORGANISM", 72, 80], ["liver", "ORGAN", 99, 104], ["patients", "ORGANISM", 118, 126], ["liver", "ORGAN", 135, 140], ["patients", "ORGANISM", 194, 202], ["patients", "SPECIES", 72, 80], ["patients", "SPECIES", 118, 126], ["patients", "SPECIES", 194, 202], ["the mortality rate", "TEST", 13, 31], ["pre-existing liver disease", "PROBLEM", 86, 112], ["liver disease", "PROBLEM", 135, 148], ["cirrhosis", "PROBLEM", 208, 217], ["significantly", "OBSERVATION_MODIFIER", 36, 49], ["higher", "OBSERVATION_MODIFIER", 50, 56], ["liver", "ANATOMY", 99, 104], ["disease", "OBSERVATION", 105, 112], ["without", "UNCERTAINTY", 127, 134], ["liver", "ANATOMY", 135, 140], ["disease", "OBSERVATION", 141, 148], ["markedly", "OBSERVATION_MODIFIER", 175, 183], ["higher", "OBSERVATION_MODIFIER", 184, 190], ["cirrhosis", "OBSERVATION", 208, 217]]], ["Moreover, patients with pre-existing liver disease required increased hospitalization.", [["liver", "ANATOMY", 37, 42], ["liver disease", "DISEASE", 37, 50], ["patients", "ORGANISM", 10, 18], ["liver", "ORGAN", 37, 42], ["patients", "SPECIES", 10, 18], ["pre-existing liver disease", "PROBLEM", 24, 50], ["increased hospitalization", "TREATMENT", 60, 85], ["liver", "ANATOMY", 37, 42], ["disease", "OBSERVATION", 43, 50], ["increased", "OBSERVATION_MODIFIER", 60, 69], ["hospitalization", "OBSERVATION", 70, 85]]], ["Another recent study reported a high mortality rates from COVID-19 among patients with chronic liver disease and cirrhosis (39) .", [["liver", "ANATOMY", 95, 100], ["chronic liver disease", "DISEASE", 87, 108], ["cirrhosis", "DISEASE", 113, 122], ["patients", "ORGANISM", 73, 81], ["liver", "ORGAN", 95, 100], ["patients", "SPECIES", 73, 81], ["Another recent study", "TEST", 0, 20], ["a high mortality rates", "PROBLEM", 30, 52], ["COVID", "TEST", 58, 63], ["chronic liver disease", "PROBLEM", 87, 108], ["cirrhosis", "PROBLEM", 113, 122], ["chronic", "OBSERVATION_MODIFIER", 87, 94], ["liver", "ANATOMY", 95, 100], ["disease", "OBSERVATION", 101, 108], ["cirrhosis", "OBSERVATION", 113, 122]]], ["The authors demonstrated that patients with liver cirrhosis could result in decompensation of the liver and mortality.", [["liver", "ANATOMY", 44, 49], ["liver", "ANATOMY", 98, 103], ["liver cirrhosis", "DISEASE", 44, 59], ["decompensation of the liver", "DISEASE", 76, 103], ["patients", "ORGANISM", 30, 38], ["liver", "ORGAN", 44, 49], ["liver", "ORGAN", 98, 103], ["patients", "SPECIES", 30, 38], ["liver cirrhosis", "PROBLEM", 44, 59], ["decompensation of the liver and mortality", "PROBLEM", 76, 117], ["liver", "ANATOMY", 44, 49], ["cirrhosis", "OBSERVATION", 50, 59], ["decompensation", "OBSERVATION", 76, 90], ["liver", "ANATOMY", 98, 103]]], ["Patients with cirrhosis had poor outcomes with an overall mortality rate of 40%.", [["cirrhosis", "DISEASE", 14, 23], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["cirrhosis", "PROBLEM", 14, 23], ["mortality rate", "TEST", 58, 72], ["cirrhosis", "OBSERVATION", 14, 23]]], ["Those with decompensated cirrhosis had a mortality rate between 43 and 63%, compared with 12% for patients with hepatic disease but without cirrhosis (39) .", [["hepatic", "ANATOMY", 112, 119], ["cirrhosis", "DISEASE", 25, 34], ["hepatic disease", "DISEASE", 112, 127], ["cirrhosis", "DISEASE", 140, 149], ["patients", "ORGANISM", 98, 106], ["hepatic", "ORGAN", 112, 119], ["patients", "SPECIES", 98, 106], ["decompensated cirrhosis", "PROBLEM", 11, 34], ["a mortality rate", "TEST", 39, 55], ["hepatic disease", "PROBLEM", 112, 127], ["cirrhosis", "PROBLEM", 140, 149], ["decompensated", "OBSERVATION_MODIFIER", 11, 24], ["cirrhosis", "OBSERVATION", 25, 34], ["hepatic", "ANATOMY", 112, 119], ["disease", "OBSERVATION", 120, 127], ["without", "UNCERTAINTY", 132, 139], ["cirrhosis", "OBSERVATION", 140, 149]]], ["In that investigation, there were many COVID-19 positive patients who had no respiratory problems, suggesting that patients with chronic liver disease should get priority for COVID-19 testing even in the absence of typical COVID-19 symptoms.", [["respiratory", "ANATOMY", 77, 88], ["liver", "ANATOMY", 137, 142], ["respiratory problems", "DISEASE", 77, 97], ["chronic liver disease", "DISEASE", 129, 150], ["patients", "ORGANISM", 57, 65], ["patients", "ORGANISM", 115, 123], ["liver", "ORGAN", 137, 142], ["patients", "SPECIES", 57, 65], ["patients", "SPECIES", 115, 123], ["respiratory problems", "PROBLEM", 77, 97], ["chronic liver disease", "PROBLEM", 129, 150], ["COVID-19 testing", "TEST", 175, 191], ["typical COVID-19 symptoms", "PROBLEM", 215, 240], ["no", "UNCERTAINTY", 74, 76], ["respiratory problems", "OBSERVATION", 77, 97], ["chronic", "OBSERVATION_MODIFIER", 129, 136], ["liver", "ANATOMY", 137, 142], ["disease", "OBSERVATION", 143, 150]]], ["The probable reasons for poor outcomes in COVID-19 with pre-existing liver disease require further investigation; however, it seems that there is interplay between local liver injury and systemic disturbances (38) .CONCLUSIONS AND RECOMMENDATIONSAbnormal liver function test markers are more common in patients with severe COVID-infection.", [["liver", "ANATOMY", 69, 74], ["liver", "ANATOMY", 170, 175], ["liver", "ANATOMY", 255, 260], ["liver disease", "DISEASE", 69, 82], ["liver injury", "DISEASE", 170, 182], ["COVID-infection", "DISEASE", 323, 338], ["liver", "ORGAN", 69, 74], ["liver", "ORGAN", 170, 175], ["liver", "ORGAN", 255, 260], ["patients", "ORGANISM", 302, 310], ["patients", "SPECIES", 302, 310], ["COVID", "TEST", 42, 47], ["pre-existing liver disease", "PROBLEM", 56, 82], ["further investigation", "TEST", 91, 112], ["local liver injury", "PROBLEM", 164, 182], ["systemic disturbances", "PROBLEM", 187, 208], ["RECOMMENDATIONSAbnormal liver function test markers", "TEST", 231, 282], ["severe COVID-infection", "PROBLEM", 316, 338], ["probable reasons for", "UNCERTAINTY", 4, 24], ["liver", "ANATOMY", 69, 74], ["disease", "OBSERVATION", 75, 82], ["liver", "ANATOMY", 170, 175], ["injury", "OBSERVATION", 176, 182], ["liver", "ANATOMY", 255, 260], ["severe", "OBSERVATION_MODIFIER", 316, 322], ["infection", "OBSERVATION", 329, 338]]], ["Available study findings support the hypothesis that liver injury might be associated with severe outcomes in COVID-19 patients.", [["liver", "ANATOMY", 53, 58], ["liver injury", "DISEASE", 53, 65], ["liver", "ORGAN", 53, 58], ["patients", "ORGANISM", 119, 127], ["patients", "SPECIES", 119, 127], ["Available study", "TEST", 0, 15], ["liver injury", "PROBLEM", 53, 65], ["liver", "ANATOMY", 53, 58], ["injury", "OBSERVATION", 59, 65]]], ["However, there is still lacks important data on larger studies to determine causality between COVID-19 and liver damage.", [["liver", "ANATOMY", 107, 112], ["liver damage", "DISEASE", 107, 119], ["COVID-19", "GENE_OR_GENE_PRODUCT", 94, 102], ["liver", "ORGAN", 107, 112], ["larger studies", "TEST", 48, 62], ["COVID", "TEST", 94, 99], ["liver damage", "PROBLEM", 107, 119], ["liver", "ANATOMY", 107, 112], ["damage", "OBSERVATION", 113, 119]]], ["The mechanism of liver injury in COVID-19 infection is not well-understood yet and seems to be multifactorial.", [["liver", "ANATOMY", 17, 22], ["liver injury", "DISEASE", 17, 29], ["COVID-19", "CHEMICAL", 33, 41], ["infection", "DISEASE", 42, 51], ["liver", "ORGAN", 17, 22], ["COVID-19", "ORGANISM", 33, 41], ["COVID-19", "SPECIES", 33, 41], ["liver injury", "PROBLEM", 17, 29], ["COVID-19 infection", "PROBLEM", 33, 51], ["liver", "ANATOMY", 17, 22], ["injury", "OBSERVATION", 23, 29], ["infection", "OBSERVATION", 42, 51]]], ["The patients with advanced hepatic disease and those after liver transplantation are at high risk of progression to severe disease course.", [["hepatic", "ANATOMY", 27, 34], ["liver", "ANATOMY", 59, 64], ["hepatic disease", "DISEASE", 27, 42], ["patients", "ORGANISM", 4, 12], ["hepatic", "ORGAN", 27, 34], ["liver", "ORGAN", 59, 64], ["patients", "SPECIES", 4, 12], ["advanced hepatic disease", "PROBLEM", 18, 42], ["liver transplantation", "TREATMENT", 59, 80], ["severe disease course", "PROBLEM", 116, 137], ["advanced", "OBSERVATION_MODIFIER", 18, 26], ["hepatic", "ANATOMY", 27, 34], ["disease", "OBSERVATION", 35, 42], ["liver", "ANATOMY", 59, 64], ["transplantation", "OBSERVATION", 65, 80], ["severe", "OBSERVATION_MODIFIER", 116, 122], ["disease", "OBSERVATION", 123, 130]]], ["Therefore, it is recommended to identify and care for patients with chronic liver disease with priority within the limited healthcare resources.", [["liver", "ANATOMY", 76, 81], ["chronic liver disease", "DISEASE", 68, 89], ["patients", "ORGANISM", 54, 62], ["liver", "ORGAN", 76, 81], ["patients", "SPECIES", 54, 62], ["chronic liver disease", "PROBLEM", 68, 89], ["liver", "ANATOMY", 76, 81], ["disease", "OBSERVATION", 82, 89]]], ["COVID-19 patients with liver injury are advised to be treated with drugs that are able to inhibit inflammatory responses and protect liver functions.", [["liver", "ANATOMY", 23, 28], ["liver", "ANATOMY", 133, 138], ["liver injury", "DISEASE", 23, 35], ["patients", "ORGANISM", 9, 17], ["liver", "ORGAN", 23, 28], ["liver", "ORGAN", 133, 138], ["patients", "SPECIES", 9, 17], ["liver injury", "PROBLEM", 23, 35], ["drugs", "TREATMENT", 67, 72], ["inflammatory responses", "PROBLEM", 98, 120], ["liver", "ANATOMY", 23, 28], ["injury", "OBSERVATION", 29, 35], ["liver", "ANATOMY", 133, 138]]], ["In addition, the detrimental effects of certain drugs on the liver injury during hospitalization should be monitored and evaluated regularly.", [["liver", "ANATOMY", 61, 66], ["liver injury", "DISEASE", 61, 73], ["liver", "ORGAN", 61, 66], ["certain drugs", "TREATMENT", 40, 53], ["the liver injury", "PROBLEM", 57, 73], ["liver", "ANATOMY", 61, 66], ["injury", "OBSERVATION", 67, 73]]], ["Attention should also pay toward modulating innate immune dysfunction in severe cases.", [["immune dysfunction", "DISEASE", 51, 69], ["modulating innate immune dysfunction in severe cases", "PROBLEM", 33, 85], ["severe", "OBSERVATION_MODIFIER", 73, 79]]], ["Moreover, the effects of pre-existing liver disease on treatment and clinical outcomes of COVID-19 should be determined.", [["liver", "ANATOMY", 38, 43], ["liver disease", "DISEASE", 38, 51], ["COVID-19", "CHEMICAL", 90, 98], ["liver", "ORGAN", 38, 43], ["pre-existing liver disease", "PROBLEM", 25, 51], ["treatment", "TREATMENT", 55, 64], ["COVID", "TEST", 90, 95], ["liver", "ANATOMY", 38, 43], ["disease", "OBSERVATION", 44, 51]]], ["Future research should focus on the potential causes of liver damage in severe patients with COVID-19 infection.AUTHOR CONTRIBUTIONSThe author confirms being the sole contributor of this work and has approved it for publication.", [["liver", "ANATOMY", 56, 61], ["liver damage", "DISEASE", 56, 68], ["COVID-19", "CHEMICAL", 93, 101], ["infection", "DISEASE", 102, 111], ["liver", "ORGAN", 56, 61], ["patients", "ORGANISM", 79, 87], ["patients", "SPECIES", 79, 87], ["liver damage", "PROBLEM", 56, 68], ["COVID-19 infection", "PROBLEM", 93, 111], ["liver", "ANATOMY", 56, 61], ["damage", "OBSERVATION", 62, 68], ["severe", "OBSERVATION_MODIFIER", 72, 78], ["infection", "OBSERVATION", 102, 111]]]], "91b34f9bae2a0a6addf2a70f5a8a326820fa411c": [["Coronaviruses (CoVs) are known to cause endemic respiratory infections (OC43, 229E and NL63 -CoV) as well as epidemic disease, as experienced with the emergence of SARS-CoV (2003) and the Middle East respiratory syndrome coronavirus (MERS-CoV, 2012).", [["respiratory", "ANATOMY", 48, 59], ["respiratory infections", "DISEASE", 48, 70], ["SARS-CoV", "DISEASE", 164, 172], ["respiratory syndrome coronavirus", "DISEASE", 200, 232], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 0, 13], ["CoVs", "GENE_OR_GENE_PRODUCT", 15, 19], ["NL63 -CoV", "GENE_OR_GENE_PRODUCT", 87, 96], ["SARS-CoV", "ORGANISM", 164, 172], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 188, 232], ["MERS-CoV", "ORGANISM", 234, 242], ["SARS-CoV", "SPECIES", 164, 172], ["Middle East respiratory syndrome coronavirus (MERS-CoV", "SPECIES", 188, 242], ["Coronaviruses (CoVs", "PROBLEM", 0, 19], ["endemic respiratory infections", "PROBLEM", 40, 70], ["OC43", "TEST", 72, 76], ["NL63", "TEST", 87, 91], ["epidemic disease", "PROBLEM", 109, 125], ["SARS", "PROBLEM", 164, 168], ["the Middle East respiratory syndrome coronavirus", "PROBLEM", 184, 232], ["endemic", "OBSERVATION_MODIFIER", 40, 47], ["respiratory", "ANATOMY", 48, 59], ["infections", "OBSERVATION", 60, 70], ["Middle", "ANATOMY_MODIFIER", 188, 194], ["respiratory syndrome", "OBSERVATION", 200, 220]]], ["[1, 2] Research following the SARS outbreak led to identification of additional human coronaviruses, and the notion that several of these have their roots in the animal world.", [["roots", "ANATOMY", 149, 154], ["SARS", "DISEASE", 30, 34], ["human", "ORGANISM", 80, 85], ["human", "SPECIES", 80, 85], ["human coronaviruses", "SPECIES", 80, 99], ["additional human coronaviruses", "PROBLEM", 69, 99]]], ["Therefore, the emergence of the Middle East respiratory syndrome coronavirus (MERS-CoV) triggered a fast response, given concerns of their potential for further spread.", [["Middle East respiratory syndrome coronavirus", "DISEASE", 32, 76], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 32, 76], ["MERS-CoV", "ORGANISM", 78, 86], ["Middle East respiratory syndrome coronavirus", "SPECIES", 32, 76], ["MERS-CoV", "SPECIES", 78, 86], ["the Middle East respiratory syndrome coronavirus", "PROBLEM", 28, 76], ["further spread", "PROBLEM", 153, 167], ["Middle", "ANATOMY_MODIFIER", 32, 38], ["respiratory syndrome", "OBSERVATION", 44, 64]]]], "PMC7447864": [["IntroductionNowadays the COVID-19 plays a major role in creating a race between chemists and vaccine manufacturers to arrive at a successful treatment for this terrible virus.", [["COVID-19", "DNA", 25, 33], ["vaccine manufacturers", "TREATMENT", 93, 114], ["a successful treatment", "TREATMENT", 128, 150], ["this terrible virus", "PROBLEM", 155, 174]]], ["Chloroquine and, its analogue, hydroxychloroquine are now floating on the surface as a suggestion to be the first line defense for the body against this virus.", [["surface", "ANATOMY", 74, 81], ["body", "ANATOMY", 135, 139], ["Chloroquine", "CHEMICAL", 0, 11], ["hydroxychloroquine", "CHEMICAL", 31, 49], ["Chloroquine", "CHEMICAL", 0, 11], ["hydroxychloroquine", "CHEMICAL", 31, 49], ["Chloroquine", "SIMPLE_CHEMICAL", 0, 11], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 31, 49], ["surface", "CELLULAR_COMPONENT", 74, 81], ["body", "ORGANISM_SUBDIVISION", 135, 139], ["Chloroquine", "TREATMENT", 0, 11], ["its analogue", "TREATMENT", 17, 29], ["hydroxychloroquine", "TREATMENT", 31, 49], ["this virus", "PROBLEM", 148, 158]]], ["From the chemical point of view, the small molecule chloroquine directs our attention to synthesize a small molecule similar in size to chloroquine in the hope of success in getting a new vaccine for COVID-19 and to avoid possible side effects of using of large molecules of chloroquine.IntroductionDepending on the activities of 4-aminoantipyrine and some of its derivatives in, pharmacology,1 medicine,2 therefore, some of the 4-aminopyridine derivatives were used to detect the liver diseases3 and also, in clinical treatment.4,5 Previous studies have been explored to show the effect of 4-aminoantipyrine on human serum albumin and its effect on DNA.6,7 Some 4-aminoantipyrine derivatives showed leishmanicidal, antioxidant, and antimicrobial activities.8 All of this encouraged us to go through the synthesis of new derivative of 4-aminoantipyrine in the hope of reaching a vaccine that can defeat the virus or even have a promising effect on other microorganisms.IntroductionOsteoarthritis (OA) is a painful condition with progressive reduction of articular cartilage, soft tissue swelling at the joints, and bone cyst.9 There is no remedy for OA with available therapies, and pain relievers were recommended to alleviate the pain.10 The OA pain continues a medical problem, however, animal OA models are being created to enhance the knowledge of OA-related pain processes and reveal new treatment objectives.IntroductionThere are a lot of OA patients, but no modifying drugs have been developed to treat efficiently OA, and the available medicines are just to relieve symptoms of OA.11 Joint replacement is, therefore, the only therapy accessible to OA patients reaching the final phase of OA, indicating the pressing need to develop effective anti-OA medications.", [["liver", "ANATOMY", 481, 486], ["serum", "ANATOMY", 618, 623], ["articular cartilage", "ANATOMY", 1054, 1073], ["soft tissue", "ANATOMY", 1075, 1086], ["joints", "ANATOMY", 1103, 1109], ["bone cyst", "ANATOMY", 1115, 1124], ["anti-OA", "ANATOMY", 1751, 1758], ["chloroquine", "CHEMICAL", 52, 63], ["chloroquine", "CHEMICAL", 136, 147], ["COVID-19", "CHEMICAL", 200, 208], ["chloroquine", "CHEMICAL", 275, 286], ["4-aminoantipyrine", "CHEMICAL", 330, 347], ["4-aminopyridine", "CHEMICAL", 429, 444], ["liver diseases3", "DISEASE", 481, 496], ["4-aminoantipyrine", "CHEMICAL", 591, 608], ["4-aminoantipyrine", "CHEMICAL", 663, 680], ["4-aminoantipyrine", "CHEMICAL", 835, 852], ["IntroductionOsteoarthritis", "DISEASE", 969, 995], ["OA", "DISEASE", 997, 999], ["swelling", "DISEASE", 1087, 1095], ["bone cyst", "DISEASE", 1115, 1124], ["OA", "DISEASE", 1150, 1152], ["pain", "DISEASE", 1183, 1187], ["pain", "DISEASE", 1232, 1236], ["OA pain", "DISEASE", 1244, 1251], ["OA", "DISEASE", 1353, 1355], ["pain", "DISEASE", 1364, 1368], ["OA", "DISEASE", 1446, 1448], ["OA", "DISEASE", 1523, 1525], ["OA", "DISEASE", 1587, 1589], ["OA", "DISEASE", 1657, 1659], ["OA", "DISEASE", 1697, 1699], ["chloroquine", "CHEMICAL", 52, 63], ["chloroquine", "CHEMICAL", 136, 147], ["COVID-19", "CHEMICAL", 200, 208], ["chloroquine", "CHEMICAL", 275, 286], ["4-aminoantipyrine", "CHEMICAL", 330, 347], ["4-aminopyridine", "CHEMICAL", 429, 444], ["4-aminoantipyrine", "CHEMICAL", 591, 608], ["4-aminoantipyrine", "CHEMICAL", 663, 680], ["4-aminoantipyrine", "CHEMICAL", 835, 852], ["chloroquine", "SIMPLE_CHEMICAL", 52, 63], ["chloroquine", "SIMPLE_CHEMICAL", 136, 147], ["chloroquine", "SIMPLE_CHEMICAL", 275, 286], ["4-aminoantipyrine", "SIMPLE_CHEMICAL", 330, 347], ["4-aminopyridine derivatives", "SIMPLE_CHEMICAL", 429, 456], ["liver", "ORGAN", 481, 486], ["4-aminoantipyrine", "SIMPLE_CHEMICAL", 591, 608], ["human", "ORGANISM", 612, 617], ["serum", "ORGANISM_SUBSTANCE", 618, 623], ["albumin", "GENE_OR_GENE_PRODUCT", 624, 631], ["DNA", "CELLULAR_COMPONENT", 650, 653], ["4-aminoantipyrine derivatives", "SIMPLE_CHEMICAL", 663, 692], ["leishmanicidal", "SIMPLE_CHEMICAL", 700, 714], ["4-aminoantipyrine", "SIMPLE_CHEMICAL", 835, 852], ["articular cartilage", "TISSUE", 1054, 1073], ["soft tissue", "TISSUE", 1075, 1086], ["joints", "MULTI-TISSUE_STRUCTURE", 1103, 1109], ["bone", "TISSUE", 1115, 1119], ["patients", "ORGANISM", 1449, 1457], ["Joint", "MULTI-TISSUE_STRUCTURE", 1593, 1598], ["patients", "ORGANISM", 1660, 1668], ["anti-OA", "SIMPLE_CHEMICAL", 1751, 1758], ["human", "SPECIES", 612, 617], ["patients", "SPECIES", 1449, 1457], ["patients", "SPECIES", 1660, 1668], ["human", "SPECIES", 612, 617], ["the small molecule chloroquine", "TREATMENT", 33, 63], ["a small molecule", "PROBLEM", 100, 116], ["chloroquine", "TREATMENT", 136, 147], ["a new vaccine", "TREATMENT", 182, 195], ["COVID", "TREATMENT", 200, 205], ["side effects", "PROBLEM", 231, 243], ["chloroquine", "TREATMENT", 275, 286], ["aminoantipyrine", "TREATMENT", 332, 347], ["the 4-aminopyridine derivatives", "TREATMENT", 425, 456], ["the liver diseases3", "PROBLEM", 477, 496], ["clinical treatment", "TREATMENT", 510, 528], ["Previous studies", "TEST", 533, 549], ["aminoantipyrine", "TREATMENT", 593, 608], ["human serum albumin", "TREATMENT", 612, 631], ["DNA", "PROBLEM", 650, 653], ["Some 4-aminoantipyrine derivatives", "TREATMENT", 658, 692], ["leishmanicidal, antioxidant", "TREATMENT", 700, 727], ["antimicrobial activities", "TREATMENT", 733, 757], ["new derivative of 4-aminoantipyrine", "TREATMENT", 817, 852], ["a vaccine", "TREATMENT", 877, 886], ["the virus", "PROBLEM", 903, 912], ["other microorganisms", "PROBLEM", 948, 968], ["IntroductionOsteoarthritis (OA", "PROBLEM", 969, 999], ["a painful condition", "PROBLEM", 1004, 1023], ["progressive reduction of articular cartilage", "PROBLEM", 1029, 1073], ["soft tissue swelling at the joints, and bone cyst", "PROBLEM", 1075, 1124], ["remedy", "TREATMENT", 1139, 1145], ["OA", "PROBLEM", 1150, 1152], ["available therapies", "TREATMENT", 1158, 1177], ["pain relievers", "PROBLEM", 1183, 1197], ["the pain", "PROBLEM", 1228, 1236], ["The OA pain", "PROBLEM", 1240, 1251], ["a medical problem", "PROBLEM", 1262, 1279], ["animal OA models", "PROBLEM", 1290, 1306], ["OA", "PROBLEM", 1353, 1355], ["pain processes", "PROBLEM", 1364, 1378], ["new treatment objectives", "PROBLEM", 1390, 1414], ["modifying drugs", "TREATMENT", 1466, 1481], ["OA", "PROBLEM", 1523, 1525], ["the available medicines", "TREATMENT", 1531, 1554], ["symptoms of OA", "PROBLEM", 1575, 1589], ["Joint replacement", "TREATMENT", 1593, 1610], ["therapy", "TREATMENT", 1635, 1642], ["OA", "PROBLEM", 1697, 1699], ["effective anti-OA medications", "TREATMENT", 1741, 1770], ["small", "OBSERVATION_MODIFIER", 37, 42], ["small", "OBSERVATION_MODIFIER", 102, 107], ["size", "OBSERVATION_MODIFIER", 128, 132], ["liver", "ANATOMY", 481, 486], ["diseases3", "OBSERVATION", 487, 496], ["leishmanicidal", "OBSERVATION_MODIFIER", 700, 714], ["progressive", "OBSERVATION_MODIFIER", 1029, 1040], ["reduction", "OBSERVATION_MODIFIER", 1041, 1050], ["articular cartilage", "ANATOMY", 1054, 1073], ["soft tissue", "ANATOMY", 1075, 1086], ["swelling", "OBSERVATION", 1087, 1095], ["joints", "ANATOMY", 1103, 1109], ["bone", "ANATOMY", 1115, 1119], ["cyst", "OBSERVATION", 1120, 1124], ["no", "UNCERTAINTY", 1136, 1138], ["OA", "OBSERVATION_MODIFIER", 1244, 1246], ["pain", "OBSERVATION", 1247, 1251], ["new", "OBSERVATION_MODIFIER", 1390, 1393], ["Joint", "ANATOMY", 1593, 1598], ["replacement", "OBSERVATION", 1599, 1610]]], ["One of the unresolved problems in OA pathogenesis is the contribution of the inflammatory response and oxidative stress to the beginning and growth of OA.IntroductionDuring OA pathogenesis, in the joint bodies of OA patients and OA-like animals, a variety of inflammatory mediators, including cytokines, development factors, and prostaglandin E2, were noted to be increased.12", [["joint bodies", "ANATOMY", 197, 209], ["OA", "DISEASE", 34, 36], ["OA", "DISEASE", 151, 153], ["OA", "DISEASE", 173, 175], ["OA", "DISEASE", 213, 215], ["OA", "DISEASE", 229, 231], ["prostaglandin E2", "CHEMICAL", 329, 345], ["prostaglandin E2", "CHEMICAL", 329, 345], ["OA", "CANCER", 34, 36], ["OA", "PATHOLOGICAL_FORMATION", 151, 153], ["joint bodies", "MULTI-TISSUE_STRUCTURE", 197, 209], ["patients", "ORGANISM", 216, 224], ["prostaglandin E2", "SIMPLE_CHEMICAL", 329, 345], ["inflammatory mediators", "PROTEIN", 259, 281], ["cytokines", "PROTEIN", 293, 302], ["development factors", "PROTEIN", 304, 323], ["patients", "SPECIES", 216, 224], ["OA pathogenesis", "PROBLEM", 34, 49], ["the inflammatory response", "PROBLEM", 73, 98], ["oxidative stress", "PROBLEM", 103, 119], ["OA", "PROBLEM", 151, 153], ["IntroductionDuring OA pathogenesis", "PROBLEM", 154, 188], ["OA", "PROBLEM", 229, 231], ["inflammatory mediators", "PROBLEM", 259, 281], ["cytokines", "PROBLEM", 293, 302], ["development factors", "PROBLEM", 304, 323], ["prostaglandin E2", "TREATMENT", 329, 345], ["unresolved", "OBSERVATION_MODIFIER", 11, 21], ["problems", "OBSERVATION", 22, 30], ["OA", "OBSERVATION", 34, 36], ["inflammatory", "OBSERVATION", 77, 89], ["oxidative stress", "OBSERVATION", 103, 119], ["OA", "OBSERVATION_MODIFIER", 173, 175], ["pathogenesis", "OBSERVATION", 176, 188], ["joint", "ANATOMY", 197, 202], ["bodies", "ANATOMY_MODIFIER", 203, 209], ["OA", "OBSERVATION_MODIFIER", 213, 215], ["OA", "OBSERVATION", 229, 231], ["inflammatory", "OBSERVATION_MODIFIER", 259, 271], ["increased", "OBSERVATION_MODIFIER", 364, 373]]]], "bfd2c3f52f7e66fbeedfafd3a5dbaefef1e1f20f": [["uninfected patients were admitted to decreasing numbers of available Internal Medicine (IM) beds.", [["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19], ["Internal Medicine (IM) beds", "TREATMENT", 69, 96]]], ["Pre-outbreak, SZ had four functioning IM departments.", [["SZ", "DISEASE", 14, 16], ["SZ", "PROBLEM", 14, 16]]], ["During the outbreak, the hospital developed five patient COVID-19 isolation wards and a dedicated Intensive Care Unit (ICU).", [["patient", "ORGANISM", 49, 56], ["patient", "SPECIES", 49, 56]]], ["There were fewer Emergency Department (ED) patients, but COVID-19 isolation wards filled up quickly.", [["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51], ["COVID", "TEST", 57, 62]]], ["During the peak of the outbreak, two IM Departments were converted to COVID-19 isolation wards.", [["COVID-19 isolation wards", "TREATMENT", 70, 94]]], ["As a result of the increase in COVID-19 patients, closure of IM wards, re-assignment of staff, and dynamic changes in available community placement options, we investigated the impact of the outbreak on IM patients not admitted for COVID-19.| ME THODSWe reviewed IM admissions during March 15-April 30, 2020 for patients without COVID-19.", [["patients", "ORGANISM", 40, 48], ["patients", "ORGANISM", 206, 214], ["patients", "ORGANISM", 312, 320], ["patients", "SPECIES", 40, 48], ["patients", "SPECIES", 206, 214], ["patients", "SPECIES", 312, 320], ["COVID", "TEST", 31, 36], ["closure of IM wards", "TREATMENT", 50, 69], ["community placement options", "TREATMENT", 128, 155], ["COVID", "TEST", 232, 237], ["COVID", "TEST", 329, 334], ["increase", "OBSERVATION_MODIFIER", 19, 27]]], ["The term \"outlier\" was used to describe patients with longer hospital lengths of stay.", [["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 40, 48]]], ["For this analysis, we compare length of stay \u226510 days between the two groups.", [["this analysis", "TEST", 4, 17]]], ["Functional status of the patients was approximated using the Norton scale.", [["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33], ["the Norton scale", "TREATMENT", 57, 73]]], ["The Norton scale has traditionally been used to assess risk for pressure ulcers.", [["ulcers", "DISEASE", 73, 79], ["ulcers", "PATHOLOGICAL_FORMATION", 73, 79], ["The Norton scale", "TREATMENT", 0, 16], ["pressure ulcers", "PROBLEM", 64, 79], ["pressure", "OBSERVATION_MODIFIER", 64, 72], ["ulcers", "OBSERVATION", 73, 79]]], ["5 However, it is also a valid assessment tool for predicting hospitalisation length, complications during hospitalisation and in-hospital mortality in elderly patients admitted to an IM department.", [["patients", "ORGANISM", 159, 167], ["patients", "SPECIES", 159, 167], ["a valid assessment", "TEST", 22, 40]]], ["6, 7 The scale consists of five questions addressing physical condition, mental condition, activity level, patient mobility, frequency and type of incontinence.| ME THODSThe score ranges from 5-20; less than 10 (very high risk), 10-14 (high risk), 15-18 (medium risk) and greater than 18 (low risk).", [["incontinence", "DISEASE", 147, 159], ["patient", "ORGANISM", 107, 114], ["patient", "SPECIES", 107, 114], ["incontinence", "PROBLEM", 147, 159], ["ME THODSThe score", "TEST", 162, 179]]], ["Use of the scale is obligatory at SZ, and an assessment is conducted at the time of admission to the IM wards from the ED, and once a week thereafter.", [["obligatory at SZ", "PROBLEM", 20, 36], ["an assessment", "TEST", 42, 55]]], ["The last value during the admission was used for this analysis.| ME THODSDescriptive statistics were utilised to assess characteristics of the study population.", [["this analysis", "TEST", 49, 62], ["the study population", "TEST", 139, 159]]], ["Comparison of quantitative variables in two independent groups were performed using the t test.| RE SULTSDuring March 15-April 30, 2020 there were 409 patients admitted to IM compared with a mean of 557 over the previous 3 years (Table 1) .", [["patients", "ORGANISM", 151, 159], ["patients", "SPECIES", 151, 159], ["the t test", "TEST", 84, 94]]], ["Fewer patients were admitted to the ED ( Figure 2 ) and the IM wards during this time.", [["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14]]], ["With regards to patient gender, in-hospital mortality rate, number discharged, number discharged home (ie, vs a healthcare facility) and the mean Norton score, there did not appear to be a significant difference between the two groups.", [["patient", "ORGANISM", 16, 23], ["patient", "SPECIES", 16, 23], ["the mean Norton score", "TEST", 137, 158], ["significant", "OBSERVATION_MODIFIER", 189, 200], ["difference", "OBSERVATION", 201, 211]]], ["In both groups, more than half of the patients were considered high or very high risk according to the Norton score, consistent with lower functional status for this study.", [["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46], ["the Norton score", "TEST", 99, 115], ["this study", "TEST", 161, 171], ["consistent with", "UNCERTAINTY", 117, 132]]], ["Patients admitted during the outbreak to IM were younger and had shorter mean hospital stays by over 2 days, when compared with the previous 3 years.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["The median length of stay was the same, but the interquartile range was shortened by 1 day for the group of patients admitted during the outbreak.", [["patients", "ORGANISM", 108, 116], ["patients", "SPECIES", 108, 116], ["median", "OBSERVATION_MODIFIER", 4, 10], ["length", "OBSERVATION_MODIFIER", 11, 17]]], ["There were no difference between the two groups with regards to the number of patients admitted for \u226510 days.| D ISCUSS I ONThis was an extremely dynamic period in Israel.", [["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 78, 86], ["no", "UNCERTAINTY", 11, 13], ["difference", "OBSERVATION_MODIFIER", 14, 24]]], ["During this period, the overall number of patients presenting to the Emergency Department (ED) was visibly less than the previous 3 years.", [["patients", "ORGANISM", 42, 50], ["patients", "SPECIES", 42, 50]]], ["While there were fewer patients admitted to IM via the ED, there were progressively fewer IM departments.", [["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31]]], ["During one of the peak days of the outbreak, the number of IM wards had been decreased from four to two.", [["decreased", "OBSERVATION_MODIFIER", 77, 86]]], ["Additionally, a small 14-bed satellite unit was established to help decompress the IM wards.", [["a small 14-bed satellite unit", "TREATMENT", 14, 43], ["small", "OBSERVATION_MODIFIER", 16, 21]]], ["By this time, five isolation wards had been rapidly established, including an ICU ward for COVID-19 patients.", [["patients", "ORGANISM", 100, 108], ["patients", "SPECIES", 100, 108]]], ["Therefore, in comparison to the previous year, four IM wards had been replaced by two IM wards and five COVID-19 isolation wards ( Figure 3 ).| D ISCUSS I ONThere are reports of hospitals having to shutdown wards and reallocate personnel and resources to be able to care for the influx of COVID-19 patients.", [["patients", "ORGANISM", 298, 306], ["patients", "SPECIES", 298, 306], ["five COVID", "TREATMENT", 99, 109]]], ["8 While no approach has been standard, there What's known \u2022 Hospitals in Israel had to adapt to the surge in COVID-19 patients, including training and deploying staff to work in newly formed COVID-19 isolation wards.What's new\u2022 While fewer numbers of patients were seen in the Emergency Department, non-COVID-19 patients continued to be admitted to a rapidly decreasing number of internal medicine beds at our institution.What's new\u2022 The COVID-19 outbreak was associated with changes in non-COVID-19 internal medicine patient characteristics and hospital length of stay.What's new\u2022 Research should focus on how outbreaks affect entire hospital populations and community resources.What's newwill be a need to look back and assess individual site response to the pandemic, as well as to formulate a plan for the current effort and future healthcare epidemics.What's newPatients admitted to IM were significantly younger, as older patients may have been admitted to isolation wards, died at home or feared coming to the hospital, thinking it an epicentre of infection.", [["infection", "DISEASE", 1055, 1064], ["patients", "ORGANISM", 118, 126], ["patients", "ORGANISM", 251, 259], ["patients", "ORGANISM", 312, 320], ["patient", "ORGANISM", 518, 525], ["patients", "ORGANISM", 928, 936], ["patients", "SPECIES", 118, 126], ["patients", "SPECIES", 251, 259], ["patients", "SPECIES", 312, 320], ["patient", "SPECIES", 518, 525], ["patients", "SPECIES", 928, 936], ["internal medicine beds", "TREATMENT", 380, 402], ["The COVID", "TEST", 434, 443], ["infection", "PROBLEM", 1055, 1064], ["infection", "OBSERVATION", 1055, 1064]]], ["9 While not classically used for assessing the casemix of patients, the use of the Norton scale is obligatory for every IM admission at our facility and does describe many aspects of the patient's physical and mental attributes.", [["patients", "ORGANISM", 58, 66], ["patient", "ORGANISM", 187, 194], ["patients", "SPECIES", 58, 66], ["patient", "SPECIES", 187, 194], ["the Norton scale", "TREATMENT", 79, 95]]], ["More complex, albeit possibly harder to derive, metrics for assessing functional assessment do exist as well.", [["assessing functional assessment", "TEST", 60, 91]]], ["10 We observed a significantly decreased hospital length of stay, without an increase in mortality.", [["an increase in mortality", "PROBLEM", 74, 98], ["significantly", "OBSERVATION_MODIFIER", 17, 30], ["decreased", "OBSERVATION_MODIFIER", 31, 40], ["hospital length", "OBSERVATION_MODIFIER", 41, 56], ["increase", "OBSERVATION_MODIFIER", 77, 85]]], ["After admitting the first infected patient, the hospital director established a team dedicated to overseeing patient flow from admission to discharge.", [["patient", "ORGANISM", 35, 42], ["patient", "ORGANISM", 109, 116], ["patient", "SPECIES", 35, 42], ["patient", "SPECIES", 109, 116]]], ["Some IM residents and senior physicians were home in isolation, caring for children no longer at school during the day or retasked to COVID-19 isolation wards.", [["children", "ORGANISM", 75, 83], ["children", "SPECIES", 75, 83]]], ["While the administration was actively engaged and promoted regular top-down and bottom-up communication, burn-out was a concern on the IM as well as the isolation wards.", [["burn", "DISEASE", 105, 109], ["the IM", "TREATMENT", 131, 137]]], ["Proper planning allowed SZ to remain functional and even shorten IM patient length of stay.", [["patient", "ORGANISM", 68, 75], ["patient", "SPECIES", 68, 75], ["SZ", "PROBLEM", 24, 26]]], ["Further studies and research should address how outbreaks affect the entire hospital populations and surrounding community resources.D I SCLOS U R E SWe confirm that all authors of this paper have fulfilled the conditions of the IJCP regarding contribution to the concept, design and drafting of the manuscript.", [["Further studies", "TEST", 0, 15]]]]}